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Professional antigen presenting cells (APC: myeloid dendritic cells (DC) and 
macrophages (MΦ); B lymphocytes) mediate highly efficient HIV-1 infection of CD4+ T cells, 
termed trans infection, that could contribute to HIV-1 pathogenesis. We have previously shown 
that lower cholesterol content in DC and B lymphocytes is associated with a lack of HIV-1 trans 
infection in HIV-1 infected nonprogressors (NP). Here we assessed whether HIV-1 trans 
infection mediated by another major APC, MΦ, is deficient in NP due to altered cholesterol 
metabolism. When comparing healthy HIV-1 seronegatives (SN), rapid progressors (PR), and 
NP, we found that monocyte-derived MΦ from NP did not mediate HIV-1 trans infection of 
autologous CD4+ T cells, in contrast to efficient trans infection mediated by SN and PR MΦ. 
MΦ trans infection efficiency was directly associated with the number of DC-specific 
intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN)-expressing MΦ. 
Significantly fewer NP MΦ expressed DC-SIGN. Unesterified (free) cholesterol in MΦ cell 
membranes was significantly lower in NP than PR, as well as virus internalization in early 
endosomes. Furthermore, simvastatin (SIMV), decreased the subpopulation of DC-SIGN+ MΦ, 
as well as MΦ cis and trans infection. Notably, SIMV decreased cell membrane cholesterol and 
led to lipid raft dissociation, effectively mimicking the incompetent APC trans infection 
environment characteristic of NP. Our data support that DC-SIGN and membrane cholesterol are 
central to MΦ trans infection, and a lack of these limits HIV-1 disease progression. Lastly, we 
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identified differentially expressed miRNA in NP and PR plasma which may contribute to the 
altered cholesterol phenotype we have identified in NP APC. Understanding the mechanisms of 
HIV-1 trans infection has great public health importance. For example, targeting the ability of 
MΦ to drive HIV-1 dissemination in trans could significantly enhance HIV-1 therapeutic 
strategies.  
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1.0  IMPORTANCE AND RATIONALE 
Globally, over 35 million people are currently living with human immunodeficiency 
virus-1 (HIV-1), and despite several decades of research, the development of a successful 
prophylactic vaccine against or successful cure for HIV-1 infection remains elusive. The 
development and implementation of combination antiretroviral therapy (cART), which can 
effectively lower HIV-1 viral load to undetectable levels, has greatly decreased the morbidity 
and mortality associated with HIV-1 infection. However, some individuals battle persistently low 
CD4/CD8 ratios (1) and virus rebound despite cART (2). Unsuccessful treatment has also been 
attributed to delayed diagnoses and late onset of therapy (3). Even in the event of cART-
mediated viral suppression, there is a reservoir of HIV-1 infected CD4+ lymphocytes (CD4+ T 
cells) in the circulation and in tissue (4) that successfully evades immune surveillance, and 
contributes to incomplete viral clearance or eradication despite treatment (5-8).  
Many host, microbe, and environmental factors act concurrently to establish the unique 
microenvironment found within each HIV-1 positive individual and determine their associated 
prognosis. The complexity of HIV-1 pathogenesis has complicated the development of a 
successful cure or vaccine, demanding the identification of novel mechanisms for treatment and 
prevention. Without cART, fewer than 5% of seropositive individuals can control HIV-1 
infection and prevent progression to AIDS (9). Collectively referred to as nonprogressors (NP) 
this group of individuals represents an enigma in the field of HIV-1. Protective factors, such as 
the ∆32 deletion in the HIV-1 coreceptor CCR5 gene (10-12) or the presence of specific  HLA 
alleles (13), have been associated with a lack of or lower susceptibility to HIV-1 infection, as 
well as protection from disease progression. Interestingly, some NP in the Multicenter AIDS 
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Cohort Study (MACS) lack ∆32 homozygosity or heterozygosity as well as known protective 
HLA types, and we believe these NP serve as the ideal natural model within which novel 
mechanisms for controlling HIV-associated disease can be unveiled.  
The presence of a latent HIV reservoir within CD4+ T cells in the circulation and in tissue 
(4) that successfully evades immune surveillance is thought to be a barrier preventing virus
clearance despite cART. Trans infection, i.e. transfer of virus from cell-to-cell, of CD4+ T cells 
is believed to be a crucial event contributing to viral persistence during cART (14, 15). CD4+ T 
cell trans infection mediated by professional antigen presenting cells (APC), i.e., dendritic cells 
(DC), macrophages, and B lymphocytes (B cells), yields much higher virus replication in T cells 
compared to both direct cis infection of T cells and T cell-to-T cell trans infection (16). Transfer 
of virus during direct contact from one cell to another through the infectious synapse represents a 
mechanism to evade immune responses, particularly in lymphoid tissue, thereby aiding the 
maintenance of an infected CD4+ latent HIV-1 reservoir. As APC-to-T cell trans infection is an 
important method of massive virus replication, it is an essential form of HIV-1 dissemination to 
be studied. Additionally, elucidation of trans infection mechanisms will provide novel targets for 
prophylactic and therapeutic medicine, as well as potentially help in identifying and eliminating 
the viral reservoir.  
We have recently demonstrated that DC and B cells of NP do not trans infect autologous 
or heterologous CD4+ T cells. In addition, we have found an association with decreased DC and 
B cell total cholesterol content and their inability to trans infect (17). This was the first time 
trans infection was linked to HIV-1 pathogenesis and disease progression. Cholesterol-rich 
macrophages, known as foam cells, are heavily involved in cardiac plaque development (18, 19), 
a common risk factor of cardiovascular disease, which is a known comorbidity in HIV-1 infected 
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individuals (20). Although monocyte-derived macrophages (MΦ) are known to trans infect 
CD4+ T cells (21) with HIV, their cholesterol content and trans infection ability has not been 
studied in association with disease progression. While past research has focused on the impact of 
virion envelope cholesterol content on HIV-1 infection and pathogenesis (22, 23), the role of 
cellular cholesterol in MΦ – mediated HIV-1 trans infection is unknown. Understanding the role 
of cholesterol in HIV-1 trans infection will provide insight into novel mechanisms of HIV-1 
pathogenesis and disease control.  
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2.0  INTRODUCTION 
2.1 HIV-1 PUBLIC HEALTH 
HIV Pandemic 
It is believed that the current HIV pandemic originated in Central Africa in the early 
1920s (24). However, HIV was not identified as the causative agent of Acquired Immune 
Deficiency Syndrome (AIDS) until 1983 (25). The arrival of HIV and the AIDS epidemic to the 
United States in 1980 and the subsequent death of thousands of people generated a demand for 
research and a cure by the western world. Yet, despite several decades of research, the 
development of a successful prophylactic vaccine against or successful cure for HIV infection 
remains elusive. The discovery of antiretroviral drugs in the 1990s and implementation of cART 
in the mid-1990s, has since increased the quality of life and life expectancy of many seropositive 
individuals (26). Yet cART drug resistance is on the rise. Today HIV remains one of the most 
fatal infectious diseases, second only to tuberculosis, worldwide (27). With over 36 million 
people living with HIV globally, 1.8 million new infections occur each year, and approximately 
one million HIV-related deaths annually (28), the need for novel therapeutics is outstanding.  
The origin of the HIV pandemic in humans can be traced back to inter- or cross- species 
transmission of Simian immunodeficiency virus from non-human primates to humans in Africa 
(29). Multiple instances of  inter-species transfer of simian immunodeficiency virus is believed 
to explain the generation of two types of HIV, HIV-1 and HIV-2, within which multiple groups 
of genetically different HIV have formed, groups A – H for HIV-2 and M, N, O, and P for HIV-
1, within which some groups are even further categorized into subtypes (29). These groups vary 
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in many ways including, infectivity, pathogenicity, and geographical prevalence (29, 30). The 
most common type of HIV-1 infection in North America, South America, Europe, and Australia 
is HIV-1 group M subtype B, while subtype C is the most common type identified in Africa and 
Asia (31). Although HIV-1 and -2 share both virological features and infection requirements, 
such as receptors for virus entry, replication cycle, and mechanisms of pathogenicity (32), HIV-1 
strains are more infectious, as well as cause more severe disease and faster disease progression 
compared to HIV-2 strains (32, 33). Therefore, HIV-1 is more widely studied and is henceforth 
the focus of the work presented. 
HIV-1 transmission, replication, and restriction 
HIV-1 is a blood-borne pathogen that is transmitted by the exchange of infected bodily 
fluids. HIV-1 can be transmitted sexually via the urogenital or gastrointestinal tract, as well as 
through contact with infectious blood, most commonly via contaminated needles during 
intravenous drug use (34). Transmission can also occur from infected mother to child if the child 
is exposed to infectious maternal blood or breast milk intrapartum or during breast feeding (35).  
Following transmission, HIV-1 productive infection of CD4+ T cells is the primary 
method by which virus replication occurs and new progeny virions are formed. The ability of cell 
free virus to enter target host cells, replicate, and produce new infectious virions is known as 
productive cis infection. Cis infection is a complex pathway that requires specific cellular 
conditions. The HIV-1 envelope glycoprotein gp120 binds to the CD4 on the host cells, causing 
a conformational change that allows the binding of gp41 to the host co-receptor, either CCR5 or 
CXCR4. The gp41 protein inserts into the host cell PM, mediating the fusion of the virus envelop 
and cell PM. Once the genome containing nucleocapsid enters the host cell, a viral enzyme, 
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reverse transcriptase, reverse transcribes the single-stranded RNA viral genome into double-
stranded DNA. The viral DNA is then transported into the cell nucleus and integrated into the 
host genome facilitated by the viral enzyme integrase. Once integrated, upon cellular activation, 
the viral DNA is transcribed into mRNA that serves as viral genome for packaging into new 
progeny virions or is translated into viral proteins. The viral proteins are either transported to and 
expressed in the host PM, i.e. envelope glycoproteins, or packaged with the viral genome into 
newly formed viral nucleocapsids. New virions bud from the host cell encompassed by an 
envelope derived from the host cell PM (36).  
Despite the hijacking of host cell machinery by HIV-1, human immune cells deploy 
multiple defense mechanisms, commonly known as restriction factors, which limit of block 
infection. These host factors target various steps in the HIV-1 cis infection pathway. For 
example, APOBEC3G hinders reverse transcription and replication of the HIV-1 genome (37). 
Additionally, TRIM5α causes rapid un-coating of the nucleocapsid (38), and tetherin blocks the 
release of new mature virions budding from the cell surface (39). Interestingly, certain HIV-1 
host restriction factors are expressed in particular cell types, and their expression can be 
constitutive or induced, for example by interferon (IFN) during innate immune responses. 
SAMHD1 is highly expressed in myeloid-derived cells, such as dendritic cells (DC), and is 
considered responsible for the low infection and replication efficiency of HIV-1 in DC (40). 
Although CD4+ T cells express APOBEC3G, they also contain an intrinsic factor that inhibits 
APOBEC3G activity, which contributes to the less effective ability of CD4+ T cells to block 
HIV-1 reverse transcription and replication leading to their high susceptibility to infection.  
HIV-1 also contains counter mechanisms to bypass or block host restriction factors. 
Intracellularly, HIV-1 protein vif facilitates the degradation of APOBEC3G (41), while HIV-1 
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non-virion associated env, nef, and vpu can effectively sequester tetherin through competitive 
binding on the cell surface allowing budding of intact virions (42). Despite tissue-resident MΦ 
expression of SAMHD1, when such cells are in a G1 state HIV-1 can bypass the restriction 
function of SAMHD1 and replicate efficiently (43). Additionally, several HIV-1 proteins act to 
decrease detectability of the virus and infected cells by the host immune system. For example, 
the viral protein nef down-regulates MHC Class 1 expression to decrease viral antigen 
presentation and subsequent natural killer cell and cytotoxic CD8+ T cell responses (44). Also, 
the CD4+ T cell response can be altered by nef through the down-regulation of CD4, altering T 
cell receptor functions (45). Lastly, HIV-1 can evade HIV-1 specific adaptive immune responses 
such as antibody neutralization and CD8+ T cell cytotoxicity due to high genomic mutation rates, 
resulting in epitope escape and antigenic variation. Nef also can be excreted in exosomes and act 
in a paracrine fashion on neighboring cells (46).  When the virus wins this tug-of-war, it 
establishes a primary infection and causes disease.  
HIV-1 disease and therapeutics 
Following transmission and primary infection, HIV-1-associated disease is divided into 
three phases, acute infection, chronic clinical latency, and AIDS. During acute infection, robust 
viral replication increases resulting in peak plasma viremia levels mirrored by a dramatic 
decrease in blood CD4+ T cell counts. Concurrently, immune activation in response to the 
infection occurs and infected individuals develop common influenza-like symptoms, such as a 
fever and body aches, often leading to misdiagnose, or remain asymptomatic. After a several 
weeks, individuals enter the chronic phase of HIV-1 infection during which an effective anti-
HIV-1 immune response lowers viral load and a recovery of CD4+ T cells is observed. However, 
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due to the establishment of an undetectable latent viral reservoir, consisting of inactive, non-
replicating infected cells, the virus is not fully cleared from the body. Without cART, the chronic 
phase lasts anywhere from six months to seven years after which an irreversible increase in viral 
load and decrease of CD4+ T cell count below 200 cells/ mm3 triggers the onset of AIDS and 
ultimately death (47, 48). However, with proper access and adherence to cART, the development 
of AIDS can be delayed for decades, if not a lifetime (26). 
cART helps control viral load and immune activation, thereby decreasing virus 
transmission, as well as HIV-1-associated disease, comorbidities, and mortality (49). 
Antiretroviral drugs target several steps of the HIV-1 replication cycle, including virus binding, 
reverse transcription, integration, and viral protease function. Combination therapies utilizing 
nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, 
protease inhibitors, and integrase strand transfer inhibitors lead to greater virus suppression and 
control compared to previously used single drug therapy (49).  
While cART can effectively treat chronic infection with proper access and drug 
adherence, it does not eliminate latently infected cells. Once integration has occurs, viral DNA 
resembles host DNA and is therefore not easily distinguishable for excision and elimination from 
infected cells. There is a latent reservoir of HIV-1 infected CD4+ T cells in the circulation and in 
tissue (4) that successfully evades immune surveillance, even in the presence of cART, and is 
believed to contribute to incomplete viral clearance or eradication though treatment. The 
inability of the host immune system to eliminate the HIV-1 reservoir despite decades of research 
and therapeutic discoveries is the primary reason HIV-1 causes lifelong chronic infection for 
which we lack a sterilizing cure. 
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Natural HIV-1 Disease Control 
Despite the success of cART, resistance to antiretroviral drugs is becoming more 
prevalent globally, and while not epidemiologically recorded in the United States of America, it 
is being monitored in much of South and Central America, as well as several African and Asian 
countries by the World Health Organization (50). The rise of antiretroviral drug resistance has 
demanded a need for novel therapeutic targets and strategies for HIV-1 control and elimination. 
Without combination antiretroviral therapy (cART) fewer than 5% of seropositive individuals 
can naturally control HIV-1 infection and prevent progression to AIDS (9). These few 
individuals consist of viremic controllers (VC; 50 – 2,000 plasma HIV-1 RNA copies/ml), elite 
controllers (EC; consistent undetectable RNA), and long term nonprogressors (LTNP; CD4+ 
counts > 500/mm3 and varying levels of detectable RNA) which we collectively refer to as 
nonprogressors (NP). NP represent an enigma in the field of HIV-1 and serve as a natural model 
of HIV-1 disease suppression wherein we can define mechanisms preventing disease 
progression.  
Several virological, immunological, and genetic factors have been found to be associated 
with HIV-1 disease progression. Early case reports suggested that infection with a weaker or less 
virulent virus leads to less pathogenesis and slower progression (51-53). However, other studies 
have produced confounding results (54, 55), suggesting that some, but not all, cases of 
nonprogression are a result of the specific infecting virus. Nonprogression is also associated with 
the production of anti - HIV-1 antibodies (56), strong CTL responses (57), and the production of 
a specific cytokine profile(58, 59).  Additionally, the presence of certain single nucleotide 
polymorphisms (SNPs) in MHC class I and III genes are associated with nonprogression (60), 
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and the delta 32 mutation in the CCR5 and the presence of HLA B57 genotype are associated 
with nonprogression (61).  
However, these characteristics do not explain all cases of nonprogression. It is important 
to note that in the MACS, elite and viremic controllers are characterized based on their plasma 
viral load at particular points after seroconversion, while long term nonprogressors are 
alternatively characterized solely based on their CD4+ T cell count over time, regardless of viral 
load. Due to the heterogeneity of the NP classifications, it is likely that there is more than one 
genetic or biological feature responsible for the NP phenotype.  Illuminating the magnitude and 
mechanisms of cholesterol involvement in HIV-1 trans-infection will further our understanding 
of HIV-1 persistence and disease progression. Revealing novel events essential for HIV-1 disease 
control an elimination likely lies within studying differences between groups of HIV-1 infected 
individuals with different virological and disease progression patterns. 
2.2 HIV-1 TRANS INFECTION 
2.2.1 What is Trans Infection? 
Trans infection, i.e. the transfer of virus from one cell to another cell is believed to aid in 
virus escape from immune surveillance, as well as facilitate highly efficient infection of CD4+ T 
cells and contribute to HIV-1 persistence during cART. HIV-1 trans infection has been shown to 
occur from CD4+ T cells to other CD4+ T cells, CD4+ T cells to APC (16), as well as APC to 
CD4+ T cells. CD4+ T cell trans infection mediated by professional antigen presenting cells 
(APC), i.e., DC, MΦ, and B lymphocytes (B cells), yields much higher virus replication in CD4+ 
T cells compared to both direct, cis infection of CD4+ T cells and CD4+ T cell-to-T cell trans 
infection (16). This may be particularly pertinent to APC interactions with CD4+ T cells in 
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lymphoid tissue, a prominent location of HIV-1 replication. During antigen presentation by APC, 
the close proximity between the APC and CD4+ T cells is necessary for MHC – T cell receptor 
within the immunological synapse, the space between the two cells. During trans infection, HIV-
1 can be passed from the APC to the T cell with greater ease due to the close proximity of the 
cells. This passage of virus from APC-to- T cell is proposed to facilitate pathogen transmission 
under the radar of humoral immune factors such as neutralizing antibodies (62) and is 
hypothesized to contribute to HIV-1 persistence during cART. We have recently demonstrated 
that DC and B cells of NP do not trans infect autologous or heterologous CD4+ T cells (17), 
linking trans infection to HIV-1 pathogenesis and disease progression for the first time. 
2.2.2 Trans Infection Mechanisms. 
Cis infection 
Trans infection of CD4+ T cells mediated by DC has been shown to occur following de 
novo cis infection of DC. At least 48 hour after infection, progeny virions budding from the DC 
utilize the small space between the DC and CD4+ T cells during cell-to-cell interactions as a 
virological synapse where they infect the T cells (63). However, HIV-1 replication in DC varies 
based on the maturation state of the DC. Due to the effectiveness of HIV-1 host restriction factors 
expressed by DC, the amount of trans infection that occurs following DC cis infection is likely 
minimal in vivo. Langerhans cells have also been shown to trans infect CD4+ memory T cells 
following cis infection (64). Due to Langerhans cells residing in skin and mucosal membranes, 
HIV-1 trans infection mediated by Langerhans cells could facilitate HIV-1 penetration and 
dissemination from peripheral sites of infection. Unlike DC, MΦ are highly susceptible to 
infection with M-tropic HIV-1 (65). Although MΦ have been shown to pass HIV-
12 
1 to CD4+ T cell following MΦ cis infection, this mechanism of trans infection is minimal (66). 
Studies have demonstrated that blocking HIV-1 fusion with the PM decreases both DC and LC 
trans infection, but not entirely (64, 67). This suggests that trans infection following cis infection 
is not the only mechanism by which virus is transferred from APC to CD4+ T cells. Indeed, 
following exposure to HIV-1, APC have been shown to trans infect CD4+ T cell in the absence of 
cis infection(16). Furthermore, B cells, which lack the ability to support HIV-1 cis infection, are 
known to trans infect CD4+ T cells very efficiently (68).  
Endocytosis. 
APC have been found to internalize intact virions independent of CD4/co-receptor 
interactions or fusion. DC, LC, MΦ, and B cells can also mediate HIV-1 trans infection in 
multiple ways following receptor-mediated endocytosis. DC and B cells have been shown to take 
up HIV-1 through DC-SIGN-mediated endocytosis (68, 69). The virus is then passaged through 
the intracellular endosomal network within until it is regurgitated or exocytosed, alone or in 
association with exosomes, into the immunological / infectious synapse where it efficiently 
infects CD4+ T cells (70, 71). CD169 (siglec-1) mediates the capture of retroviruses by 
macrophages lining the sinus region of LN and its passage to B cells within LN follicles (72). 
Despite this, virus transfer does not result in virus replication in the B cell, and it is feasible that 
upon activation, B cells could subsequently trans infect CD4+ T cells, including T helper 
follicular cells (Thf), which are a primary population of cells within which virus production 
occurs (73). Although proteins such as DC-SIGN (68, 74) and siglec-1 (75) have been found to 
mediate HIV-1 transfer from DC and B cells to CD4+ T cells, such a factor has not been 
identified for MΦ. 
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Infected CD4+ T cells can pass HIV-1 to neighboring uninfected CD4+ T cells through 
connected membrane nanotubes in vitro (76). Nanotubes are extensions of the plasma membrane 
which have the ability to fuse with PMs from other cells, effectively connecting the cytoplasm of 
two cells. These connections facilitate the passage of molecules, proteins, and even pathogens 
(77). DC also generate nanotubes and upon stimulation with CD40L and IFNγ, the network of 
nanotubes formed by DC is significantly enhanced (78). In addition to exocytosis of internalized 
HIV-1, the transfer of internalized HIV-1 from DC to CD4+ T cells through nanotubes, or larger 
microtubules is an additional proposed mechanism of trans infection. HIV-1 infection has also 
been shown to induce nanotubes in MΦ through which virus could potentially be passaged (79).  
Extracellular Hitchhiking. 
HIV-1 can attach to the surface of several cell types in multiple ways including 
interacting with CD4 (80), DC-SIGN (81, 82), mannose binding C-type lectin receptors (83-86), 
and heparan sulfate proteoglycans expression (87-90). Through these interactions, HIV-1 can 
alternatively remain on the surface of cells, often within extracellular invaginations of the PM, 
known as crypts, common to MΦ and DC (16). This allows the virus to better evade antibody 
binding until the APC interacts with other target cells, during which the virus can detach from 
the APC and more easily infect target CD4+ T cells or other APC in close proximity (16). This 
has been demonstrated for several cell types including spermatozoa (87), basophils (91), mucosal 
mast cells (92), dendritic cells (93), and B cells (94-96).  
Transfer of virus in trans during direct contact from one cell to another through the 
infectious synapse represents a possible way to evade host immune detection, such as antibody-
mediated opsonization and cytotoxic T cell recognition. This undetected spread of virus likely 
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aids in HIV-1 persistence and reservoir maintenance. Although CD4+ T cell-to-T cell trans 
infection may account for some virus spread during HIV-1 latency, the superior robustness of 
APC – mediated CD4+ T cell trans suggests it plays a larger role in HIV-1 pathogenesis and 
disease. 
2.2.3 Trans infection Relevance to HIV-1 Disease. 
Trans infection is challenging to study in vivo due to the advanced technical requirements 
for visualizing and measuring molecular interactions between HIV-1 and cells in a living animal 
model. However, the potential impact of HIV-1 trans infection on HIV-1 – associated disease is 
considerably significant.  If the features of HIV-1 trans infection determined by in vitro studies 
are representative of natural HIV-1 infection, trans infection is likely implicated in multiple 
stages of acute and chronic infection.  
Virus Dissemination and Enhanced Replication. 
The earliest stages of HIV-1 infection (i.e. virus exposure, establishment of the primary 
infection, and virus dissemination) are heavily targeted by prophylactic and therapeutic measures. 
Many cell types in the periphery of the urogenital and gastrointestinal tracts mediate virus 
infection and dissemination after sexual exposure through a variety of non-specific and cell-
specific interactions previously described. Infected semen is the primary source of HIV-1 
transmission and spermatozoa carrying bound HIV-1 can efficiently trans infect DC, MΦ, and 
CD4+ T cells (87), three cell types that are found in vaginal and colorectal submucosa and 
support HIV-1 replication. However, CD4+ T cell and macrophage concentrations are low in the 
lower and upper vagina relative to DC (97). APC are the primary cell type found in the female 
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cervix (98), and upon disruption of the mucosal layer Langerhans cells are the first cells infected 
with HIV-1 following sexual exposure. Other APC within the local tissue infected with or non-
productively associated with through binding or endocytosis of virus as they interact with 
various cell types in the peripheral tissue aiding in the establishment of primary infection. Upon 
infection or antigen detection and migration to secondary lymphoid tissues, they can serve as 
sentinels into the body. It has been visually observed that MΦ pass virus in trans to B cells 
within LN (72). Additionally, due to their ability to enter the central nervous system, HIV-1 
harboring MΦ mediate dissemination of virus into the brain and have been implicated in HIV - 
associated neurocognitive disorder (HAND). 
It is feasible that MΦ and DC entering the LN, as well as B cells, can pass HIV-1 
efficiently in trans to highly abundant CD4+ T cells leading to an amplification of virus. Robust 
virus replication in CD4+ T cells is a hallmark of acute HIV-1 infection causing a sharp spike in 
viremia prior to control of virus and the chronic stage of disease (48). Overtime, chronic immune 
activation as a result of HIV-1 infection can lead to tissue and organ damage affecting the liver, 
heart, and nervous system (30).  
Maintenance of the HIV-1 Reservoir. 
HIV-1 trans infection is believed to be a critical factor contributing to viral persistence 
during cART (14, 15). In addition to contributing to virus dissemination, robust replication, and 
subsequent long-term HIV-1 – associated comorbidities such as chronic immune activation and 
HAND, low levels of HIV-1 trans infection may be a mechanism by which the viral reservoir is 
maintained.  HIV-1 trans infection from DC to CD4+ T cells has recently been shown to occur 
despite the presence of certain antiretroviral drugs, such as tenofovir and raltegravir (99). Low 
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levels of virus transfer to nearby susceptible cells could facilitate the growth of the population of 
productively or latently infected cells under the radar of the immune system.  In this capacity, 
trans infection could be a relevant mechanism of virus spread and replication considered for 
targeting during kick and kill studies and novel therapeutic development.  
HIV-1 Disease Progression. 
We have previously shown that an inability of DC and B cell to trans infect autologous 
CD4+ T cells with HIV-1 is associated with non-progression. We further identified a positive 
association between APC cholesterol content and trans infection ability (17). This was the first 
time trans infection was linked to HIV-1 disease progression. However, the mechanisms by 
which APC cellular cholesterol influences their trans infection ability and the ways in which 
HIV-1 trans infection contributes to disease progression remain unknown. A better 
understanding of the factors controlling trans infection in HIV-1 infected individuals may 
provide insight about therapeutic targets for disease control. 
2.2.4 DC-SIGN and Trans Infection. 
Many of the factors controlling trans infection ability or efficiency by a particular cell are 
related to the various mechanisms of trans infection described above. Since the first step in all 
three of the trans infection pathways (cis-mediated, endocytosis, and extracellular hitchhiking) 
require virus binding, the presence or absence of surface proteins and molecules known to 
mediate virus attachment, greatly dictate the ability of a cell to capture virus for eventual trans 
infection (16). HIV-1 CCR5 co-receptor blocking, which interrogates virus binding and the cis 
route of trans infection, decreases trans infection (64). This suggests that HIV-1 attachment to 
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APC via direct or indirect facilitators of cis infection is important for subsequent trans infection. 
DC-SIGN is known to mediate cis infection of cells by HIV-1 (81), as well as other viruses,
including dengue virus (100) and ebola virus (101). The absence or blocking of DC-SIGN, 
known to mediate HIV-1 binding and endocytosis, can prevent trans infection of HIV-1 from 
DC to CD4+ T cells (74). Although DC-SIGN has historically been considered a DC specific 
marker, IL-4 and CD40L activation of B cells induces DC-SIGN expression in approximately 
10% of B cells (68), and it is essential for B cell trans infection of HIV-1 (68). In vivo, DC-SIGN 
is constitutively expressed on MΦ in lymph nodes (102), as well as adult lung and uterine tissue 
(103). In vitro, macrophage-stimulating colony factor (M-CSF) differentiation (104) or 
granulocyte-macrophage colony-stimulating factor (GM-CSF) differentiation and IL-13 
stimulation (105) of MΦ also induce DC-SIGN expression. Although MΦ expression of DC-
SIGN is well documented, the role of DC-SIGN in MΦ-mediated HIV-1 trans infection in the 
context of disease progression has not been determined. 
2.3 CHOLESTEROL AND HIV-1 
2.3.1 Cell Function. 
Cholesterol is a naturally occurring lipid that is an essential component of all mammalian 
cells (106). It is required for cell survival and plays a role in many structural and biological 
functions of the cell (107, 108). Cholesterol is the primary component of PM lipid rafts, along 
with sphingolipids and various other proteins (109, 110). Lipid rafts serve as regions of stability 
in the membrane thereby influencing membrane fluidity, trafficking, protein sorting, as well as 
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cell – to – cell interactions and signaling (111-113).  Cholesterol metabolism and cellular storage 
play a well- documented role in cardiovascular disease (114). Cholesterol loaded cells, such as 
macrophages, are primary components of arterial plaques and atherosclerosis, the main cause of 
cardiovascular disease (115). In addition, alternations in cholesterol are implicated in several 
forms of cancer (116), as well as diabetes and Alzheimer’s disease (117). Additionally, many 
viruses have come to both indirectly and directly take advantage of the presence of cholesterol in 
host target cells. Determining the ways in which cellular cholesterol impacts disease viral 
infections and subsequent outcomes requires an understanding of how cholesterol homeostasis, 
trafficking and compartmentalization occurs within cells. 
2.3.2 Cellular Cholesterol Homeostasis. 
Cellular cholesterol metabolism relies on an intricate balance of cholesterol uptake, efflux, 
and intracellular synthesis. Cholesterol enters cells as part of low density lipoprotein 
(LDL) complexes. LDL and oxidized LDL are endocytosed into early endosomes mediated by 
their respective receptors, the LDL receptor (LDLR) and CD36 (118, 119). Within endosomes, 
oxidized LDL is reduced by cholesterol esterase into unesterified free cholesterol (FC) and 
oxysterols. The majority of FC is incorporated in cellular membranes, primarily the PM (120). 
When intracellular cholesterol levels rise, oxysterols act as a ligand for nuclear receptors, such as 
PPARg, LXRs, and RXRs, which when bound initiate transcription of cholesterol transporter 
proteins ABCA1 and ABCG1 which can actively transport cholesterol to the PM for efflux of 
excess FC out of the cell to acceptor high density lipoprotein (HDL) complexes (121). FC can 
also passively diffuse from the PM to acceptors (122). Alternatively, when intracellular levels of 
cholesterol are low, absence of FC in the endoplasmic reticulum activates sterol regulatory 
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element-binding proteins (SREBPs) which increases LDLR production and expression on the 
cell surface to aid in cholesterol uptake (123).  
FC is commonly converted to esterified cholesterol, or cholesterol esters, in order to be 
more effectively packaged into lipoprotein complexes. Once cholesterol is effluxed to an 
acceptor, such as Apolipoprotein rich HDL and LDL complexes, it is transported to other parts of 
the body.  HDL then facilitates cholesterol excretion through reverse cholesterol transport 
(RCT). The removal of cholesterol from plaque imbedded cells by HDL through RCT is an 
important natural mechanism of reducing atherosclerosis (124, 125). Once RCT is accepted from 
cells, it is transported by HDL through the blood to the liver from which it is excreted through 
the urinary tract directly as cholesterol or after conversion to bile acid (126).  
Alternatively, cholesterol can be synthesized de novo within in cells by the mevalonate 
pathway. More specifically, cholesterol is generated from acetyl CoA mediated by the rate 
limiting HMG-CoA reductase, followed by a series of 19 enzymatic reactions (127). Cholesterol 
synthesis is regulated by the presence of absence of sterols detected in the cells.  In the absence of 
FC in the endoplasmic reticulum, activated SREBPs also initiate intracellular de novo cholesterol 
synthesis by inducing HMG CoA reductase synthesis (123). 
2.3.3 Cholesterol and HIV-1 Infection. 
Cellular cholesterol is required for HIV-1 cis (128, 129) and trans infection (130) and is 
therefore likely essential for HIV-1 pathogenesis. In addition, cholesterol has been implicated in 
mechanisms of infection for many other viruses (131-140). Cholesterol within APC and target 
cell membranes, as well as the virions, has been shown to play a crucial role in HIV-1 binding, 
fusion, and entry of target cells (128, 129, 141, 142) as well as HIV-1 endocytosis by APC.  
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The role of cholesterol in HIV-1 cis infection has been thoroughly studied.  The 
concentration of cholesterol in cells targeted by HIV-1, as well as the envelope of the virus 
affects cis infection efficiency. Cholesterol content in cell PMs is important for HIV-1 binding. 
CXCR4 and CCR5 coreceptor functional integrity requires cholesterol in membrane lipid rafts 
(143, 144), and cell membrane cholesterol depletion leads to an increase in resistance to both R5- 
and X4- tropic HIV-1 infection (129). Furthermore, sufficient cholesterol and lipid rafting is 
important for the function of endocytosis mediating receptors. For example, DC-SIGN localizes 
in cholesterol-rich lipid rafts on the cell surface (50) and relies on rafting to for efficient 
internalization of ligands (50, 145). Additionally, cholesterol in the virus envelope is required for 
fusion with the target cell membrane and subsequent infection (128). In fact it has been shown 
that HIV-1 virions prefer to bud from PM areas rich in lipid rafts (22).  
Glycosphingolipid content of the cell membrane from which the HIV-1 virion is derived 
dictates the ability of immature and mature DC to trans infect the virus (146).  In addition to 
independently mediating HIV-1 binding (142), cholesterol is implicated in HIV-1 uptake by APC 
and trans infection. Increased cholesterol efflux through the activation of PPARg and LXR 
significantly decreases DC trans infection of HIV-1 to CD4+ T cells (130). Previously, our lab 
identified a relationship between APC cholesterol, HIV-1 trans infection, and disease 
progression. More specifically, significantly lower DC and B cell cholesterol content was 
associated with a complete lack of HIV-1 trans infection by NP DC and B cells (17). While 
extensive work has characterized the association of cholesterol with binding, entry, and budding 
of HIV-1 particles from target CD4+ T cells, few studies have analyzed the mechanisms by which 
cellular cholesterol content controls the course of HIV-1 passage through APC in the setting of 
trans infection. Analyzing virus-APC interactions in NP compared to PR and SN will 
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provide insight into disease progression of these individuals. More importantly, it will help 
identify essential components of trans infection that might serve as therapeutic targets for 
preventing HIV-1 progression to AIDS, elimination of the latent HIV-1 reservoir, or ultimately 
virus clearance. 
2.3.4 Statin Alterations of HIV-1 Infection. 
Several studies and clinical trials have analyzed the potential uses of statins as an HIV-1 
therapy. Statins have been assessed for their ability to lower chronic inflammation and immune 
activation associated with HIV-1 infection (147-149), combat cART-associated dyslipidemia and 
cardiovascular disease risk (150, 151), as well as decrease overall mortality in HIV-1 
seropositive individuals (152). To date, these studies collectively suggest that the use of statins 
does not significantly augment current HIV-1 treatment regimes. However, a recent study found 
that individuals currently taking statins have fewer documented cases of viral rebound after 
therapeutic viral suppression (153). Importantly, these studies were all conducted on groups of 
HIV-1 infected individuals on cART and a more recent study has shown that cART drugs 
significantly alter statin pharmacokinetics, including SIMV (154). In cART naïve individuals, 
statin treatment reduces viral load, which rebounds after statin interruption (155). Since cell-to-
cell transmission reduces the susceptibility of HIV-1 to cART (14) there is a need for novel 
therapeutics that target HIV-1 trans infection in addition to cART. However, further re-
evaluation of the effect of statins is required to determine their potential as an anti-HIV-1 
therapeutic. 
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2.4 MACROPHAGES AND HIV-1 
2.4.1 Multifunctional MΦ. 
MΦ are immune cells with great functional diversity. In addition to aiding in immune 
surveillance and responses they are important for the removal of necrotic cell debris, wound 
healing, and lipid metabolism (156). Coincidentally, MΦ are implicated in the pathophysiology 
of noninfectious diseases such as ischemic heart disease (157), multiple sclerosis (158), diabetes 
(159), kidney disease (160), asthma (161), among others (162). In addition to their involvement 
in noninfectious disease, they are targeted by several viruses (163-168), including HIV-1 (65). 
Secondary to the CD4+ T cell, MΦ are the primary cells infected by HIV-1 and are involved in 
HIV-1 pathogenesis and disease progression. Due to their central location at the intersection of 
HIV-1 infection, cholesterol metabolism, and the anti-HIV-1 immune response, MΦ serve as an 
avenue by which the interaction of these factors can be studied.  
2.4.2 Front Line Defense and Antigen Presentation. 
MΦ are prominent and efficient phagocytic and antigen presenting cells. Following 
differentiation from monocytes, a small percentage of MΦ remain in the blood and circulate 
through the body, while the majority translocate into peripheral tissue where they continually 
survey the extracellular environment through pinocytosis. They also engulf larger constituents of 
the extracellular space, such as protein complexes, exosomes, and even pathogens, through 
phagocytosis (169). Additionally, they mediate active receptor mediated endocytosis of a number 
biological complexes, as well as pathogens (170-172). Their expression of pathogen recognition 
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receptors, such as DC-SIGN and Toll-like receptors, allows for efficient detection of intact 
pathogens on the surface and within endocytosed vesicles, as well as in the cytoplasm following 
infection.  
Following pathogen detection, MΦ aid in the recruitment of other immune cells to the 
site of infection through the induction of an innate proinflammatory response. Intracellular 
pathogens are then processed into peptide antigens for presentation by class I and class II MHC 
molecules as MΦ migrate out of the tissue and through the blood and lymph system to lymphoid 
organs rich in lymphocytes. MΦ then return to the peripheral tissue were they reside and 
continue surveillance (173).  
Some MΦ reside in the outer sinus of lymphoid organs on guard for entering cell-free or 
cell-associated pathogens, and retroviruses traveling to lymph nodes can be picked up by 
macrophages and passed in trans to B cells in follicles (72), which may aid in the entry to HIV-1 
into lymph node T cell zones, and ultimately the enhancement of HIV-1 replication. However, 
unlike their antigen presenting counterparts, the DC and the B cells, MΦ are crucial for systemic 
processes other than antigen presentation and mounting an effective immune response, such as 
wound healing and cholesterol metabolism. 
2.4.3 Wound Healing and Cholesterol Metabolism. 
MΦ which have internalized excessive lipoproteins, known as cholesterol-rich foam cells, 
are commonly found in arterial plaques and are heavily involved in cardiac plaque development 
(18, 19). More specifically, oxidized LDL (ox-LDL) induces plaque endothelial cell production 
of inflammatory mediators which results in an accumulation of MΦ. An increase in cholesterol 
uptake paired with a decrease in cholesterol efflux leads to MΦ lipid – overloading and foam 
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cells embedding in the growing plaque. Various autocrine and paracrine factors influence foam 
cell formation (174). MΦ ER stress up regulates CD36 expression and subsequent foam cell 
formation (175), and extracellular factors such as ox-LDL and the cytokine thymic stromal 
lymphopoietin promote MΦ lipid accumulation by increasing CD36 mediated cholesterol uptake 
and decreasing ABCA-1 mediated cholesterol efflux (176, 177). Anti-atherosclerotic therapies 
designed to decrease foam cell formation target these factors and their mechanisms (178). 
However, HIV-1 has mechanisms that decrease cholesterol efflux from infected cells to maintain 
higher cholesterol content which increases cell susceptibility to infection and is beneficial for 
progeny virions, as previously discussed. More specifically, the HIV-1 encoded protein nef alters 
MΦ ability to maintain cellular cholesterol homeostasis by binding ABCA1 and thereby 
decreasing RCT (179).  
2.4.4 MΦ and HIV-1. 
MΦ are the primary targets for CCR5 coreceptor using, or R5-tropic HIV-1 strains (180). 
In response, MΦ target virus for degradation, induce IFN-mediated immune responses, and 
express HIV-1 restriction factors, such as APOBEC3G and SAMHD1 (see “HIV-1 restriction 
factors and therapies”), which limit virus replication as previously discussed. However, HIV-1 
have developed mechanisms to negatively regulate such MΦ antiviral measures.  HIV-1 encoded 
vpr protein can block MΦ degradation of the newly synthesized viral env protein (181). MΦ 
comprise up to 10% of HIV-1 infected cells in infected individuals (182), and although MΦ were 
one of the first cells types shown to trans infect CD4+ T cells with HIV-1 (183), their cholesterol 
content and trans infection ability has not been studied in association with HIV-1 disease 
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progression. Due to their intimate interactions with T cells, the role of MΦ in trans infection may 
be of paramount importance for HIV-1 replication, persistence, and pathogenesis.  
2.5 A ROLE FOR MIRNA IN HIV-1 DISEASE PROGRESSION 
2.5.1 miRNA – Health and Disease. 
MicroRNA (miRNA) are endogenous small non-coding RNA sequences, commonly 
between 21 and 25 nucleotides long, that act to silence and in some cases enhance the expression 
of genes by interfering with protein expression post transcriptionally. Mature miRNA are 
generated from longer per-miRNA transcribed and processed in the nucleus into 70nt with a stem 
loop structure. Once processed into mature miRNA, they are translocated to the cytoplasm where 
they interact with mRNA prior to translation along the ER. miRNA most commonly bind to the 
3’ untranslated region (UTR) of the target mRNA, without altering coding regions and repress 
subsequent translation (184), known as RNA interference (RNAi). Perfect complementary 
binding of miRNA causes cleavage of the target mRNA by the RNA-induced silencing complex 
(RISC) associated with the miRNA (185). When a miRNA does not have sufficient 
complementary binding, translation of the mRNA is repressed without cleavage (186). 
 MiRNA encoded by human cells play important roles in the regulation of gene 
expression. They influence the differentiation, function, and survival of many cell types 
including B cells (187), T cells (188), endothelial cells (189), natural killer T cells (190), and 
macrophages (191), among others (192). miRNA are also linked to human pathologies, such as 
cancer (193) and neurological disease (194-196). Despite the initial excitement surrounding the 
discovery of miRNA for their therapeutic potential, the development of gene expression altering 
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miRNA treatments has been limited, primarily due to unwanted off-target effects (197). 
However, novel research is progressing the design and use of miRNA for therapy (198).  
Due to their relatively short sequence, mRNA target sequences of many miRNA are 
found in multiple locations within the transcriptome. This allows miRNA to serve multiple 
biological functions. For example, the human miRNA miR-122 targets the NOD2 gene and is 
implicated in Crohn’s disease (199), but also down regulates VEGFC gene expression which has 
positive implications for bladder cancer (200). In addition to their regulation of gene expression 
for normal cell function and homeostasis (192), some human miRNA aid in fighting infections 
and decreasing pathogen burden. 
2.5.2 MiRNA and Cholesterol Metabolism. 
MiRNA are also implicated in cardiovascular disease and atherosclerosis. The 
posttranscriptional regulation of expression of proteins involved in cholesterol metabolism by 
miRNA is a key element in cholesterol homeostasis (201). MiRNA are involved in cholesterol 
sensing, efflux, and uptake by cells.  
Multiple miRNA have been found to target SREBP expression, a protein essential for 
intracellular cholesterol sensing. Interestingly, they act in a positive feedback loop initiated by 
SREBP to inactivate SREBP suppressors. For example, miR-182 lowers protein expression of 
FBXW7 (202) and miR-24 targets INSIG1 (203), two proteins involved in SREBP functional 
suppression. This leads to an increase in SREBP cholesterol sensing ability. 
The two SREBP genes, SREBF1 and SREBF2, which encode proteins SREBP1 and 
SREBP2, contain introns that encode miR-33b and miR-33a, respectively (204). Humans express 
two copies of miR-33, referred to as miR-33a and miR-33b. The SREBP-1 proteins are primarily 
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involved in lipogenesis, while SREBP-2 proteins are more involved in cholesterol metabolism 
(205). Consequently, miR-33a co-regulates cholesterol efflux through the down regulation of 
ABCA1 expression in human cells thereby decreasing ABCA1-mediated cholesterol efflux 
(206). MiR-33 expression in MΦ also plays a role in MΦ differentiation, as well as metabolism, 
which is particularly pertinent in the development of atherosclerosis (207). In fact, anti-miR-33a 
treatment studies have demonstrated that in the absence of miR-33a, cholesterol efflux from cells 
increases from human cells, and miR-33a knockout results in decreased arterial plaque 
progression in mice (208). Additionally, miRNA are now considered viable targets for novel 
atherosclerosis treatments (209). Other miRNA, such as miR-144 (210) and miR-26 (211), are 
known to target and down regulate protein synthesis of ABCA1. Alternatively, LXR negatively 
regulates cholesterol efflux through inducing the synthesis of miR-613 from SREBP-1c, which 
in turn inhibits expression of LXR, thereby decreasing ABCA1 synthesis and cholesterol efflux 
(212). 
In addition to cholesterol efflux, miRNA have been implicated in the uptake of 
cholesterol. When miRNA down regulate the activity of SREBPs, expression of cholesterol 
synthesis and uptake genes, such as HMG CoA reductase and the LDL receptor, controlled by 
SREBPs are also down regulated due to their regulation by SREBPs (213). Additionally, miRNA 
can directly target proteins that mediate cholesterol uptake. For example, miR-27a and miR-133a 
directly target and decrease expression of the LDL receptor (214) and CD36 (215), respectively. 
Due to their extensive regulation of cholesterol metabolism, miRNA likely play a role in 
cholesterol homeostasis differences observed in APC of NP and PR.  
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2.5.3 MiRNA and HIV-1 Infection. 
Since the discovery of the therapeutic potential of miRNA, the relationship between 
miRNA and HIV-1 infection and disease has been studied. Individual miRNA, as well as 
miRNA profiles are associated with host cell – HIV-1 interactions, susceptibility to HIV-1 
infection, the immune response to HIV-1 infection, as well as disease progression. 
Understanding the role of miRNA in HIV-1 infection and disease is essential for determining if 
they can be targeted or used in treatment.  
MiRNA profiles during HIV-1 infection. 
Several studies have demonstrated that host miRNA profiles are altered following HIV-1 
infection, however the manner in which is unclear. More specifically, the expression of miRNA 
involved in the regulation of cell proliferation, apoptosis, and immune activation, is altered in 
PBMC following HIV-1 infection (216). This suggests that altered miRNA profiles may be 
involved in immune dysregulation during infection. Additional work further suggests that the 
down-regulation of miRNA is more abundant than up-regulation in PBMC after HIV-1 infection 
and that highly abundant miRNA associated with T cell function were down-regulated  (217).  
However, it is unclear whether changes in miRNA profiles are caused by the host 
response to infection or the virus directly. Changes in miRNA profiles proceeding HIV-1 
infection can be an indirect result of the physiological and immunological response to exposure 
to the pathogen. Alongside mRNA expression, ex vivo activation or inactivation of CD4+ T cells 
with anti-CD3 or IL-10, respectively, can alter miRNA expression (217). Alternatively, HIV-1 
proteins can directly mediate miRNA expression. The presence of HIV-1 nef in cells, as well as 
excreted in exosomes, is associated with altered miRNA profiles in the cells and exosomes, and 
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nef containing exosomes are enriched for miRNA that target genes involved in immune 
activation and inflammation (218). It is possible that regulation of cellular miRNA expression 
and excretion through exosomes is another mechanism by which HIV-1 regulates the host 
response in favor of virus survival. This suggests that host miRNA play a role in determining 
HIV-1 – associated disease. 
MiRNA and HIV-1 associated disease. 
Since miRNA profiles change in response to HIV-1 infection and studies and HIV-1 can 
directly influence miRNA expression, it is becoming clearer that the mechanism of gene 
expression regulation mediated by miRNA is paramount to HIV-1 – host interactions. 
Additionally, more evidence is mounting for a role of miRNA in host susceptibility to HIV-1 
infection, as well as subsequent vial pathogenesis and disease progression.  
MiRNA expression is also associated individual susceptibility to HIV-1 transmission. A 
recent study revealed that HESN peripheral blood mononuclear cells (PBMC) and plasma have 
unique miRNA expression profiles that differentiate them from other healthy seronegative 
individuals and HIV-1 seropositive individuals. HESN express significantly higher levels of 
miRs-29a, 138, 150, 190, and 223 compared to HIV-1 positive individuals. More importantly, 
HESN express higher levels of miR-29a and miR-223 compared to healthy control (219), 
suggesting that these two miRNA are implicated in protecting HESN from infection.    
Host cell susceptibility to HIV-1 infection varies by cell type. In some cases, this is a 
result of lack of expression of essential factors for infection, such as the primary receptor and co-
receptors. Yet, while MΦ are highly susceptible to infection in vitro and in vivo, the monocytes 
from which they are derived are far less susceptible despite their expression of the HIV-1 
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receptor and co-receptors (220). In one study, circulating monocytes from healthy individuals 
were found to express high levels of miRNA known to limit HIV-1 replication (220). However, 
another study found anti- HIV-1 miRNA were up-regulated in MΦ rather than monocytes (221). 
Due to such contradictory findings, the extent to which miRNA dictate HIV-1 restriction is not 
clear. Overall, the literature suggests that miRNA play a more general role in HIV-1 infection 
rather than serve as primary determinants of cell susceptibility (222). 
MiRNA have been further implicated in disease progression and the development of 
HIV-1 associated diseases. In addition to influencing the induction of HIV-1 latency (223), 
miRNA have been studied for their contribution to natural control of disease. Studies comparing 
HIV-1 seropositive progressors and nonprogressors or controllers revealed that there are miRNA 
profile differences in such groups (217, 224). These studies contributed to our understanding of 
miRNA profiles in individuals based on serostatus and disease state. Houzet et.al. assessed 
PBMC of PR, LTNP, and VC with unknown therapy status, while Reynoso et.al. assessed 
PBMC and plasma from EC and healthy seronegatives. These studies have contributed to our 
understanding of miRNA profiles in individuals based on serostatus and disease state, however a 
comprehensive study of therapy naïve NP is required for better insight into the role of miRNA in 
natural disease control in the absence of cART.  
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3.0  STATEMENT OF PURPOSE 
Globally, over 35 million people are currently living with HIV-1, and cART fewer than 
5% of seropositive individuals can naturally control HIV-1 infection and prevent progression to 
AIDS. NP represent an enigma in the field of HIV-1 and serve as a natural model of HIV-1 
disease suppression wherein we can define mechanisms preventing disease progression. Trans 
infection, i.e. transfer of virus from cell-to-cell, of CD4+ T lymphocytes is believed to be a 
crucial event contributing to HIV-1 persistence during cART. APC - mediated trans infection 
yields much higher virus replication in T cells compared to both cis infection of T cells and T 
cell-to-T cell trans infection. This may be particularly pertinent to APC interactions with T cells 
in lymphoid tissue, a prominent location of HIV-1 replication.  
Our lab showed that lower cholesterol content in DC and B cells is associated with a total 
lack of trans-infection in NP (17). In addition to immune surveillance and antigen presentation, 
MΦ are involved in lipid metabolism (156), yet their role in HIV-1 trans infection is unknown.  
We hypothesized that unique differences in MΦ cholesterol content contributes to lower 
association of HIV-1 with MΦ, thereby contributing to the lack of trans infection and 
disease progression characteristic of NP. I proposed three specific aims to identify cholesterol-
associated biological patterns and gene expression determinants of HIV-associated disease 
progression to further elucidate the effect of cholesterol metabolism on HIV-cell interactions 
during cis and trans infection.     
32 
4.0  SPECIFIC HYPOTHESES AND AIMS 
4.1 AIM 1 
Goal: Characterize MΦ cholesterol content and MΦ ability to mediate HIV-1 trans infection of 
CD4+ T cells in SN, NP, and PR 
Hypothesis: Lower MΦ cholesterol content is associated with an inability to trans infect CD4+ T 
cells. 
Methods Summary: MΦ, DC, and B cells were assessed for total cellular cholesterol, as well as 
used for in vitro studies to investigate APC cis and trans infection of CD4+ T cells in SN, NP, 
and PR. To further delineate the mechanism of cholesterol in trans infection, cell membrane – 
associated unesterified (free) cholesterol, and lipid rafting was assessed in MΦ.   
Sub-aims 
4.1.1 Aim 1a. MΦ, DC, and B cell trans infection in SN 
4.1.2 Aim 1b. MΦ trans infection of NP and PR 
4.1.3 Aim 1c. MΦ cis infection (high MOI) SN, NP, and PR 
4.1.4 Aim 1d. Cholesterol characterization in MΦ of SN, NP, and PR 
4.2 AIM 2 
Goal: Investigate the role of cell cholesterol in MΦ trans infection. 
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Hypothesis: Alterations in MΦ cholesterol metabolism influence MΦ-mediated trans infection 
efficiency by regulating MΦ – virus interactions. 
Methods Summary: SN, NP, and PR MΦ were phenotyped by flow cytometry to assess surface 
expression of proteins important in HIV-1 cis and trans infection. Additionally, MΦ cholesterol 
content was manipulated to assess the importance of cholesterol in MΦ – mediated cis and trans 
infection. MΦ binding and internalization of HIV-1 was assessed in NP and PR.  
Sub-aims 
4.2.1 Aim 2a. MΦ phenotyping for known regulators of trans infection 
4.2.2 Aim 2b. SIMV effect on MΦ cis infection 
4.2.3 Aim 2c. SIMV effect on MΦ - mediated trans infection 
4.2.4 Aim 2d. Effect of altered cholesterol homeostasis on MΦ virus binding and 
internalization in NP 
4.3 AIM 3 
Goal: Identify potential mechanisms of differential cholesterol metabolism in NP and PR. 
Hypothesis: Regulators of cholesterol metabolism are differentially expressed in NP and PR 
Methods Summary: RNA extracted from NP and PR MΦ were assessed for mRNA expression 
levels corresponding to proteins involved in HIV-1 trans infection and cholesterol metabolism 
pathways including cellular cholesterol uptake, efflux, and synthesis. MiRNA extracted from NP 
and PR plasma was used to generate and assess miRNA profiles using NanoString technology to 
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identify miRNA that may be involved in disease progression, trans infection, and cholesterol 
metabolism. 
Sub-aims 
4.3.1 Aim 3a. Expression levels of proteins associated with nonprogression by PCR 
4.3.2 Aim 3b. Expression levels of proteins involved in MΦ cholesterol metabolism by 
PCR 
4.3.3 Aim 3c. MiRNA screening of NP and PR plasma by NanoString 
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5.0  RESULTS 
5.1.1 Aim 1a. MΦ, DC, and B cell trans infection in SN 
MΦ-mediated HIV-1 trans infection enhances autologous CD4+ T cell virus production in 
SN 
To establish our model for assessing HIV-1 trans infection mediated by MΦ, we cultured 
monocyte-derived MΦ from 10 SN recruited from the Multicenter AIDS Cohort Study (MACS) 
(Table 1). 
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Table 1. Virological and genotypic characterization of SN, NP, and PR. 
*Years HIV-1 seropositive prior to cART therapy while enrolled in the Multicenter AIDS Cohort
Study (MACS). N/A = not applicable; > indicates individuals were seropositive upon enrollment
into the MACS. Mean CD4+ T cell count and Mean HIV-1 load were calculated from compiled
data from all visits while enrolled in the MACS prior to ART.
MΦ were loaded with a low multiplicity of infection (MOI) of HIV-1 R5-tropic Bal 
(MOI 10-3), followed by co-culture with autologous CD4+ T cells and assessment of HIV-1 p24 
core antigen in cell-free supernatant. We chose to load MΦ with an MOI of 10-3 because it is 
suboptimal for efficient cis infection of CD4+ T cells, yet it is highly effective in APC-T cell 
trans infection (17). Under these conditions, MΦ-mediated trans infection of HIV-1 to 
autologous CD4+ T cells was detected in eight of 10 SN. The trans infection of the eight SN was 
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demonstrated by detectable HIV-1 p24 by 4-12 days of co-culture (Fig.1A). This was 
comparable to our established models of trans infection mediated by activated B cells (Fig. 1B) 
and monocyte-derived DC (Fig. 1C) from the same SN. By day 12 of co-culture, MΦ-mediated 
trans infection of CD4+ T cells was significantly greater (P< 0.05) than virus production in cis 
infected CD4+ T cells (Fig. 1D). Moreover, as seen with MΦ, both B cell- and DC-mediated 
trans infection enhanced overall production of p24 compared to T cell cis infection (Fig. 1E and 
1F). 
Notably, none of the APC types mediated detectable trans infection in the 2 of the ten SN 
tested (SN4 (orange) and SN5 (purple); Figs. 1D, 1E, 1F). These results were confirmed by 
repeated testing of APC from these same MACS participants at different clinic visits.  
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Figure 1. MΦ - mediated trans infection enhances virus production in autologous CD4+ T 
cell in SN. 
(A) SN MΦ (n = 8), (B) B cells (n = 7), and (C) DC (n = 6) pulsed with HIV-1 Bal (MOI 10-3)
were co-cultured with autologous activated CD4+ T cells for 12 days. Supernatant was assessed
for p24 concentration at days 4, 8, and 12. (D) CD4+ T cells pulsed with a higher concentration
of HIV-1 Bal (MOI 10-1) and analyzed for cis infection were compared to MΦ, (E) B cell, and
(F) DC trans infection at day 12. * = p< 0.05. Histograms are expressed as mean + SE.
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MΦ trans infection efficiency is not due to CD4+ T cell susceptibility to HIV-1 infection. 
MΦ loaded with the low concentration of HIV-1 (MOI 10-3) and cultured alone for cis 
infection in parallel to each trans infection experiment demonstrated negative or minimal levels 
of p24 for all SN (Fig. 2A). We also did not detect infection in cis-exposed CD4+ T cells at the 
low MOI (10-3) (Fig. 2B) with the exception of one participant (SN3). As expected, CD4+ T cells 
from all SN, including SN4 and SN5, were susceptible to cis infection with a high concentration 
of HIV-1 (MOI 10-1) (Fig. 2C). Although SN4 and SN5 in the cohort did not support detectable 
trans infection, no correlation was found between MΦ trans infection and autologous CD4+ T 
cell cis infection efficiency (Appendix C, Supplemental Fig. 1). Taken together, these data 
support that both myeloid- and lymphoid-derived APC share a common feature essential for 




(A) MΦ pulsed with HIV-1 Bal (MOI 10-3) were cultured alone to control for MΦ cis infection
in the co-cultures (n = 10). (B) CD4+ T cells were pulsed with HIV-1 Bal (MOI 10-3) as a cis
control and compared to MΦ – T cell co-cultures (n = 10). (C) CD4+ T cells were pulsed with a
higher concentration of HIV-1 Bal (MOI 10-1) as a cis control to assess susceptibility to infection
(n = 10). * = p< 0.05. Histograms are expressed as mean + SE.
Figure 2. MΦ trans infection efficiency is not due to CD4+ T cell susceptibility to HIV-1 
infection. 
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5.1.2 Aim 1b. MΦ trans infection of NP and PR 
MΦ mediate HIV-1 trans infection in PR but not NP 
Previous work from our lab demonstrated that DC- and B cell-mediated trans infection 
was defective in NP while being completely functional in PR (17). Therefore, we sought to 
determine if MΦ-mediated trans infection was also altered in NP compared to PR and SN. We 
assessed trans infection efficiency of MΦ from 5 PR, 5 NP, and 10 SN (Table 1). PBMC 
samples used were acquired while individuals were cART naïve and not taking cholesterol-
lowering medication.  
MΦ exposed to the low concentration (MOI 10-3) of HIV-1 were co-cultured with 
autologous CD4+ T cells for 12 days; co-culture supernatants were assessed over time for HIV-1 
p24 production. Under these conditions, MΦ-mediated trans infection was undetectable in all NP 
tested throughout the 12 days of co-culture, while MΦ from PR were able to trans infect 
autologous CD4+ T cells. In addition, MΦ trans infection in PR was not significantly different 
from that of SN beyond day 4 (Fig. 3A). Cis infection controls of CD4+ T cells alone with the 
low MOI used for trans infection experiments were very low or undetectable in all clinical 
groups (Fig. 3B). However, CD4+ T cells from all PR and NP (Fig. 3C) were susceptible to cis 
infection with a higher MOI (10-1). Taken together, these data show that MΦ derived from NP do 
not efficiently transfer HIV-1 to autologous CD4+ T cells, which are capable of supporting HIV-
1 CD4+ T cis infection, in accordance with our previous DC and B cell data (17).    
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(A) MΦ from PR, NP, and SN were pulsed with HIV-1 Bal (MOI 10-3) and co-cultured with
autologous activated CD4 T cells for 12 days. Supernatant was assessed for P24 concentrations
at days 4, 8, and 12. (B) CD4 T cells were pulsed with HIV-1 Bal (MOI 10-3) as a cis control and
compared to MΦ – T cell co-cultures. (C) CD4 T cells were also pulsed with a higher
concentration of HIV-1Bal (MOI 10-1) as a cis control to assess susceptibility to infection. PR
n=5, NP n=5, and SN n=10. * = p< 0.05. Histograms are expressed as mean + SE.
Figure 3. MΦ-mediated trans infection is negative in NP compared to PR and SN. 
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5.1.3 Aim 1c. MΦ cis infection (high MOI) SN, NP, and PR 
MΦ susceptibility to HIV-1 cis infection is associated with HIV-1 disease progression, but 
not required for HIV-1 trans infection 
As demonstrated in Figs. 1A and 2B, MΦ cis infection was not required for MΦ trans 
infection in SN, as 8 or 10 SN trans infected despite undetectable MΦ cis infection. Next, MΦ 
susceptibility to HIV-1 cis infection was assessed across the three study groups using a higher 
concentration of virus. MΦ were exposed to HIV-1 Bal (MOI 10-1) and cultured for 12 days. 
Four of the 10 SN exhibited detectable p24 by day 12 (Fig. 4A). However, no correlation was 
found between MΦ trans and cis infection efficiency in SN (Appendix C, Supplemental Fig. 
2). MΦ cis infection was only detected in 1 NP (NP2) (Fig. 4B). However, it was detected in 4 of 
5 PR (PR1, 2, 4, and 5) (Fig. 4C). Importantly, when compared at day 12, the magnitude of MΦ 
positive cis infection was significantly higher in PR than NP (Fig. 4D). These findings further 




(A) MΦ from SN, (B) NP, and (C) PR pulsed with HIV-1 Bal (MOI 10-1) were cultured alone
and analyzed by p24 ELISA at days 4, 8, and 12. (D) P24 content was compared from day 12
supernatant of SN (n = 10), NP (n = 4), and PR (n = 5). *p < 0.05.
Figure 4. MΦ cis infection is significantly higher in PR than NP. 
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5.1.4 Aim 1d. Cholesterol characterization in MΦ of SN, NP, and PR 
NP MΦ have lower total cellular than PR 
We have previously shown that alterations in cellular cholesterol metabolism correlate 
with the inability of APC from NP to efficiently trans infect CD4+ T cells (17). Therefore, we 
sought to determine if cellular cholesterol levels in MΦ were linked to HIV-1 trans infection and 
disease progression by quantifying total esterified and unesterified (free) cholesterol. In SN 
participants, total cholesterol was highest in MΦ, which was significantly higher than the B and 
T cells but not significantly different than DC. However, total cholesterol in DC trended lower 
than in MΦ (Fig. 5A). When comparing clinical groups, total cholesterol concentration of MΦ 
was significantly lower in NP than PR (Fig. 5B), suggesting that there is a cholesterol-dependent 
mechanism of trans infection in MΦ, in line with our previous findings in DC and B cells (17).  
(A) Total cholesterol measured by Amplex Red of SN MΦ (n = 10), DC (n = 8), activated CD4+
T cells (n = 10), and activated B cells (n = 8). (B) MΦ total cholesterol content was measured in
NP and PR by Amplex Red.
Figure 5. MΦ have lower total cellular than PR.
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NP MΦ have lower cell membrane-associated cholesterol than PR 
To further elucidate the effect of decreased MΦ cholesterol in NP, we assessed the level 
of cell membrane-associated cholesterol as well as lipid rafting in NP and PR MΦ by flow 
cytometry using filipin III, a naturally occurring fluorescent polyene antibiotic that binds 
unesterified cholesterol (225), and the lipid raft containing GM1 specific marker cholera toxin 
subunit B (CTx-B). Membrane-associated cholesterol was significantly lower in NP MΦ 
compared to that of PR (Fig. 6A). Although some PR MΦ had very high levels of lipid raft 
staining, overall the lipid rafting detection of PR was similar to NP (Fig. 6B). Interestingly, 
despite similar intensities of CTx-B staining in NP and PR, single cell fluorescent images 
(acquired with the Millipore ImageStream X Mark II flow cytometer) revealed more punctate 
“rafting” of the CTx-B staining of PR compared to NP MΦ (Fig. 6C). This suggests lipid rafting 
distribution may indeed be different in NP than PR. Together, these data support that the 
presence of sufficient cholesterol in MΦ, specifically MΦ cell membranes, could be driving MΦ-
mediated trans infection.  
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(A) NP and PR MΦ were exposed to fillipin III for cell membrane cholesterol-specific labeling
and analyzed by flow cytometry.  (B) MΦ were exposed to CTx-B for lipid raft labeling and
analyzed by flow cytometry with a Millipore ImageStream. (C) Representative images of NP and
PR MΦ labelled with CTx-B analyzed using an ImageStream.
Figure 6. NP MΦ have lower cell membrane-associated cholesterol than PR. 
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5.1.5 Aim 2a. MΦ phenotyping for known regulators of trans infection 
The number of DC-SIGN expressing MΦ correlates with trans infection efficiency 
To identify potential factors influencing MΦ trans and cis infection efficiency, MΦ were 
phenotyped by flow cytometry. To assess MΦ differentiation, CD16 expression, which is low on 
monocytes and high on macrophages (226), was compared on CD14+ monocytes (Day 0) and 
cultured macrophages (Day 7). A significant increase in CD16 expression levels (mean 
fluorescence intensity or MFI) was observed in the cultured macrophages (Fig. 7A and 7B).  
 
(A) Gating strategy and live cell selection for MΦ phenotype by flow cytometry. (B) CD16
surface expression level (MFI) of SN CD14+ monocytes (Day 0) and cultured MΦ (Day 7) was
assessed by flow cytometry (n = 9). Histogram is expressed as mean + SE.
Figure 7. M-CSF stimulates MΦ differentiation from CD14+ monocytes. 
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Trans infection of CD4+ T cells is believed to occur by two different, but not mutually 
exclusive, pathways following DC or MΦ exposure to virus: (1) through rapid virus uptake via 
endocytosis into vesicles, and (2) 48h after de novo infection (16). Because MΦ are both 
susceptible to cis infection with R5-topic HIV-1 and capable of trans infection, cells were 
analyzed for classic markers associated with cis infection as well as HIV-1 endocytosis. MΦ 
surface expression of the primary HIV-1 receptor CD4, and co-receptor CCR5 for R5-tropic 
HIV-1Bal, was analyzed. CD4 expression level was significantly lower in HIV-1 infected NP 
compared to SN, and similar to MΦ expression in HIV-1 infected PR, while CCR5 expression 
was similar among the three groups (Fig. 8A). The C-type lectin, DC-SIGN facilitates 
endocytosis-mediated HIV-1 trans infection (68, 74). The sialic acid binding adhesion molecule, 
Siglec-1 has also been implicated in HIV-1 trans infection (75). Surface expression of both DC-
SIGN and Siglec-1 was also assessed on MΦ. Expression levels of both glycoproteins did not 
differ among the three groups (Fig. 8B). However, a significantly lower percentage of NP MΦ 
were DC-SIGN positive compared to PR, while no difference was seen in the percentage of 
Siglec-1 positive cells (Fig. 8C). MFI of all four markers was variable within SN (Fig. 8A and 
8B). Both cholesterol and DC-SIGN staining appeared dimmer in NP compared to SN and PR 
(Fig. 9).  Collectively, these data suggest that the lack of MΦ-mediated trans infection seen in 
NP is associated with the expression of DC-SIGN, known to be involved in HIV-1 attachment 
(74, 227) and endocytosis (69). 
50 
 
(A) Representative fluorescence intensity histograms and individual mean fluorescence intensity
(MFI) of MΦ measured by flow cytometry at culture day 7 for surface expression of CD4,
CCR5, (B) CD209 (DC-SIGN), and CD169 (Siglec-1). (C) Percentage of MΦ displaying surface
expression of DC-SIGN and Siglec-1 was analyzed by flow cytometry and compared among SN
(n = 9 or 10), NP (n = 5), and PR (n = 5). *p < 0.05.
Figure 8. The number of DC-SIGN+ MΦ is lower in NP compared to PR. 
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Representative images from SN, NP, and PR MΦ labelled with Filipin III (blue) and DC-SIGN 
(green) followed by imaging using confocal microscopy.  
Figure 9. NP MΦ have lower cell membrane-associated cholesterol than PR. 
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MΦ trans and cis infection of HIV-1 are facilitated by DC-SIGN 
In addition to observed differences in the number of MΦ expressing DC-SIGN in NP 
compared to PR, the number of DC-SIGN+ MΦ positively correlated with trans infection 
efficiency in SN (Fig. 10A). To investigate further the role of DC-SIGN in HIV-1 trans 
infection, antibody blocking experiments were done as detailed in Materials and Methods. 
Blocking of DC-SIGN prior to virus exposure reduced MΦ susceptible to cis infection by 72% 
compared to isotype- treated MΦ by day 12 (Fig. 10B).  In addition, blocking DC-SIGN on MΦ 
prior to virus exposure and co-culture with autologous CD4+ T cells reduced MΦ trans infection 
by 87% by day 12 (Fig. 10C). Blocked MΦ stained negative for DC-SIGN by flow cytometry 
compared to isotype-treated MΦ, supporting a successful occlusion of DC-SIGN (Fig. 10D). 
These data indicate that a DC-SIGN-dependent mechanism of MΦ-virus engagement is pivotal 
for both MΦ cis and trans infection.   
 
(A) SN MΦ- mediated trans infection efficiency and percentage of DC-SIGN positive MΦ were
assessed for association by linear regression (p = 0.0280, F = 7.177, R2 = 0.4729) (n = 10). (B)
Anti-DC-SIGN and isotype control treated SN MΦ were pulsed with HIV-1 Bal, MOI 10-1, and
Figure 10. The number of DC-SIGN+ MΦ is positively correlated with MΦ-mediated cis 
and trans infection efficiency. 
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cultured alone, or with MOI 10-3 and cultured with autologous CD4+ T cells to assess cis (C) and 
trans infection, respectively (n = 5). (D) SN MΦ were treated with a monoclonal antibody 
against CD209 (DC-SIGN) or an isotype control then assessed by flow cytometry for DC-SIGN 
detectability (n = 2).  *p < 0.05. Histograms are expressed as mean + SE.  
5.1.6 Aim 2b. SIMV effect on MΦ cis infection 
SIMV decreases MΦ cis infection 
It has previously been shown that SIMV decreases total cholesterol and HIV-1 trans 
infection ability of DC and B cells. To test the role of cholesterol in MΦ trans infection, we 
assessed whether SIMV, an inhibitor of cholesterol synthesis, would interfere with MΦ cis or 
trans infection. For this, MΦ treated with SIMV prior to virus exposure were used in cis and 
trans infection assays, as described in the Materials and Methods. Cis infection of MΦ was 
significantly decreased by 90% (Fig. 11).  
SN MΦ left untreated or treated with 1ug/ml SIMV for 24 hours were assessed for cis infection. 
(n = 4). (C) *p < 0.05. Histograms are expressed as mean + SE.  
Figure 11. SIMV lowers MΦ cis infection. 
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5.1.7 Aim 2c. SIMV effect on MΦ - mediated trans infection 
SIMV decreases MΦ trans infection 
MΦ-mediated trans infection trended down sharply (Fig, 12A; p=0.06) in the presence of 
SIMV. We then assessed the impact of SIMV on the ability of MΦ to enhance infection of CD4+ 
T cells in trans compared to cell free CD4+ T cell cis infection. Consistent with our data in Fig. 
1D, untreated MΦ loaded with HIV-1 significantly enhanced infection in trans compared to 
CD4+ T cell cis infection by day 12 (Fig. 12B). However, SIMV-treated MΦ were unable to 
enhance infection in trans compared to cis infection in four of five SN samples tested (Fig. 12C). 
Although SIMV did not completely abrogate MΦ cis or trans infection, in both cases SIMV 
treatment lead to a decrease in P24 production. Most importantly, SIMV blocked the ability of 
MΦ to significantly enhance infection of CD4+ T cells compared to cis infection.  
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(A) SN MΦ left untreated or treated with 1ug/ml SIMV for 24 hours were assessed for trans
infection. (n = 4). (B) Untreated and (C) SIMV-treated MΦ (MS) trans infection was compared
to autologous CD4+ cis infection at day 12. *p < 0.05. Histograms are expressed as mean + SE.
SIMV decreases DC-SIGN-expressing MΦ in a cholesterol-mediated manner 
DC-SIGN RNA levels determined by RT-PCR were not different among SN, NP and PR
(Fig. 13A). We sought to determine if SIMV treatment decreased trans infection by altering DC-
SIGN protein expression on the surface of MΦ. SN MΦ treatment with SIMV followed by DC-
SIGN analysis by flow cytometry revealed that SIMV decreased the number of DC-SIGN+ MΦ 
compared to untreated cells (Fig. 13B). SIMV is a known competitor of HMG CoA reductase 
Figure 12. SIMV lowers MΦ trans infection. 
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and, in addition to serving as a source from which cholesterol is derived, HMG-CoA reductase 
also mediates protein prenylation in cells (228).  Statins are known to interfere with this pathway 
in addition to cholesterol synthesis (229). Therefore, to elucidate which pathway SIMV was 
altering DC-SIGN expression, SIMV-treated MΦ were simultaneously treated with either 
squalene or geranylgeranyl pyrophosphate (GGpp), downstream products of the cholesterol 
synthesis and protein prenylation pathways, respectively. GGpp and squalene both abrogated the 
effect of SIMV on the number of DC-SIGN+ MΦ, however the number of DC-SIGN+ MΦ 
trended higher with the squalene treatment compared to GGpp (Fig. 13C).  
 
 
(A) Total RNA extracted from SN, NP, and PR MΦ was used to measure DC-SIGN gene
expression by RT-PCR. CT of DC-SIGN probe was subtracted from the CT of RNA polymerase
II probe within each sample for a relative ∆CT value. (B) SN MΦ were untreated or treated with
1ug/ml SIMV (n = 5), or in the presence of (C) SIMV and GGpp or SIMV and squalene for 24
Figure 13. SIMV decreases the number of DC-SIGN+ MΦ and trans infection in a 
cholesterol dependent manner. 
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hours prior to analysis for DC-SIGN surface expression by flow cytometry (n = 4). Histograms 
are expressed as mean + SE. *p < 0.05. 
Cholesterol repletion recovers MΦ trans infection in NP and SN. 
Due to the lack of trans infection observed by SN4 and SN5 (Figs. 1D, 1E, 1F), in order 
to further assess their similarity to NP, we compared their cholesterol levels and DC-SIGN 
expression. SN5 MΦ had lower levels of both DC-SIGN (Fig. 14A) and total cholesterol when 
compared to SN4 (Fig. 14B). To further assess whether altered cholesterol is responsible for the 
lack of MΦ trans infection in NP, we next tested whether squalene or GGpp could recover trans 
infection in SN4, SN5, and NP. Additionally, squalene, but not GGpp, recovered MΦ-mediated 
trans infection in SN5 but not SN4 (Fig. 14C). Squalene treatment of MΦ recovered detectable 
trans infection in NP (Fig. 15). Therefore, SN5 was both functionally and phenotypically similar 
to the NP group, while phenotyping suggests SN4’s lack of trans infection is likely caused by a 
mechanism independent of cholesterol metabolism. This also strongly supports that low 
cholesterol in NP MΦ contributes to their inability to trans infect HIV-1. 
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(A) Percent of DC-SIGN+ MΦ and (B) total cholesterol of SN4 and SN5. (C) Day 12 trans
infection with untreated or 24 hour GGpp- or squalene-treated SN4 and SN5 MΦ (Two
independent experiments). Histograms are expressed as mean + SE. *p < 0.05.
Figure 14. Squalene recovers MΦ-mediated trans infection in SN with low cholesterol. 
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Day 12 trans infection with untreated or 24 hour squalene-treated NP MΦ (n = 2). Histograms 
are expressed as mean + SE.  
Figure 15. Squalene recovers MΦ-mediated trans infection in NP. 
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SIMV alters membrane-associated cholesterol and lipid rafting in MΦ 
To further understand how SIMV alters MΦ cholesterol content and the role of 
cholesterol in MΦ-mediated trans infection, we analyzed the abundance of total cellular 
cholesterol compared to membrane-associated cholesterol in SIMV-treated MΦ. Total 
cholesterol content of SIMV-treated MΦ did not decrease across a wide range of SIMV 
concentration tested (0.5 – 10ug/ml) (Fig. 16A). However, cell membrane-associated cholesterol 
was lowered by SIMV (Fig. 16B) as demonstrated by analysis of cells treated with filipin III. 
Fluorescent CTx-B labeling of untreated and SIMV treated MΦ showed that SIMV also 
significantly reduced PM lipid rafting (Fig. 16C). Intriguingly, visualization of filipin III 
cholesterol staining revealed a remarkable dissociation of cholesterol clustering or rafting after 
SIMV treatment and confirmed that cholesterol rich lipid rafting was also lowered in SIMV-
treated MΦ (Fig. 16D). These data suggest that SIMV effectively mimics the altered cholesterol 
state of MΦ observed in NP, the mechanism by which we propose SIMV significantly decreases 
HIV-1-mediated trans infection.  
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(A) SN MΦ were treated with 0.5, 1, 5, or 10ug/ml of Simvastatin and tested for total cholesterol
concentration by Amplex Red (n = 2) and (B) cell membrane cholesterol-specific staining with
Filipin III by flow cytometry (n = 2). (C) MΦ were treated with 0.5, 1, 5, or 10ug/ml of
Simvastatin, exposed to CTx-B, and analyzed by confocal microscopy to quantify lipid rafting (n
= 2). (D) Representative images from SN MΦ untreated or treated with 1ug/ml SIMV followed
by Filipin III labeling (purple) and imaging with the Millipore ImageStream. *p < 0.05.
Histograms are expressed as mean + SE.
Figure 16. SIMV alters MΦ lipid rafting. 
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5.1.8 Aim 2d. Effect of altered cholesterol homeostasis on MΦ virus binding and 
internalization in NP 
NP and PR MΦ bind similar amounts of HIV-1 
Our data thus far indicate that DC-SIGN is playing a role in HIV-1 interactions with 
macrophages. To further understand the role of virion – MΦ interactions in HIV-1 disease 
progression we assessed HIV-1 binding to MΦ. CCR5 – tropic HIV-1 binding trended lower in 
NP MΦ but was not significantly different compared to PR MΦ (Fig. 17A) as has been 
previously demonstrated (230). However, confocal microscopy visually supported less virus 
binding in NP (Fig. 17B). 
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(A) NP and PR MΦ were exposed to 12ng  p24 of AT-2 inactivated CCR5-tropic HIV-1 per 0.5
x 106 cells for 2 hours at 4°C, lysed, and analyzed for bound p24 by ELISA (n = 4). (B)
Representative DIC and fluorescent images from SN MΦ treated with RFP-tagged AT-2
inactivated CCR5-tropic virus (red) for binding assays analyzed by confocal microscopy. *p <
0.05. Histograms are expressed as mean + SE.
Figure 17. MΦ binding of HIV-1 trends lower in NP. 
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NP MΦ internalize less HIV-1 into early endosomes 
DC-SIGN is known to mediate endocytosis of intact HIV-1 virions into early endosomes
(81). We next assessed HIV-1 internalization into NP and PR MΦ. We found that significantly 
less HIV-1 was internalized into NP MΦ (Fig. 18A). Additionally, very little internalized virus 
was visible in NP by confocal microscopy, however internalized virus was more abundant in PR 
and co-localized with early endosomes (Fig. 18B). Once we determined the associations of less 
virus binding and internalization into NP MΦ, we assessed whether binding and internalization 
was lower in the 2 SN that lack MΦ trans infection. Intriguingly, both binding and 
internalization of virus to and into MΦ was lower compared SN with efficient trans infection 
(Fig. 19). Together these data show that virus – MΦ interactions, specifically virus 
internalization into early endosomes, play a role in MΦ – mediated trans infection and thereby, 
disease progression.  
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(A) NP and PR MΦ were exposed to 12ng X p24 of AT-2 inactivated CCR5 - tropic HIV-1 per
0.5 x 106 cells for 2 hours at 37°C, trypsinized, lysed, and analyzed for internalized p24 by
ELISA (n = 5). (B) Representative DIC and fluorescent images from SN MΦ treated with RFP-
tagged AT-2 inactivated CCR5-tropic virus (red) for virus internalization assays, co-stained for
early endosomes (green), and analyzed by confocal microscopy. *p < 0.05. Histograms are
expressed as mean + SE.
Figure 18. NP MΦ internalize less HIV-1 into early endosomes. 
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MΦ from trans infection positive and trans infection negative SN were assessed for virus 
binding and internalization by p24 ELISA. *p < 0.05. Histograms are expressed as mean + SE.  
Figure 19. SN MΦ lacking trans infection bind and internalize less HIV-1. 
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5.1.9 Aim 3a. Expression levels of proteins associated with lack of trans infection in NP by 
PCR 
Palladin, Siglec-10, and CD1β are not differentially expressed in NP and PR MΦ 
Archived transcriptome data generated from DC, B cells, and CD4+ T cells from 8 NP 
and 8 PR was used to identify genes and protein involved in the function of these cells in HIV-1 
progression. At the transcriptome-wide level, no genes were significantly differentially expressed 
in B cells and CD4+ T cells of NP and PR. However, multiple genes were differentially 
expressed in NP and PR DC. The top three identified were siglec-10, palladin, and CD1β (Fig. 
20), however only Palladin and CD1β were verified by PCR (completed by Marilee Clunk, et.al. 
unpublished). cDNA corresponding to Palladin and CD1β was generated from total RNA 
isolated from SN, NP, and PR MΦ was pre-amplified and further tested for expression levels by 
RT-PCR. Palladin mRNA levels were not different in NP and PR (Fig. 21A). CD1b was not 
found to be expressed in all of the MΦ samples. Intriguingly, CD1b expression was found in 




Viremic controller (VC) in this study is equivalent to NP. 
Figure 20. Transcriptome-wide analysis of NP and PR DC. 
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(A) Total RNA extracted from NP and PR MΦ was used to measure Palladin (PALLD) mRNA
by RT-PCR. Histograms are mean of technical triplicates + SE. (B) CD1β mRNA levels were
assessed by RT-PCR and expressed as the number of samples with CD1β expressing MΦ. NP (n
= 7) and PR (n = 6). *p < 0.05.
Figure 21. Fewer PR express CD1β than NP. 
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5.1.10 Aim 3b. Expression levels of proteins involved in MΦ cholesterol metabolism by 
PCR 
PR MΦ express higher levels of PPARg mRNA 
A focused analysis of cholesterol metabolism genes from archived transcriptome data 
from NP and PR DC also revealed that mediators of cholesterol efflux, including PPARγ and 
ABCA1 are differentially expressed in NP and PR (Fig. 22). We next sought to identify the 
mechanism by which levels of FC were being regulated differentially in NP and PR.  cDNA 
corresponding to sterol regulatory element-binding protein (SREBP), ATP-binding cassette 
transporter 1 (ABCA1), ATP Binding Cassette Subfamily G Member 1 (ABCG1), low density 
lipoprotein receptor (LDLR), liver X receptor alpha (LXRa), peroxisome proliferator-activated 
receptor gamma (PPARg), 3-Hydroxy-3-Methylglutaryl-CoA reductase (HMGCR), 
apolipoprotein E receptor 2 (APOER2), CD36, liver X receptor beta (LXRb), and CD1b was 
generated from total RNA isolated from SN, NP, and PR MΦ was pre-amplified and further 
tested for expression levels by RT-PCR. We found that PPARg expression was significantly 
higher in PR than NP and SN, and LDLR expression trended higher in NP (p = 0.08) (Fig. 23A). 
Expression of SREBP, ABCA1, ABCG1, LXRα, HMCGR, APOER2, CD36, and LXRβ were 
not significantly different among the 3 clinical groups (Fig. 23A).  
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Viremic controller (VC) in this study is equivalent to NP. 
Figure 22. Focused analysis of cholesterol metabolism genes in NP and PR DC. 
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(A) Total RNA extracted from NP and PR MΦ was used to measure SREBP, ABCA1, ABCG1,
LDLR, LXRα, PPARγ, HMGCR, APOER2, CD36, and LXRβ mRNA by RT-PCR. Histograms
are mean of technical triplicates + SE.  *p < 0.05.
Figure 23. PR MΦ express higher levels of PPARγ mRNA. 
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5.1.11 Aim 3c. MiRNA screening of plasma and APC by NanoString 
Based on the important role of miRNA in cholesterol metabolism and the link between 
cellular cholesterol homeostasis and HIV-1 trans infection, it is possible that the miRNA 
expression profile of NP and PR influence their trans infection efficiency and natural 
progression pattern. Since our targeted PCR data revealed very few inherent differences in MΦ 
gene expression of proteins directly involved in cholesterol uptake, synthesis, and efflux in our in 
vitro cultures we hypothesized that an extracellular plasma factor, such as miRNA, may 
influence MΦ cholesterol homeostasis in NP and PR. We sought to characterize the expression 
profile of miRNA in the plasma of 9 NP and 9 PR. Total RNA was extracted from NP and PR 
plasma and tested using human v3 miRNA Assay (NanoString Technologies). Four samples (2 
NP and 2 PR) were excluded from analysis due to variances caused by undetectable hemolysis 
and subsequent red blood cell miRNA contamination. Following normalization of the remaining 
7 NP and 7 PR samples, miRNA expression patterns revealed that the NP clustered in two 
distinct groups (Fig. 24A) indicating the NP studied may be further categorized based on 
miRNA profiles. Intriguingly, we compared average CD4+ T cell count and viral load of all 
MACS visits prior to cART initiation of the two NP clusters and found that the clusters 
significantly differed in total CD4+ T cell counts (Fig. 24B), but not viral load (Fig. 24C).  
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(A) Total RNA isolated from NP (n = 7) and PR (n = 7) plasma was tested using the NanoString
Human V3 miRNA Assay. MiRNA with at least 135 counts/ml were included in the heat map.
Gene clustering on the Y axis, as well as NP (red) and PR (green) sample clustering on the X
axis was determined using Wards Minimum Distance.  (B)  Collective CD4+ T cell count and (C)
viral load prior to cART were compared among the NP in cluster #1 (n = 4; left side of heat map)
and cluster #2 (n = 3; right side of heat map).
We next analyzed differences in miRNA expression of all NP and all PR tested. The top 
10 expressed miRNA were very similar in NP (Table 2) and PR (Table 3). The majority of 
miRNA expressed in NP and PR appeared similar and highly correlated (Fig.25), however 
several outliers suggested there were differentially expressed miRNA in NP and PR (Fig. 25, red 
arrows). We next performed a comparative analysis of miRNA profiles of NP and PR plasma. 
Two miRNA. MiR-29b-3p and miR-376a-3p, were significant differentially express in NP and 
Figure 24. NP cluster into two groups based on miRNA profiles. 
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PR. Three additional miRNA with known effects on cholesterol metabolism, miR-150-5p, miR-
144-3p, and miR-148-3p, were expressed in NP and PR, however total counts were not
significantly different (Table 4). We then investigated known human gene interactions of these 
five miRNA. miR-29b-3p has been experimentally validated to interact with 86 human 
transcripts (Appendix B, Fig. 29), miR-376a-3p with 12 human transcripts (Appendix B, Fig. 
30), miR-150-5p with 28 human transcripts (Appendix B, Fig. 31), miR-144-3p with 25 human 
transcripts (Appendix B, Fig. 32), and miR-148a-3p with 40 human transcripts (Appendix B, 
Fig. 33). These data represent preliminary results meant to screen for potential miRNA 
implicated in cholesterol metabolism in NP and PR. Future studies are planned to further mine 
the vast amount of data generated by the NanoString miRNA assay. Additionally, PCR 
validation of the differentially expressed miRNA identified and in vitro studies are also planned 
to further elucidate the role of these miRNA in APC cholesterol metabolism and HIV-1 trans 
infection.  
Table 2. The 10 most highly expressed miRNA in NP plasma. 











aInput = 3ul of total RNA; equivalent to 150ul plasma. 
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Table 3. The 10 highest expessed miRNA in PR plasma. 











aInput = 3ul of total RNA; equivalent to 150ul plasma. 
Average Log2 miRNA counts expressed in NP (n = 7; open circles) plasma compared to PR 
plasma (n = 7; closed circles) quantified using the NanoString Human V3 miRNA Assay and 
nSolver software.  
 Figure 25. Correlation between NP and PR expressed miRNA. 
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Table 4. Differentially expressed miRNA comparing NP and PR. 
Log2 FC = Log2 fold change using PR as the reference value. P value is unadjusted from an 
unpaired two-tailed T test with a Welch’s correction.   
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6.0  MATERIALS AND METHODS 
6.1 ETHICS STATEMENT 
Biological samples were acquired and studied from consented individuals according to 
University of Pittsburgh International Review Board approved protocols. All recruited 
participants were over the age of 18 and provided written consent prior to sample collection or 
use. 
6.2 PARTICIPANT SELECTION 
We studied three groups of individuals (Table 1) within the Multicenter AIDS Cohort 
Study (MACS) and/or Pitt Men’s Study (PMS) defined based on their HIV-1 serostatus and 
associated disease progression: (1) (PR) – HIV-1 seropositive individuals with a 100 cells/mm3 
annual decrease in CD4+ T cell count prior to cART (2) NP – HIV-1 seropositive individuals 
displaying a lack of progression to AIDS and CD4+ T cell count above 500 for at least 7 years 
post seroconversion without the aid of cART based on either CD4+ T cell count. (3) (SN) – 
healthy HIV-1 negative individuals whose serostatus is checked twice a year (17). We recruited 
10 SN, as well as 5 PR and 5 NP not on cART at the time of study or with frozen samples 
available prior to cART initiation. Participant reported data was used to rule out the use of 
cholesterol or lipid lowering medications during the time points of samples studied. HLA-type 
and CCR5 ∆32 genotype were considered for all participants as possible confounders of disease 
progression classification.  
79 
6.3 CELLS AND VIRUSES 
6.3.1 Cell Isolation 
CD4+ T lymphocytes, B lymphocytes, and monocytes were positively enriched from 
freshly isolated or frozen peripheral blood mononuclear cells (PBMC) (fresh from consented 
Pittsburgh MACS participants, or frozen from the MACS repository) using anti-CD4, CD19, or 
CD14 monoclonal antibody (mAb)-coated magnetic bead separation (Miltenyi Biotech), 
respectively, according to manufacturer’s instructions. 
6.3.2 APC and T cell culture 
MΦ and DC were derived from monocytes cultured with 20ng/ml M-CSF (Peprotech) for 
7 days or 1000U/ml GM-CSF (Miltenyi Biotech) and 1000 U/ml rhIL-4 (R&D systems) for 5d, 
respectively, in AIM-V medium (Gibco). CD4+ T cells and B cells were activated for 48 hours in 
RPMI with 10U/ml of delectinated IL-2 and 2ug/ml PHA (16) or 1000U/ml rhIL-4 and 0.1ug/ml 
CD40L, respectively. 
6.3.3 Viruses 
R5-tropic HIV-1 BaL grown in and purified from PM1 cells (American Type Culture 
Collection) (65), were used for cis and trans infection experiments. Virus stock titration and 
experimental p24 measurements were acquired by ELISA using the HIV-1 p24 Antigen Capture 
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Immunoassay kit (Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer 
Research), per manufacturer’s instructions. 
6.4 TRANS INFECTIONS 
Briefly, 1x106 APC were incubated with a low concentration of HIV-1 (MOI 10-3) for 2 h 
at 37C, then washed 3 times with medium. Virus-pulsed APC were co-cultured with autologous 
activated CD4+ T cell targets at a 1:10 effector : target ratio (104 : 105) in AIM-V medium, and 
p24 was quantified in cell-free supernatants at days 4, 8, and 12 post co-culture.  
6.5 CIS INFECTIONS 
Briefly, 1x106 APC or activated CD4+ T cells were incubated with low (10-3) or high (10-
1) MOIs of HIV-1 and cultured independently. P24 was quantified in cell-free supernatants at
days 4, 8, and 12 post co-culture. 
6.6 CELL PHENOTYPING 
Cells were assessed for surface and intracellular protein expression. MΦ were incubated 
with an amine binding viability dye using the LIVE/DEAD® Fixable Aqua Dead Cell Stain Kit 
(Molecular probes) for 20 minutes, then incubated with isotype controls or monoclonal 
antibodies against CD4 - V450, CD14 - APC-H7, CD16 - APC-H7, CCR5 – PE, CD169 – 
BB515 (BD Biosciences) and CD209 – APC or FITC (R&D Systems) diluted in wash buffer 
(PBS supplemented with 0.1% FBS and 0.1% NaN3) for 30 minutes. Cells were then 
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permeabilized with Perm II (BD Biosciences) for 20 minutes and labelled intracellularly with 
anti-CD68 – BV421 (BD Biosciences) for 30 minutes. Cells were fixed in 1% PFA, acquired 
with the BD LSRFortessa, and analyzed with FlowJo v10. Fluorochrome compensation was 
performed using Anti-Mouse Ig, κ/Negative Control Compensation Particles Set (BD 
Biosciences) and ArC Amine Reactive Compensation Bead Set (Thermo Fisher) prior to 
acquisition.  
6.7 CELLULAR CHOLESTEROL QUANTIFICATION 
6.7.1 Total cellular cholesterol 
Cultured cells were washed two times with PBS to remove any residual media and lysed 
with 200ul of 0.1% triton X-100 for total cellular cholesterol quantification using the Amplex 
Red Cholesterol Assay Kit as per manufacture’s instruction (Thermo Fisher). Total cholesterol 
content was normalized to total cellular protein quantified with the Micro BCA Protein Assay 
Kit as per manufacturer’s instructions (Thermofisher). Briefly, total cholesterol (ug) was divided 
by total protein (mg) for each sample. 
6.7.2 Membrane-associated cholesterol 
Cultured cells were analyzed for membrane-associated cholesterol using filipin III from 
the Cholesterol Cell-Based Detection Assay Kit (Cayman Chemical), as per manufacturer’s 
instructions, and analyzed by flow cytometry or confocal microscopy. For flow cytometric 
analysis, cells were incubated with viability dye, labelled filipin III, re-suspended in 1% PFA, 
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acquired with the BD LSRFortessa, and analyzed with FlowJo v10, or acquired with the EMD 
Milipore Amnis ImageStreamX and analyzed with IDEAS 6.2. For confocal microscopy 
analysis, MΦ were grown in glass bottom dishes coated with poly-D-lysine (MatTek). Cells were 
fixed and labeled with filipin III reagent according to the manufacturer’s instructions. Cells were 
additionally stained for DC-SIGN with an anti-CD209 – FITC (BD Biosciences) were noted. 
Cells were acquired on a Nikon A1 confocal microscope at 40X with a 3.42 zoom at the 
University of Pittsburgh Center for Biological Imaging and analyzed using NIS Elements. 
6.7.3 PM lipid rafts 
In addition to cholesterol specific labels, the GM1 ganglioside was labelled using 
Vybrant ® Alexa Fluor ® 488 Lipid Raft Labeling Kit (Molecular Probes) and analyzed by flow 
cytometry or confocal imaging. Integrated density was calculated with ImageJ2 from an average 
of five cells per image using five images per sample. 
6.8 CHOLESTEROL SYNTHESIS AND PROTEIN PRENYLATION STUDIES 
6.8.1 Statin Treatment and Recovery 
MΦ were washed free of AIM-V media after 6d of culture then treated for 24 h with a 
range of concentrations (0.5 – 10ug/ml) of SIMV (Sigma) in RPMI supplemented with charcoal-
stripped FBS (Gibco) and M-CSF prior to downstream assays. 
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During 24 hour incubation with SIMV, cells were simultaneously treated with squalene 
(Sigma) to recover cholesterol, or GGpp (Sigma) to recover protein prenylation blocked by statin 
treatment. Cells were then washed extensively prior to use in downstream assays. 
6.8.2 Cholesterol repletion 
After day 7 of culture, MΦ were incubated with 300 ug/ml of soluble cholesterol in BCD 
(Sigma) for 2 hours, then washed prior to use in downstream assays. 
6.9 CDNA PRE-AMPLIFICATION AND RT-PCR 
Total RNA was extracted from MΦ with the RNeasy Mini Kit (Qiagen) and cDNA was 
generated as per the manufacturer’s instructions. cDNA corresponding to human DC-SIGN, 
SREBP, ABCA1, ABCG1, PPARγ, LXRα, LXRβ, LDLR, CD36, HMG-CoA reductase, APOE 
receptor 2, and CD1β was pre-amplified using the TaqMan PreAmp Master Mix Kit (Applied 
Biosystems) as per manufacturer’s instructions. CD1β was also pre-amplified using IDT Taq-
Man® primers (primer 1: 5'ACTTTTGGGCTGATATCTT GGG-'3; primer 2: 5'-
CTTCCTTGCTCCTTTTGCTATG-'3; probe: 5'-/56-FAM/CTCATG 
GGA/ZEN/TCTGATATGACCGGCG/31ABkFQ/-3'). Pre-amplified cDNA was then used for 
RT-PCR using Taqman® Gene Expression Assays (Applied Biosystems) (SREBP- 
Hs01088679_g1; ABCA1- Hs01059137_m1; ABCG1- HS00245154_m1; PPARγ- 
Hs01115513_m1; LXRα- Hs00172885_m1; LXRβ- Hs01027215_g1; LDLR - Hs00181192_m1; 
CD36- Hs00354519_m1; HMGCR- Hs00168352_m1; and APOER- Hs00182998_m1) and 
TaqMan Universal Master Mix II, no UNG. RNA polymerase 2 (RNA pol2) was amplified from 
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each sample as an internal control. ∆CT values were calculated by subtracting averaged CT 
values of the gene of interest from the RNA pol2 CT within each sample.   
6.10 VIRUS BINDING AND INTERNALIZATION STUDIES 
6.10.1 Virus Binding 
MΦ were incubated with 12ng of p24 per 0.5 x 106 cells of AT-2 inactivated BaL HIV-1 
for 2 hours at 4C, washed extensively with cold PBS, pelleted, and lysed with 0.1% triton X 100. 
Cell lysates were assessed for p24 content by ELISA. For confocal analysis, cells were incubated 
with AT-2 inactivated RFP-tagged BaL HIV-1 for 2 hours at 4C, washed, mounted, and analyze 
by confocal microscopy.  
6.10.2 Virus Internalization 
MΦ were incubated with 12ng of p24 per 0.5 x 106 cells of AT-2 inactivated CCR5 – 
tropic HIV-1 for 2 hours at 37C, washed extensively with PBS, trypsinized to remove surface 
bound virus, pelleted, and lysed with 0.1% triton X 100. Cell lysates were assessed for p24 
content by ELISA. For confocal analysis, CellLight™ Early Endosomes-GFP, BacMam 2.0 
(ThermoFisher) was added to on day 6 of culture and incubated overnight. Cells were then 
washed and incubated with AT-2 inactivated RFP-tagged CCR5-tropic HIV-1 for 2 hours at 37C, 
washed, mounted, and analyze by confocal microscopy. 
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6.11 HUMAN MICROARRAY 
Total RNA was extracted from cultured NP and PR DC using the RNeasy Mini kit 
(Qiagen), per manufacturer’s instructions and used to assess mRNA levels with the HumanHT-
12 v4 Expression Bead Chip (illumina). Normalization of data was performed with Lumi 
software, and the heatmap was generated using the Limma software package in Bioconductor.   
6.12 MIRNA STUDIES 
6.12.1 MiRNA Extraction and Testing 
Plasma samples used were archived samples initially collected from heparinized blood 
tubes and frozen at -80C. Frozen plasma samples were thawed and stored on ice until use. 
Sample volumes of 600ul were microcentrifuged for 10 minutes at 500g to remove cell debris. 
Supernatant was collected and store on ice until RNA extraction. Total RNA was extracted using 
the Plasma/Serum RNA Purification Midi Kit (Norgen Biotek) as per manufactures instructions. 
Two synthesized spike-in nonhuman control miRNA (Table 5) were used to control and 
normalize for extraction variation in downstream assays (Integrated DNA Technologies). 
Table 5. Synthetic miRNA spike-in controls for NanoString Human v3 Assay. 
miRNA Sequence Length Accession Number
ath-miR159a UUUGGAUUGAAGGGAGCUCUA 21aa MIMAT0000177
cel-miR-248 AUACACGUGCACGGAUAACGCUCA 24aa MIMAT0000304
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Following the addition of the lysis buffer from the extraction kit, the sample was 
incubated at room temperature for 5 minutes. Then 20pg of each spike-in was added to each 
sample prior to continuation of the extraction protocol. Extracted RNA was diluted to 420ul with 
RNase free water, added to an Amicon Ultra-0.5 Centrifugal Filter Unit with a 3 kDa cut off, and 
microcentrifuged at 14,000 rcf for 90 minutes. The column was inverted and transferred to a 
fresh collection tube and microcentrifuged at 8,000 rcf for 2 minutes. Eluted volume was brought 
to 20ul with RNase free water if needed. Extracted RNA (3ul) was analyzed using the Human v3 
miRNA Assay (NanoString Technologies) and quantified using the nCounter® MAX Analysis 
System to assess counts of a panel of approximately 770 human miRNAs derived from miRBase. 
The assay was performed by the University of Pittsburgh Genomics Research Core.  
6.12.2 NanoString Data Analysis 
Raw NanoString RCC data files were analyzed using nSolver v3.0 Software. Technical 
negative and positive controls for counting and ligation were used to normalize for slight 
variances in counting and ligation across the samples. Spike-in counts were also used to 
normalize for extraction variances across samples. Log2 fold change values were generated 
using the PR group as the reference. Significant differences in miRNA counts between NP and 
PR calculated by nSolver were generated with a student’s two-tailed T test with a Welch’s 
correction.  
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6.12.3 MiRNA gene interaction networks and visualization 
Gene ontology and microRNA gene set enrichment networks were generated and 
assessed with miRNet (231). Network visualization were generated with a forced atlas layout.  
6.13 STATISTICAL ANALYSES 
An analysis of variance (ANOVA) was used to determine overall significant differences 
between SN, NP, and PR samples for trans infection, cis infection, phenotyping, and cholesterol 
content. ANOVA testing was followed by a post hoc test when required. A two-tailed Student t-
test will be used for comparisons of less than three groups. MiRNA assay statistical testing is 
described above under “NanoString Data Analysis”. 
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7.0  DISCUSSION 
Highly efficient trans infection of HIV-1 from APC to CD4+ T cells may contribute to 
disease progression. Previously, we found that altered cholesterol homeostasis is linked to poor 
DC and B cell HIV-1 trans infection of CD4+ T cells in NP (17). However, the extent to which 
trans infection by other APC, such as MΦ, is implicated in HIV-1 disease progression, and the 
mechanisms by which cholesterol is differentially regulated in individuals with different disease 
progression patterns is unknown.  
Given the intimate interactions between MΦ and T cells in lymphoid tissue (232), and 
previous reports that MΦ from SN mediate HIV-1 trans infection (21, 183), we sought here to 
determine if MΦ trans infection would also be deficient in NP. Due to the central role of MΦ in 
cholesterol metabolism we also sought to determine the role of cellular cholesterol in MΦ HIV-1 
trans infection ability, and what potential mechanisms regulate cholesterol homeostasis in NP 
compared to PR. Through this work, we showed for the first time that MΦ HIV-1 trans infection 
was deficient in NP and thus associated with lack of disease progression. Additionally, the 
mechanism of poor MΦ trans infection of autologous CD4+ T cells observed was a result of 
altered cell cholesterol homeostasis. We further demonstrated that NP MΦ had significantly less 
FC and PM lipid rafting, which lead to fewer DC-SIGN expressing MΦ and lower virus 
internalization into MΦ, resulting in a lack of trans infection. Lastly, we identified several 
miRNA differentially expressed in NP and PR plasma that may serve as regulators of cholesterol 
homeostasis in NP and PR.  
Collectively our data support they hypothesis that cholesterol-facilitated MΦ trans 
infection of HIV-1 to CD4+ T cells could be implicated in HIV-1 disease progression. Here I 
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discuss how our data, in concert with previous studies, illuminate the ways in which MΦ – 
mediated trans infection can contribute to HIV-1 infection, pathogenesis, and disease 
progression. Additionally, I discuss some potential mechanisms by which cholesterol facilitates 
trans infection and how targeting these pathways may have therapeutic value. 
Analysis of in vitro models of HIV-1 trans infection 
Studying trans infection in vivo poses several technological challenges. Identifying trans 
infection as a mechanism by which T cells become infected requires evidence of cell-to-cell 
passage of virus. Visualizing this transfer of virus requires live cell imaging and is limited to 
animal models. However, in vitro methods have been used to study trans infection for decades, 
and although they have been beneficial, many of them have also been flawed. We eliminated 
these flaws with our in vitro model of HIV-1 trans infection used in these studies. 
MΦ – mediated trans infection of HIV-1 has previously been demonstrated by multiple 
groups, using several in vitro models. However, early methods did not use purified or activated 
CD4+ T cells as trans infection targets (183) or differentiate well between monocyte-derived MΦ 
and DC (183, 233). By the use of activated, purified CD4+ T cells and M-CSF-differentiated MΦ 
derived from purified CD14+ monocytes, our model eliminated this ambiguity.  
Past trans infection in vitro models were unable to differentiate between different routes 
of trans infection. Trans infection is thought to occur through two pathways. The first involves 
endocytosis of intact virions which can then be passed between cells through intercellular 
connections, such as nanotubes (78), or regurgitated into a synapse between two immune cells 
(16). The second involves budding of new virions as a result of productive cis infection into a 
similar synapse (16). In prior studies, virus concentrations used for trans infection assays were 
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capable of cis infecting MΦ (130, 183, 233). While MΦ-mediated trans infection likely can 
occur in the presence of high concentrations of virus, using concentrations that result in MΦ cis 
infection enables the discrimination between trans infection resulting following de novo 
infection of MΦ or following endocytosis without productive infection. The model we used (17, 
68), exposed APC to low amounts of virus prior to co-culture with activated CD4+ T cells, and 
allowed us to assess whether HIV-1 uptake by APC, in the absence of APC cis infection, could 
be passed in trans to CD4+ T cells. We showed in SN individuals that MΦ trans infection 
enhanced virus production by autologous CD4+ T cells compared to cis infection of T cells with 
cell free virus. Using this model, our data not only confirmed that MΦ can mediate HIV-1 trans 
infection of CD4+ T cells, but also revealed that the transfer of virus can occur efficiently in the 
absence of MΦ cis infection.  
In vitro trans infection mediated by APC may serve as a potential tool for predicting 
HIV-1 disease progression. Notably, two of the 10 SN (SN4 and SN5) studied here lacked trans 
infection by all three types of APC. We have previously identified lack of APC-mediated trans 
infection as an inherent characteristic of NP, in that trans infection ability is similar pre- and 
post-seroconversion (17), suggesting trans infection could potentially be a predictor of disease 
progression. Indeed, MΦ from one individual (SN5) had cholesterol levels and DC-SIGN 
expression similar to NP, and trans infection efficiency was restored upon recovery of 
cholesterol synthesis but not protein prenylation. Additionally, both SN4 and SN5 exhibited 
lower HIV-1 internalization compared to trans infection efficient SN, However SN4 displayed 
no further NP characteristics, and likely has a cholesterol-independent blockade in the trans 
infection pathway. The high prevalence of impaired trans infection in our SN cohort (20%) 
appears to be a chance anomaly but supports the conclusion that the SN population is 
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heterogeneous and comprised of individuals with genetically determined NP characteristics. 
Therefore, SN lacking trans infection represent a unique group of individuals, from which novel 
factors of HIV-1 disease progression control can be identified.  
MΦ-mediated trans infection and systemic HIV-1 spread 
HIV-1 trans infection is challenging to study and demonstrate in vivo. However, given 
the intimate interactions between APC, such as MΦ, and CD4+ T cells in lymphoid tissue (232), 
it would be advantageous for the virus to utilize its association with  APC to more efficiently 
contact. Our data support the hypothesis that MΦ-mediated trans infection of CD4+ T cells could 
facilitate many stages of HIV-1 infection including host virus entry, inward trafficking, 
amplification, and dissemination. 
Trans infection and acute HIV-1 infection 
DC-SIGN facilitates trans infection of HIV-1 from DC (69, 74), as well as B cells (68),
to CD4+ T cells. DC-SIGN also interacts with and is a receptor for infection of several other 
viruses (100, 101). The C-type lectin is expressed on MΦ in adult lung and uterine tissue (103), 
which suggests that DC-SIGN expressing MΦ could aid in the uptake and trafficking of HIV-1 
from the female reproductive tract. Our data showed the number of DC-SIGN positive MΦ was 
positively associated with disease progression and correlated with the magnitude of SN MΦ-
mediated trans infection in SN, which supports they hypothesis that DC-SIGN-mediated HIV-1 
trans infection could be a mechanism of virus dissemination.  
With immunohistochemistry and live-cell imaging, MΦ have been visualized passing 
retroviruses to B cells in lymph nodes (72). Additionally, follicular CD4+ T helper cells (Thf) 
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have recently been identified as a reservoir of HIV-1, as well as an essential CD4+ T cell subset 
that supports HIV-1 replication and increased viral load (73). Thf are found primarily in lymph 
node T cell regions where they can interact with B cells at the edge of B cell follicles. It is 
possible that HIV-1 passed from MΦ to B cells could be further passed to Thf in primary and 
secondary lymphoid organs, such as the spleen and lymph nodes, which are known major sites of 
HIV-1 replication in vivo.  
DC-SIGN is constitutively expressed on MΦ in lymph nodes (102). We found that the 
number of DC-SIGN surface expressing MΦ was associated with HIV-1 disease progression. 
The percentage of DC-SIGN+ MΦ cultured from PR monocytes was significantly higher 
compared to that of NP, and positively associated with trans infection efficiency in SN, which 
indicates that this characteristic is not an effect of HIV-1 infection. Our data support that DC-
SIGN facilitated trans infection of HIV-1 by MΦ could contribute significantly to infection of 
Thf and the robust amplification of virus typically seen in acute infection upon HIV-1 
dissemination to lymphoid tissue. 
In addition to trafficking to lymphoid tissue, MΦ are one of the few immune cells that 
can gain access to the central nervous system, including the brain. MΦ have been shown to carry 
HIV-1 from the periphery into the brain and microglia, as well as perivascular MΦ support HIV-
1 infection (234). MΦ – mediated trans infection of brain-resident MΦ or neuronal cells could 
assist in virus replication in the brain and the pathology of HAND. Elimination or control of 
HIV-1 in the brain and limiting cognitive impairment associated with HIV-1 is challenging, even 
in the presence of cART (235). Limiting the efficiency of MΦ to carry HIV-1 to the brain pass 
virus in trans could help lower the reservoir of HIV-1 in the brain and potentially improve 
HAND outcomes in infected individuals.  
93 
Trans infection and chronic HIV-1 infection 
In addition to robust virus replication, trans infection at low levels may help aid in 
establishment of the reservoir as well as reservoir maintenance. In SN MΦ, we showed that trans 
infection occurred with high efficiency when MΦ were loaded with a concentration of HIV-1 
insufficient for cis infection of MΦ and CD4+ T cells. Trans infection of HIV-1 can be highly 
efficient and can be a way to reduce the susceptibility of HIV-1 to cART (14). Additionally, 
HIV-1 trans infection can occur in the presence of certain antiretroviral drugs (99). Additionally, 
CD4+ T cells can mediate infection in trans of other CD4+ T cells (236), which could contribute 
further to virus dissemination throughout the body.  
MΦ-mediated trans infection and disease progression 
Due to the intimate interactions between MΦ and T cells in lymphoid tissue (232), we 
hypothesized MΦ trans infection would be deficient in NP. Our data showed that MΦ-mediated 
HIV-1 trans infection was undetectable in NP and therefore associated with HIV-1 disease 
progression. However, the mechanism(s) by which a lack of trans infection influences HIV-1 
disease progression is unknown. Here we speculate the ways in which MΦ-mediated trans 
infection could influence immune activation and CD4+ T cell loss, well-known hallmarks of 
HIV-1 disease progression.  
According to the MACS, NP can be classified by their ability to control viral load or 
maintain healthy CD4+ T cell counts (see introduction section “Disease progression” for more 
detail). However, there is some overlap among subtypes of NP. For example, a healthy CD4+ T 
cell count can be strongly associated with undetectable viral load, therefore some LTNP can 
concurrently be categorized as EC. However, some LTNP maintain healthy CD4+ T cell counts 
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despite detectable and even high viral load. We studied NP with healthy CD4+ T cell counts 
regardless of viral load because CD4+ T cell count is indicative of HIV-1 disease progression. 
They also lack previously determined genetic factors associated with disease progression, and 
therefore represent a valuable population from which novel mechanisms of disease control can 
be identified. However, the heterogeneity of NP clinical characteristics, as well as the collective 
published work studying NP, suggest the manifestation of nonprogression is multifactorial and 
not the same for all individuals. Studying different groups of HIV-1 NP would further our 
understanding of the role of trans infection in HIV-1 disease and progression.  
CD4+ T cell count decline is the primary feature of HIV-1 disease progression to AIDS, 
and the cause of CD4+ T cell loss is believed to be multifactorial. HIV-1 replication and virus-
mediated apoptosis are believed to contribute, however immune activation is more highly 
associated with CD4+ T cell count decline than viral load (237). Additionally, chronic T cell 
activation, characterized by increased expression of HLA-DR, CD38, CCR5, and PD-1, is 
believed to be the primary force driving immune activation (238). In some individuals, a low 
level of virus replication can persist and contribute to chronic immune activation despite therapy 
(239). If HIV-1 trans infection can facilitate low levels of virus replication under cART, it can 
likely contribute to greater immune activation, which is more commonly observed in PR 
compared to NP (240). Consequently, lower activation of CD4+ T cells could result in fewer 
susceptible T cell targets for HIV-1 infection and lower viral load.  
MΦ-mediated trans infection of HIV-1 may also contribute to CD4+ T cell activation and 
HIV-1 – associated pathogenesis in the gastrointestinal tract (GIT). Gut-associated lymphoid 
tissue (GALT) is the primary site of HIV-1 replication in human tissue, an abundant reservoir of 
CD4+ T cells and other lymphocytes, and a major site of CD4+ T cell loss (241). MΦ densely 
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populate the intestinal mucosa, and while gut MΦ are considered less susceptible to HIV-1 
infection compared to their blood-derived counterparts (242), they can carry latent virus, even in 
the presence of cART (243). Interactions between such cells and GALT CD4+ T cells following 
virus uptake by of infection of gut-associated MΦ in the GIT and GALT could promote HIV-1 
trans infection from those MΦ to other cells. Although we analyzed blood-derived MΦ, it is 
likely that gut-resident MΦ trafficking virus to GALT may also be capable of HIV-1 trans 
infection. Therefore, HIV-1 trans infection could be a driving mechanism of virus production 
and subsequent pathogenesis in the GIT and GALT. 
Pyroptosis is a proinflammatory form of cell death induced mediated specifically by 
caspase-1. Pyroptosis of CD4+ T cells undergoing abortive HIV-1 infection can result in chronic 
inflammation and chemo attraction of target CD4+ T cells (244, 245) which could enhance the 
infection of other target cells and further cell death. This process is deemed feasible by 
mathematic models as a mechanism of slow gradual CD4+ T cell decline observed in many HIV-
1 infected individuals (246). Abortive infection as a result of HIV-1 transfer in trans infection 
can occur (247), therefore a lack of APC-mediated trans infection in NP could help decrease 
abortive CD4+ T cell infection and subsequent pyroptosis and thereby maintain healthy cell 
counts.  
Unlike B cells and DC, ex vivo tissue-resident MΦ and in vitro monocyte-derived MΦ are 
susceptible to HIV-1 infection (248), and trans infection can occur when virus is released into 
the infectious synapse following cis infection of a susceptible APC, such as MΦ (see 
introduction section “MΦ trans infection in vitro and in vivo”). As previously demonstrated 
(230), we observed that SN and PR MΦ are significantly more susceptible to cis infection than 
NP MΦ. However, in SN MΦ cis infection did not correlate with trans infection efficiency, as 5 
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of 8 SN with efficient MΦ trans infection had undetectable MΦ cis infection. Therefore MΦ 
susceptibility to cis infection was not required for trans infection. Although it may contribute, 
MΦ susceptibility to cis infection is likely not the sole factor responsible for the complete lack of 
trans infection observed in NP.  
 MΦ replication and production of HIV-1 in tissues can be a  source of virus during AIDS 
development, and the presence of opportunistic infections and interactions of MΦ with such 
antigens can increase MΦ HIV-1 production (249). The greater MΦ cis infection observed in PR 
could provide more virus for trans infection, immune activation, and subsequent CD4+ T cell 
loss throughout disease progression. As concordance with our previous study (17), we 
demonstrated that T cell susceptibility to cis infection was not different in SN, NP, and PR, 
which further supports the hypothesis that altered virus - APC interactions in NP is more likely 
to be responsible for poor trans infection, than a lack of CD4+ T cell susceptibility. Although NP 
CD4+ T cells may produce infectious virus, T cell – to – T cell infection is far less efficient than 
APC – to – T cell infection.  
Collectively, the association of MΦ cis and trans infection with HIV-1 disease 
progression suggests that MΦ interactions with HIV-1 are more complex than that of B cells and 
DC, due to their lack of and low susceptibility to cis infection, respectively. However, since MΦ, 
B cells, and DC display the same trans infection phenotype in NP, trans infection occurring 
following virus endocytosis, the trans infection pathway known to be shared by all three cell 





Cholesterol: A key factor in HIV-1 pathogenesis 
Previously, we showed that altered cholesterol homeostasis is linked to poor DC and B 
cell HIV-1 trans infection of CD4+ T cells in NP (17). In addition to aiding in immune 
surveillance and immune responses during infection, MΦ are heavily involved in lipid and 
cholesterol metabolism (156). MΦ can internalize excessive lipoproteins and become 
cholesterol-rich foam cells (18). Additionally, HIV-1 can alter MΦ ability to maintain cellular 
cholesterol homeostasis through normal necessary cholesterol transport (179). Our cellular 
cholesterol characterization and manipulation data support that MΦ cholesterol shapes trans 
infection efficiency, is associated with nonprogression, and could serve as an target for HIV-1 
therapies.  
MΦ cholesterol content influence on HIV-1 trans and cis infection 
Cholesterol is recognized as an important factor in HIV-1 infection and disease. 
Cholesterol in the PM of target cells is essential for interactions with HIV-1, and in the envelope 
of the virion it aids in virus fusion and determines infectivity (128, 129). However, the impact of 
MΦ cholesterol content on MΦ-mediated trans infection was unknown until now. We showed 
for the first time that treatment of SN MΦ with SIMV decreased MΦ-mediated HIV-1 trans 
infection, and squalene-enhanced cholesterol synthesis recovered MΦ trans infection ability in 
NP. Our data suggest that decreased cholesterol synthesis can hinder trans infection by MΦ, and 
similar to DC and B cells, MΦ can also use a cholesterol-mediated mechanism of trans infection. 
Additionally, our data demonstrated that total cholesterol was lower in NP MΦ than PR MΦ, 
which further supports the relevance of cholesterol in HIV-1 disease progression.  
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Although measuring total cholesterol can provide insight with regard to the overall 
difference in cellular cholesterol metabolism, it can not indicate the presence or location of 
specific cholesterol types, such as esterified and unesterified FC. If not esterified and effluxed, 
FC in the cytosol is rapidly transported to the PM where it contributes to lipid raft formation 
which influences membrane integrity and fluidity, as well as the function of many surface 
proteins (113). We showed NP MΦ had significantly lower FC and membrane lipid rafting than 
PR MΦ. Intriguingly, although SIMV treatment did not decrease MΦ total cholesterol, SIMV 
treatment did significantly decrease MΦ FC, as well as lipid rafting. Together, this suggests that 
PM-localized cholesterol, such as FC-rich lipid rafts, could be a regulator of HIV-1 trans 
infection and serve as a targetable component of MΦ-mediated HIV-1 trans infection.  
Changes in PM fluidity due to altered cholesterol and sphingolipid compositions can alter 
function of many cell surface proteins (110). HIV-1 interacts with several molecules and proteins 
of the MΦ surface, and such virus – cell interactions are essential for both MΦ cis and trans 
infection. This data supports that less lipid rafting in the PM of NP MΦ can result in lower or 
less functional cell surface expression of proteins or molecules important for virus – MΦ 
interactions, such as DC-SIGN mediated virus endocytosis.  
DC-SIGN localizes in cholesterol-rich lipid rafts on the cell surface (50) and relies on
rafting for efficient internalization of ligands (50, 145). Our data showed that SIMV treatment 
lowered the number of DC-SIGN expressing MΦ from SN and trans infection efficiency. 
Additionally, DC-SIGN blocking significantly decreased MΦ trans infection. Furthermore, 
fewer DC-SIGN expressing MΦ were detected in NP compared to PR. Taken together, this data 
support that low FC content of NP MΦ membranes can hinder lipid raft formation and thus 
functional surface expression of DC-SIGN which, in turn, can decrease the efficiency of trans 
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infection in NP (Figs. 27 and 25). Exposure of MΦ to oxidized low density lipoprotein can also 
decrease DC-SIGN expression (250). Due to the reliance of DC-SIGN surface expression and 
function of PM lipid rafting, decreased lipid rafting in NP MΦ could directly hinder proper 
optimal surface expression of DC-SIGN and negatively affect DC-SIGN-facilitated trans 
infection of HIV-1 by MΦ, thereby decreasing disease.  
Decreased host cell PM cholesterol content can decrease surface expression and function 
of CD4 and CCR5 (144, 251, 252). Although we did not see a difference in CD4 or CCR5 
surface expression by NP and PR MΦ, decreased lipid rafting could increase membrane fluidity 
in NP MΦ and decrease function of both proteins contributing to the decreased cis infection 
observed in NP. We postulate that DC-SIGN can enhance cis infection of MΦ, if not by directly 
facilitating viral envelope binding and fusion, then by increasing or stabilizing virus interactions 
on the surface of the cell through interactions with gp120 (253).  
MΦ in peripheral tissue, secondary lymphoid tissue, and the central nervous system can 
harbor HIV-1 (254), and MΦ cis infection can occur in the presence of cART (255). DC-SIGN – 
facilitated cis and trans infection of HIV-1 mediated by the MΦ reservoir in PR could further 
explain persistence and maintenance of the T cell reservoir in such individuals despite cART. 
More generally, this mechanism of trans and cis infection may be hijacked by other viruses to 
enhance viral dissemination as DC-SIGN (100, 101) and cholesterol are important for infection 
of many viruses (131, 132, 256). 
MΦ from 1 of the 4 NP we studied exhibited detectable cis infection, however that 
individual was not capable of trans infection of CD4+ T cells. Others have proposed that despite 
NP susceptibility to HIV-1 infection, the virus subsequently produced by NP may be poor or less 
infectious virus. HIV-1 virions require cholesterol in their envelopes which is derived from the 
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host cell membrane following budding of new virus. Due to the decreased level of FC in the cell 
membranes of NP MΦ, the virus produced from such cells may be less infectious and therefore 
less likely to efficiently infect other cells, including CD4+ T cells, in trans. Although we did not 
test the cholesterol content or infectivity of the virus isolated from NP2 MΦ, it would be of 
interest for future studies.  
A unique challenge of studying the impact of MΦ cholesterol content of HIV-1 produced 
by NP is that because NP CD4+ T cells do not have lower cholesterol content compared to that of 
PR (17), virions produced by NP CD4+ T cells likely have high envelope cholesterol levels and 
good infectivity. Therefore, analysis of the cholesterol content of virus isolated from the blood or 
tissue of NP could lead to spurious results due to the unknown cellular origin of the virus. 
However, testing cholesterol content and infectivity of virus produced by in vitro derived MΦ or 
tissue isolated MΦ from NP would be of interest for future studies, because decreasing virus 
infectivity through manipulation of cholesterol metabolism represents another potential benefit 
of targeting cholesterol with novel HIV-1 therapeutics. 
Importantly, SIMV treatment and DC-SIGN blocking did not completely abrogate MΦ 
trans infection. HIV-1 can bind DC in a cholesterol dependent manner, independently of CD4, 
DC-SIGN, mannose binding C-type lectin receptors, and heparan sulfate proteoglycans
expression (142). While DC-SIGN facilitated trans infection, it is not the only mechanism by 
which MΦ mediate trans infection. CD169 (siglec-1) can mediate the capture of retroviruses by 
macrophages lining the sinus region of LN and virus passage to B cells within LN follicles (72),\. 
However, MΦ CD169 expression was not associated with trans infection in our studies. 
Analyses of MΦ isolated from lymphoid tissue from SN, PR, and NP will help to better 
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understand the role of CD169 expression in HIV-1 trans infection and its relationship to disease 
progression.  
MΦ – virus interactions and HIV-1 trans infection 
Although we have identified a cholesterol - dependent DC-SIGN pathway of MΦ trans 
infection, how disruption of this pathway alters MΦ – virus interactions is unknown. B cells do 
not and DC only minimally support HIV-1 replication. Therefore, we hypothesized that the 
endocytosis pathway of trans infection is likely to be more heavily implicated in HIV-1 disease 
progression as it is the pathway shared by all three APC.  
We previously have shown that DC and B cells binding of HIV-1 was not different in NP 
and PR (17). Here we showed that NP and PR MΦ bound HIV-1 at similar levels, which further 
supports that total virus binding to NP APC is not responsible for altered trans infection. 
Alternatively, we showed that NP MΦ internalized significantly less HIV-1 into early endosomes 
compared to that of PR. Importantly, DC-SIGN has been shown to mediate HIV-1 endocytosis 
into early endosomes (81). Therefore, decreased FC and lipid rafting in MΦ could result in less 
binding of HIV-1 to DC-SIGN and thereby decrease DC-SIGN-facilitated endocytosis and trans 
infection.   
Treating HIV-1 with SIMV 
We showed that SIMV significantly decreased FC, lipid rafting, the number of DC-SIGN 
expressing MΦ, as well as MΦ ability to enhance T cell infection in trans compared to cis 
infection. SIMV is a frequently prescribed FDA-approved drug used to treat 
hypercholesterolemia (257), that could feasibly be repurposed for the treatment of HIV-1 
102 
infection. Statins were beneficial in several HIV-1-focused clinical trials, and could influence 
virus production and immune activation, as well as all the downstream consequences of these 
two factors on nonprogression that we previously discussed.   
Statins have been assessed for their ability to lower chronic inflammation and immune 
activation associated with HIV-1 infection (147-149), combat cART-associated dyslipidemia and 
cardiovascular disease risk (150, 151), as well as decrease overall mortality in HIV-1 
seropositive individuals (152). These studies collectively suggest that the use of statins does not 
significantly augment current HIV-1 treatment regimes. Yet, a recent study found that 
individuals currently taking statins had fewer documented cases of viral rebound after 
therapeutic viral suppression (153). Importantly, all of these studies were conducted on groups of 
HIV-1 infected individuals on cART, but certain antiretroviral drugs can significantly alter statin 
pharmacokinetics (154). Furthermore, a study on the effect of statins in a small group of HIV-1 
infected, therapy naïve individuals, showed a reduction of viral load under statin treatment, 
which rebounded after therapy interruption (155).  
Interestingly, we observed that SIMV treatment decreased the population of DC-SIGN+ 
MΦ without decreasing total MΦ cellular cholesterol. Statins competitively inhibit HMG-CoA 
reductase (258). Although HMG-CoA reductase is an essential enzyme for cholesterol synthesis 
in MΦ, it is also essential for protein prenylation (229). Protein prenylation is a form of lipid 
modification that can increase the ability of proteins to interact with cell membranes (229), and 
statins can decrease HIV-1 release from the monocyte-like U1 cell line by inhibiting the protein 
prenylation pathway (259). We showed that despite an insignificant decrease in total MΦ 
cholesterol following SIMV treatment, recovering cholesterol synthesis, unlike protein 
prenylation, also recovered DC-SIGN surface expression. This data supports that clinical SIMV 
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treatment of HIV-1 infection individuals may also decrease virus replication in this manner and 
positively influence disease outcome. Statins in combination with cART, under alternative 
administration routes less affected by cART drugs, could reduce MΦ dissemination of HIV-1 
and should be reconsidered for prophylaxis and therapy regimens. Manipulation of ABCA-1–
mediated cholesterol efflux with nuclear receptor agonists, or LDLR–mediated cholesterol 
uptake with the herb-derived compound, berberine (260), to decrease cellular cholesterol and 
lipid rafting may serve a purpose similar to SIMV. 
Regulation of cholesterol metabolism in NP APC 
Thus far, I have discussed how MΦ cholesterol content and localization can influence 
HIV-1 trans infection in relation to disease progression. However, in addition to being a 
contributor to HIV-1 infection, MΦ cholesterol content can also be a reflection of HIV-1 
infection. HIV-1 proteins, such as Nef, can interrupt cellular cholesterol homeostasis leading to 
intracellular cholesterol sequestering and an increase in cell-association cholesterol content 
(179). Yet, despite HIV-1 infection, NP MΦ maintain lower levels total cholesterol, FC, and 
lipid rafting than PR, consistent with other APC, such as DC and B cells (17). Therefore, NP 
APC likely have a unique ability to naturally reduce cellular cholesterol or counteract the HIV-1 
mechanisms of cholesterol sequestering. MΦ cholesterol homeostasis requires balancing of 
several mechanisms of cholesterol regulation including cholesterol uptake, efflux, and de novo 
synthesis. Our cholesterol metabolism-associated gene and miRNA expression data provide 
further insight into the pathway(s) through which NP MΦ may maintain a low level of 
cholesterol content during HIV-1 infection.  
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Cholesterol sensing in NP MΦ 
Through cholesterol sensing, a cell can respond to the intra- and extracellular cholesterol 
environment, as well as induce cholesterol uptake, synthesis, or efflux to achieve cholesterol 
levels needed by the cell. Our data support that MΦ from both NP and PR can efficiently sense 
their intracellular cholesterol levels. NP MΦ had greater LDLR gene expression which, in 
response to low cholesterol, could increase cholesterol uptake. Complementarily, PR MΦ had 
greater PPARγ gene expression which, in response to high cholesterol could increase cholesterol 
efflux. Nuclear receptor induced cholesterol efflux by ABCA1 can decrease HIV-1 trans 
infection by DC (130). However, our data suggests that the differential expression of PPARγ by 
NP and PR MΦ is a result of or a response to the different NP and PR MΦ cholesterol content 
rather than the cause of lower cholesterol content and trans infection in NP compared to PR. 
Increased expression of the efflux-mediating cholesterol transport protein, ABCA1 is a 
characteristic of NP DC (17).  
We also observed that more NP had CD1β expressing MΦ, which better equips these 
cells for lipid antigen presentation because MΦ can generate and present lipid-based antigens 
using CD1β. HIV-1 nef and vpr can down-regulate CD1 expression on DC (261), which may 
represent a mechanism used by the virus to evade immune detection of infected cells by CD1-
restricted NKT cells (262). Better lipid antigen presentation by NP MΦ due to a greater 
abundance of CD1β-expressing cells could contribute to better anti-HIV-1 immune responses 
and slower disease progression, two characteristics of NP (263). However, our data assessing 
gene expression levels of essential genes involved in cholesterol uptake, efflux, and synthesis did 
not explain the mechanisms contributing to the differences in cholesterol levels we see in NP and 
PR MΦ either. Exosomes disseminated from HIV-1 infected cells can facilitate HIV-1 trans 
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infection (264), as well as transport proteins and RNAs, including miRNA (265). We 
hypothesized that the low cholesterol state of NP APC is a result of extracellular factors, such as 
miRNA, signaling molecules, or Apolipoproteins, all of which have been shown to alter cellular 
cholesterol metabolism (201, 266, 267).  
MiRNA and HIV-1 non-progression 
Several miRNA can regulate gene expression of proteins involved in human cellular 
cholesterol homeostasis (201, 268, 269), including miR-148a-3p (270, 271), miR-144-3p (272, 
273), and miR-150-5p (274). miR-148a-3p directly negatively regulates LDLR and ABCA1 
expression in Huh7 cells, and in vivo, single nucleotide polymorphisms in the miRNA promoter 
have been associated with altered levels of circulating LDL (275). miR-144-3p can also directly 
target and decrease ABCA-1 levels in hepatic cells and has been associated with a decrease in 
circulating HDL levels (272), indicative of decreased ABCA-1 mediated efflux of cholesterol 
from hepatocytes to extracellular HDL molecules. Our data showed that both miR-148a-3p and 
miR-144-3p expression trended higher in PR plasma compared to NP, which suggests that these 
miRNA could be implicated in the cholesterol metabolism differences in NP and PR APC, 
particularly PR DC which express less ABCA-1 than NP DC (17). MiRNA, such as miR-148a, 
expressed by and released from cells in exosomes could act on cells encountered in circulation, 
and effect MΦ, DC, and B cells. Overall, lower concentrations of circulating miR-148a-3p and 
miR-144-3p in NP, could limit down-regulation of proteins involved in cholesterol metabolism 
leading to higher levels of cholesterol efflux, lower APC cellular cholesterol, and inefficient 
HIV-1 trans infection.    
In addition to regulators of cholesterol metabolism, miR-148a-3p and miR-144-3p have 
been categorized as an immune-related miRNA (273, 276). miR-148a can bind and decrease 
106 
expression of HLA-C, and variance in the HLA-C UTR can decrease miR-148a binding ability, 
and is associated with better HIV-1 control (277, 278). These studies, along with our data, 
suggest that the down-regulation of miR-148a expression therapeutically, may serve to combat 
HIV-1 disease by lowering APC cholesterol, limiting HIV-1 trans infection, and increase HLA-
C-mediated anti-HIV-1 immune responses.  
MiRNA have also been implicated in or associated with HIV-1 pathogenesis and disease 
directly. MiR-29b-3p can reduce HIV-1 production from 293T cells (279) and is essential for IL-
21-mediated suppression of HIV-1 in CD4+ T cells (280). Although we did not observe a
difference in CD4+ T cell production of virus in NP and PR, we described higher expression of 
miR-29b-3p in NP compared to PR plasma, which supports that circulating miR-29b-3p could 
impact HIV-1 disease progression by influencing HIV-1 production by other immune cells such 
as MΦ.  
miR-150-5p can directly target and decrease expression of CXCR4, altering the ability of 
cells to interact with stromal cell-derived factor-1 resulting in a decrease in cell mobility and 
migration (281). MiR150-5p is primarily produced by MΦ and adipose tissue and can decrease 
cholesterol efflux in THP-1 cells through the down-regulation of Adiponectin receptor 2 (274). 
Importantly, down-regulation of adiponectin receptor 2 can induce expression of LXRα and 
thereby APO E production (274). Our data demonstrating an upward trend in miR-150-5p 
expression in NP plasma compared to PR support that an increase in the extracellular cholesterol 
acceptor, APO E, in NP could facilitate increased cholesterol efflux from MΦ, resulting in lower 
MΦ cholesterol in the absence enhanced ABCA-1 expression. 
We also reported significantly higher levels of miR-376a-3p in the plasma of NP 
compared to PR. miR-376a-3p represses insulin-like growth factor receptor (282), and therefore 
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has been proposed as an anti-cancer agent. However, other studies have also found that miR-
376a-3p down-regulates KLF15 (283), a known suppressor of cell proliferation, caspase 3, and 
caspase 8 (283, 284), thereby acting as a potential enhancer of cancer cell proliferation. Although 
there is currently no evidence in the literature that miR-376a-3p is directly involved in HIV-1 
pathogenesis or cholesterol metabolism, miR-376a is significantly lower in the serum of obese 
individuals compared to healthy controls and inversely associated with serum cholesterol and 
LDL-C levels (285), which suggests miR-376a-3p could be involved in cholesterol metabolism 
in ways that have not yet been determined.  
Overall, our miRNA expression data suggest that the miRNA expressed in NP plasma 
that we discussed could cause increased MΦ cholesterol efflux and ultimately lower MΦ FC and 
lipid rafting, if not due to increased ABCA-1 expression, then due to increased production and 
presence of extracellular apolipoproteins (Fig. 26). Additionally, our data support that specific 
miRNA expression profiles of NP plasma could be a factor contributing to lower APC 
cholesterol levels we have observed in NP. Further interrogation of the pathway(s) through 
which NP MΦ maintain a low level of cholesterol content during HIV-1 infection could provide 
greater insight into how we can target trans infection with novel therapies.  
108 
Figure 26. Summary schematic of the potential cholesterol homeostasis pathway 
components targeted by miRNA differentially expressed in NP and PR. 
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Conclusions and future work 
We evaluated the involvement of MΦ-mediated HIV-1 trans infection in disease 
progression, assessed the role of cellular cholesterol in MΦ trans infection efficiency, and 
identified a potential mechanism by which cholesterol homeostasis is differentially regulated in 
NP and PR APC. We showed that MΦ-mediated trans infection is associated with HIV-1 disease 
progression. We also demonstrated the importance of FC and lipid rafting in MΦ for efficient 
DC-SIGN – mediated endocytosis of HIV-1 and subsequent trans infection of CD4+ T cells in
PR, which is lacking in NP (Figs. 27 and 28). Additionally, we showed SIMV treatment not only 
lowered the DC-SIGN+ MΦ population, but also limited MΦ cis and trans infection efficiency, 
two features characteristic of NP. Lastly, we identified differential expression of miRNA 
involved in HIV-1 infection and cholesterol metabolism, miR-29b-3p and miR-376a-3p, in NP 
and PR, which likely contributes to the altered cholesterol homeostasis observed in NP. By 
altering APC cholesterol metabolism we can decrease HIV-1 trans infection and potentially 
further reduce dissemination of virus and the size of the latent reservoir.  
Although significant advancements have been made in our understanding of cholesterol 
regulation of HIV-1 trans infection by MΦ, our data has generated new questions and promising 
leads that need to be further pursed. Future directions for this work include furthering our 
understanding of APC-mediated HIV-1 trans infection in vivo and the methods by which 
cholesterol lower agents can be used to decrease HIV-1 trans infection. Understanding HIV-1 
trans infection in different MΦ types, such as tissue resident and lymph node surveying MΦ, 
may be important for assessing the required reach therapies targeting the elimination of the HIV-
1 reservoir. 
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Further defining the role of cholesterol in lack of HIV-1 endocytosis in NP and targeting 
HIV-1 endocytosis with cholesterol manipulation in PR would also be of interest for future 
studies. Additionally, determining the influence of the miRNA identified by our work on APC 
cholesterol metabolism and trans infection ability through functional studies in vitro would help 
determine if there is a novel role for these miRNA in HIV-1 disease progression and whether 
targeting their expression has anti-HIV-1 therapeutic potential.  
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Figure 27. Schematic of the role of cholesterol in HIV-1 trans infection by MΦ in PR. 
In HIV-1+ PR, 1) unesterified free cholesterol (FC) and esterified cholesterol (EC) are abundant 
in the MΦ and T cell, specifically 2) in the PM where it aggregates to form lipid rafts. 3) 
Abundant lipid rafting allows for abundant DC-SIGN expression on the MΦ surface and HIV-1 
binding. 4) This leads to DC-SIGN - mediated virion endocytosis, intracellular transport, and 
release of virus into the virological synapse where 5) optimal infection of CD4+ T cells occurs in 
trans. At low MOIs, trans infection occurs in the absence of MΦ and T cell cis infection. 
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Figure 28. Schematic of the role of cholesterol in HIV-1 trans infection by MΦ in NP. 
In HIV-1+ NP, 1) MΦ display significantly lower levels of total cholesterol which we 
hypothesize is mediated by extracellular elements such as miRNA, signaling molecules, or 
Apolipoproteins facilitating greater cholesterol efflux. 2) Subsequently, lower levels of FC in the 
PM results in significantly less lipid rafting and DC-SIGN expression. 3) Consequently, DC-
SIGN - mediated virion 4) endocytosis does not occur at a rate sufficient enough to 5) mediate 
CD4+ T cell infection in trans.    
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8.0  PUBLIC HEALTH IMPORTANCE 
Despite the success of combination antiretroviral therapy, neither a vaccine nor a cure for 
HIV-1 infection has been developed, demonstrating a need for novel prophylactic and 
therapeutic strategies to further lower the public health burden of HIV-1 infection. The 
functional breadth of the reservoir of latently infected MΦ under cART is becoming more 
relevant for cure and therapeutic research (286-288). Actively infected MΦ, including DC-SIGN 
expressing MΦ in mucosal membranes (289), transmit and disseminate HIV-1 (248). MΦ-
mediated trans infection is a feasible source of HIV-1 replication and dissemination in the 
presence of very low quantities of virus. Understanding how this cell-to-cell spreading of virus 
by MΦ impacts disease progression is of importance for development of novel treatment and 
curative HIV-1 therapeutics. 
Here we showed that efficiency of MΦ-mediated HIV-1 trans infection of CD4+ T cells 
is a unique characteristic associated with control of disease progression and impaired in HIV-
infected NP. In vitro treatment of MΦ from healthy donors with SIMV lowers their cholesterol 
content which results in a strongly reduced trans infection ability, similar to the levels of MΦ 
from NP. Taken together, my data support the hypothesis that MΦ-mediated HIV-1 trans 
infection plays a role in HIV-1 infection and disease progression.  Furthermore, the use of SIMV, 
or other cholesterol lowering agents, to decrease this mechanism of virus transfer should be 
considered for future HIV-1 therapeutic development, as well as for incorporation into methods 
for the elimination of the HIV-1 reservoir and ultimately an HIV-1 cure.  
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APPENDIX A: ABBREVIATIONS 
ABCA1: ATP-binding cassette transporter 1 
ABCG1: ATP Binding Cassette Subfamily G Member 1 
AIDS: Acquired Immunodeficiency Syndrome 
APC: Antigen presenting cell 
APOBEC3G: Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G 
APOER2: Apolipoprotein E receptor 2 
ART: Antiretroviral therapy 
B cell: B lymphocytes 
BCD: β-cyclodextrin 
cDNA: complementary deoxyribonucleic acid 
CTx-B: Cholera Toxin subunit B 
DC: Dendritic cell 
DC-SIGN: Dendritic cell-specific Intercellular adhesion molecule-3-grabbing non-
integrin 
ELISA: Enzyme-linked immunosorbent assay 
FBS: Fetal bovine serum 
FC: Unesterified free cholesterol 
GALT: Gut-associated lymphoid tissue 
GGpp: Geranylgeranyl pyrophosphate 
GIT: Gastrointestinal tract 
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GM-CSF: Granulocyte-macrophage colony-stimulating factor 
HAND: HIV-associated neurocognitive disorder 
HESN: Highly-exposed seronegative 





LDLR: Low density lipoprotein receptor 
LTNP: Long term nonprogressor 
LXRα: Liver X receptor alpha 
LXRβ: Liver X receptor beta 
mAb: Monoclonal antibody 
MACS: Multicentered AIDS Cohort Study 
M-CSF: Macrophage colony-stimulating factor 
miRNA: microRNA 
MOI: Multiplicity of infection 
MS: SIMV-treated MΦ 
MΦ: Macrophage 
NP: HIV-1 seropositive nonprogressor 
PALLD: Palladin 
PBMC: Peripheral blood mononuclear cells 
PBS: Phosphate buffered saline 
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PFA: Paraformaldehyde 
PM: Plasma membrane 
PPARγ: Peroxisome proliferator-activated receptor gamma 
PR: HIV-1 seropositive progressor 
RCT: Reverse cholesterol transport 
RFP: Red fluorescent protein 
RNA: Ribonucleic acid 
RNAi: RNA interference 
RT-PCR: Reverse transcriptase polymerase chain reaction 
SIMV: Simvastatin 
SIV: Simian immunodeficiency virus 
SN: HIV-1 seronegative 
SREBP: Sterol regulatory element-binding protein 
VC: Viremic controller 
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APPENDIX B: MIRNA GENE INTERACTION NETWORKS 
Figure 29. Has-miR-29b-3p experimentally verified human gene interactions. 
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Figure 30. Has-miR-376a-3p experimentally verified human gene interactions. 
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Figure 31. Has-miR-150-5p experimentally verified human gene interactions. 
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Figure 32. Has-miR-144-3p experimentally verified human gene interactions. 
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Figure 33. Has-miR-148a-3p experimentally verified human gene interactions. 
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APPENDIX C: SUPPLEMENTAL DATA 
MΦ- mediated trans infection efficiency association with CD4+ T cell cis infection (MOI 10-1) 
(p =0.6486, F =0.2299, R2 =0.0369) 
Supplemental Figure 1. MΦ trans infection efficiency is not associated with CD4+ T cell 




Mφ- mediated trans infection efficiency association with Mφ cis infection (MOI 10-1) (p 
=0.6140, F =0.2827, R2 =0.045) 




1. Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, et al. HIV-infected
individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered
T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS
morbidity and mortality. PLoS pathogens. 2014;10(5):e1004078.
2. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical
progression and virological failure on highly active antiretroviral therapy in HIV-1
patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet.
1999;353(9156):863-8.
3. May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, et al. Impact on life
expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to
antiretroviral therapy. Aids. 2014;28(8):1193-202.
4. Barouch DH, Deeks SG. Immunologic strategies for HIV-1 remission and eradication.
Science. 2014;345(6193):169-74.
5. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al.
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.
Science. 1997;278(5341):1295-300.
6. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, et al. Presence of an
inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proceedings of
the National Academy of Sciences of the United States of America. 1997;94(24):13193-7.
7. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent
infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in
patients on effective combination therapy. Nature medicine. 1999;5(5):512-7.
8. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery
of replication-competent HIV despite prolonged suppression of plasma viremia. Science.
1997;278(5341):1291-5.
9. Walker BD, Yu XG. Unravelling the mechanisms of durable control of HIV-1. Nature
reviews Immunology. 2013;13(7):487-98.
126 
10. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al. Resistance to
HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine
receptor gene. Nature. 1996;382(6593):722-5.
11. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM.
CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort
Study (MACS). Lancet. 1998;352(9131):866-70.
12. Ioannidis JP, Rosenberg PS, Goedert JJ, Ashton LJ, Benfield TL, Buchbinder SP, et al.
Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease
progression: An international meta-analysis of individual-patient data. Annals of internal
medicine. 2001;135(9):782-95.
13. Goulder PJ, Walker BD. HIV and HLA class I: an evolving relationship. Immunity.
2012;37(3):426-40.
14. Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, Milo R, et al. Cell-to-cell spread of HIV
permits ongoing replication despite antiretroviral therapy. Nature. 2011;477(7362):95-8.
15. Sigal A, Baltimore D. As good as it gets? The problem of HIV persistence despite
antiretroviral drugs. Cell host & microbe. 2012;12(2):132-8.
16. Rinaldo CR. HIV-1 Trans Infection of CD4(+) T Cells by Professional Antigen Presenting
Cells. Scientifica. 2013;2013:164203.
17. Rappocciolo G, Jais M, Piazza P, Reinhart TA, Berendam SJ, Garcia-Exposito L, et al.
Alterations in cholesterol metabolism restrict HIV-1 trans infection in nonprogressors.
mBio. 2014;5(3):e01031-13.
18. de Villiers WJ, Smart EJ. Macrophage scavenger receptors and foam cell formation.
Journal of leukocyte biology. 1999;66(5):740-6.
19. Linton MF, Fazio S. Class A scavenger receptors, macrophages, and atherosclerosis.
Current opinion in lipidology. 2001;12(5):489-95.
20. Hemkens LG, Bucher HC. HIV infection and cardiovascular disease. European heart
journal. 2014;35(21):1373-81.
21. Waki K, Freed EO. Macrophages and Cell-Cell Spread of HIV-1. Viruses.
2010;2(8):1603-20.
22. Nguyen DH, Hildreth JE. Evidence for budding of human immunodeficiency virus type 1
selectively from glycolipid-enriched membrane lipid rafts. Journal of virology.
2000;74(7):3264-72.
127 
23. Ono A, Freed EO. Plasma membrane rafts play a critical role in HIV-1 assembly and
release. Proceedings of the National Academy of Sciences of the United States of
America. 2001;98(24):13925-30.
24. Wise J. HIV pandemic originated in Kinshasa around 1920, say scientists. Bmj.
2014;349:g5967.
25. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al.
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune
deficiency syndrome (AIDS). Science. 1983;220(4599):868-71.
26. Sabin CA. Do people with HIV infection have a normal life expectancy in the era of
combination antiretroviral therapy? BMC medicine. 2013;11:251.
27. Colin Mathers GS, Wahyu Retno Mahanani, Jessica Ho, Doris Ma Fat and Dan Hogan.




28. World Health Organization. HIV/AIDS Fact Sheet 2017 [Available from:
http://www.who.int/mediacentre/factsheets/fs360/en/.
29. Peeters M, Jung M, Ayouba A. The origin and molecular epidemiology of HIV. Expert
review of anti-infective therapy. 2013;11(9):885-96.
30. Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment,
and prevention. Lancet. 2014;384(9939):258-71.
31. Hemelaar J. The origin and diversity of the HIV-1 pandemic. Trends in molecular
medicine. 2012;18(3):182-92.
32. Gilbert PB, McKeague IW, Eisen G, Mullins C, Gueye NA, Mboup S, et al. Comparison
of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. Statistics in
medicine. 2003;22(4):573-93.
33. Kanki PJ, Travers KU, S MB, Hsieh CC, Marlink RG, Gueye NA, et al. Slower
heterosexual spread of HIV-2 than HIV-1. Lancet. 1994;343(8903):943-6.
34. Shaw GM, Hunter E. HIV transmission. Cold Spring Harbor perspectives in medicine.
2012;2(11).
35. Bulterys M, Lepage P. Mother-to-child transmission of HIV. Current opinion in pediatrics.
1998;10(2):143-50.
 128 
36. Ferguson MR, Rojo DR, von Lindern JJ, O'Brien WA. HIV-1 replication cycle. Clinics in 
laboratory medicine. 2002;22(3):611-35. 
37. Iwatani Y, Chan DS, Wang F, Maynard KS, Sugiura W, Gronenborn AM, et al. 
Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. 
Nucleic acids research. 2007;35(21):7096-108. 
38. Stremlau M, Perron M, Lee M, Li Y, Song B, Javanbakht H, et al. Specific recognition 
and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. 
Proceedings of the National Academy of Sciences of the United States of America. 
2006;103(14):5514-9. 
39. Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, Johnson MC, et al. 
Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell. 
2009;139(3):499-511. 
40. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, et al. 
SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted 
by Vpx. Nature. 2011;474(7353):654-7. 
41. Stopak K, de Noronha C, Yonemoto W, Greene WC. HIV-1 Vif blocks the antiviral 
activity of APOBEC3G by impairing both its translation and intracellular stability. 
Molecular cell. 2003;12(3):591-601. 
42. Malim MH, Bieniasz PD. HIV Restriction Factors and Mechanisms of Evasion. Cold 
Spring Harbor perspectives in medicine. 2012;2(5):a006940. 
43. Mlcochova P, Sutherland KA, Watters SA, Bertoli C, de Bruin RA, Rehwinkel J, et al. A 
G1-like state allows HIV-1 to bypass SAMHD1 restriction in macrophages. The EMBO 
journal. 2017;36(5):604-16. 
44. Blagoveshchenskaya AD, Thomas L, Feliciangeli SF, Hung CH, Thomas G. HIV-1 Nef 
downregulates MHC-I by a PACS-1- and PI3K-regulated ARF6 endocytic pathway. Cell. 
2002;111(6):853-66. 
45. Garcia JV, Miller AD. Serine phosphorylation-independent downregulation of cell-surface 
CD4 by nef. Nature. 1991;350(6318):508-11. 
46. Campbell TD, Khan M, Huang MB, Bond VC, Powell MD. HIV-1 Nef protein is secreted 
into vesicles that can fuse with target cells and virions. Ethnicity & disease. 2008;18(2 
Suppl 2):S2-14-9. 
47. Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ. Pathogenesis of HIV infection: 
what the virus spares is as important as what it destroys. Nature medicine. 
2006;12(3):289-95. 
129 
48. Pantaleo G, Graziosi C, Fauci AS. The immunopathogenesis of human immunodeficiency
virus infection. The New England journal of medicine. 1993;328(5):327-35.
49. Looney D, Ma A, Johns S. HIV therapy-the state of art. Current topics in microbiology
and immunology. 2015;389:1-29.
50. Cambi A, de Lange F, van Maarseveen NM, Nijhuis M, Joosten B, van Dijk EM, et al.
Microdomains of the C-type lectin DC-SIGN are portals for virus entry into dendritic
cells. The Journal of cell biology. 2004;164(1):145-55.
51. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Brief report:
absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1
infection. The New England journal of medicine. 1995;332(4):228-32.
52. Mariani R, Kirchhoff F, Greenough TC, Sullivan JL, Desrosiers RC, Skowronski J. High
frequency of defective nef alleles in a long-term survivor with nonprogressive human
immunodeficiency virus type 1 infection. Journal of virology. 1996;70(11):7752-64.
53. Iversen AK, Shpaer EG, Rodrigo AG, Hirsch MS, Walker BD, Sheppard HW, et al.
Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected
asymptomatic individual. Journal of virology. 1995;69(9):5743-53.
54. Blankson JN, Bailey JR, Thayil S, Yang HC, Lassen K, Lai J, et al. Isolation and
characterization of replication-competent human immunodeficiency virus type 1 from a
subset of elite suppressors. Journal of virology. 2007;81(5):2508-18.
55. Julg B, Pereyra F, Buzon MJ, Piechocka-Trocha A, Clark MJ, Baker BM, et al. Infrequent
recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV
elite controllers. Clinical infectious diseases : an official publication of the Infectious
Diseases Society of America. 2010;51(2):233-8.
56. Zagury JF, Sill A, Blattner W, Lachgar A, Le Buanec H, Richardson M, et al. Antibodies
to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of
Tat toxoid as an HIV-1 vaccine. Journal of human virology. 1998;1(4):282-92.
57. Harrer T, Harrer E, Kalams SA, Elbeik T, Staprans SI, Feinberg MB, et al. Strong
cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with
stable nonprogressing HIV type 1 infection. AIDS research and human retroviruses.
1996;12(7):585-92.
58. Clerici M, Balotta C, Meroni L, Ferrario E, Riva C, Trabattoni D, et al. Type 1 cytokine
production and low prevalence of viral isolation correlate with long-term nonprogression
in HIV infection. AIDS research and human retroviruses. 1996;12(11):1053-61.
 130 
59. Jacobs ES, Keating SM, Abdel-Mohsen M, Gibb SL, Heitman JW, Inglis HC, et al. 
Cytokines Elevated in HIV Elite Controllers Reduce HIV Replication In Vitro and 
Modulate HIV Restriction Factor Expression. Journal of virology. 2017;91(6). 
60. Guergnon J, Dalmasso C, Broet P, Meyer L, Westrop SJ, Imami N, et al. Single-
nucleotide polymorphism-defined class I and class III major histocompatibility complex 
genetic subregions contribute to natural long-term nonprogression in HIV infection. The 
Journal of infectious diseases. 2012;205(5):718-24. 
61. Piacentini L, Biasin M, Fenizia C, Clerici M. Genetic correlates of protection against HIV 
infection: the ally within. Journal of internal medicine. 2009;265(1):110-24. 
62. Abela IA, Berlinger L, Schanz M, Reynell L, Gunthard HF, Rusert P, et al. Cell-cell 
transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. 
PLoS pathogens. 2012;8(4):e1002634. 
63. Turville SG, Santos JJ, Frank I, Cameron PU, Wilkinson J, Miranda-Saksena M, et al. 
Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. 
Blood. 2004;103(6):2170-9. 
64. Sugaya M, Hartley O, Root MJ, Blauvelt A. C34, a membrane fusion inhibitor, blocks 
HIV infection of langerhans cells and viral transmission to T cells. The Journal of 
investigative dermatology. 2007;127(6):1436-43. 
65. Honeycutt JB, Wahl A, Baker C, Spagnuolo RA, Foster J, Zakharova O, et al. 
Macrophages sustain HIV replication in vivo independently of T cells. The Journal of 
clinical investigation. 2016;126(4):1353-66. 
66. Peressin M, Proust A, Schmidt S, Su B, Lambotin M, Biedma ME, et al. Efficient transfer 
of HIV-1 in trans and in cis from Langerhans dendritic cells and macrophages to 
autologous T lymphocytes. Aids. 2014;28(5):667-77. 
67. Ketas TJ, Frank I, Klasse PJ, Sullivan BM, Gardner JP, Spenlehauer C, et al. Human 
immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active 
against both direct and trans infection of primary cells. Journal of virology. 
2003;77(4):2762-7. 
68. Rappocciolo G, Piazza P, Fuller CL, Reinhart TA, Watkins SC, Rowe DT, et al. DC-SIGN 
on B lymphocytes is required for transmission of HIV-1 to T lymphocytes. PLoS 
pathogens. 2006;2(7):e70. 
69. Kwon DS, Gregorio G, Bitton N, Hendrickson WA, Littman DR. DC-SIGN-mediated 
internalization of HIV is required for trans-enhancement of T cell infection. Immunity. 
2002;16(1):135-44. 
 131 
70. Wu L, KewalRamani VN. Dendritic-cell interactions with HIV: infection and viral 
dissemination. Nature reviews Immunology. 2006;6(11):859-68. 
71. Garcia E, Pion M, Pelchen-Matthews A, Collinson L, Arrighi JF, Blot G, et al. HIV-1 
trafficking to the dendritic cell-T-cell infectious synapse uses a pathway of tetraspanin 
sorting to the immunological synapse. Traffic. 2005;6(6):488-501. 
72. Sewald X, Ladinsky MS, Uchil PD, Beloor J, Pi R, Herrmann C, et al. Retroviruses use 
CD169-mediated trans-infection of permissive lymphocytes to establish infection. 
Science. 2015;350(6260):563-7. 
73. Perreau M, Savoye AL, De Crignis E, Corpataux JM, Cubas R, Haddad EK, et al. 
Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, 
replication, and production. The Journal of experimental medicine. 2013;210(1):143-56. 
74. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, et 
al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection 
of T cells. Cell. 2000;100(5):587-97. 
75. Izquierdo-Useros N, Lorizate M, Puertas MC, Rodriguez-Plata MT, Zangger N, Erikson 
E, et al. Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection 
through recognition of viral membrane gangliosides. PLoS biology. 
2012;10(12):e1001448. 
76. Sowinski S, Jolly C, Berninghausen O, Purbhoo MA, Chauveau A, Kohler K, et al. 
Membrane nanotubes physically connect T cells over long distances presenting a novel 
route for HIV-1 transmission. Nature cell biology. 2008;10(2):211-9. 
77. Davis DM, Sowinski S. Membrane nanotubes: dynamic long-distance connections 
between animal cells. Nature reviews Molecular cell biology. 2008;9(6):431-6. 
78. Zaccard CR, Watkins SC, Kalinski P, Fecek RJ, Yates AL, Salter RD, et al. CD40L 
Induces Functional Tunneling Nanotube Networks Exclusively in Dendritic Cells 
Programmed by Mediators of Type 1 Immunity. Journal of immunology. 
2015;194(3):1047-56. 
79. Eugenin EA, Gaskill PJ, Berman JW. Tunneling nanotubes (TNT) are induced by HIV-
infection of macrophages: a potential mechanism for intercellular HIV trafficking. 
Cellular immunology. 2009;254(2):142-8. 
80. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of 
an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing 
human antibody. Nature. 1998;393(6686):648-59. 
81. Baribaud F, Pohlmann S, Doms RW. The role of DC-SIGN and DC-SIGNR in HIV and 
SIV attachment, infection, and transmission. Virology. 2001;286(1):1-6. 
 132 
82. Bashirova AA, Geijtenbeek TB, van Duijnhoven GC, van Vliet SJ, Eilering JB, Martin 
MP, et al. A dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin 
(DC-SIGN)-related protein is highly expressed on human liver sinusoidal endothelial cells 
and promotes HIV-1 infection. The Journal of experimental medicine. 2001;193(6):671-8. 
83. Nguyen DG, Hildreth JE. Involvement of macrophage mannose receptor in the binding 
and transmission of HIV by macrophages. European journal of immunology. 
2003;33(2):483-93. 
84. Fanibunda SE, Modi DN, Gokral JS, Bandivdekar AH. HIV gp120 binds to mannose 
receptor on vaginal epithelial cells and induces production of matrix metalloproteinases. 
PloS one. 2011;6(11):e28014. 
85. Fanibunda SE, Velhal SM, Raghavan VP, Bandivdekar AH. CD4 independent binding of 
HIV gp120 to mannose receptor on human spermatozoa. Journal of acquired immune 
deficiency syndromes. 2008;48(4):389-97. 
86. Borggren M, Jansson M. The evolution of HIV-1 interactions with coreceptors and 
mannose C-type lectin receptors. Progress in molecular biology and translational science. 
2015;129:109-40. 
87. Ceballos A, Remes Lenicov F, Sabatte J, Rodriguez Rodrigues C, Cabrini M, Jancic C, et 
al. Spermatozoa capture HIV-1 through heparan sulfate and efficiently transmit the virus 
to dendritic cells. The Journal of experimental medicine. 2009;206(12):2717-33. 
88. Poiesi C, De Francesco MA, Baronio M, Manca N. HIV-1 p17 binds heparan sulfate 
proteoglycans to activated CD4(+) T cells. Virus research. 2008;132(1-2):25-32. 
89. de Witte L, Bobardt M, Chatterji U, Degeest G, David G, Geijtenbeek TB, et al. 
Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proceedings of the 
National Academy of Sciences of the United States of America. 2007;104(49):19464-9. 
90. Saphire AC, Bobardt MD, Zhang Z, David G, Gallay PA. Syndecans serve as attachment 
receptors for human immunodeficiency virus type 1 on macrophages. Journal of virology. 
2001;75(19):9187-200. 
91. Jiang AP, Jiang JF, Guo MG, Jin YM, Li YY, Wang JH. Human Blood-Circulating 
Basophils Capture HIV-1 and Mediate Viral trans-Infection of CD4+ T Cells. Journal of 
virology. 2015;89(15):8050-62. 
92. Jiang AP, Jiang JF, Wei JF, Guo MG, Qin Y, Guo QQ, et al. Human Mucosal Mast Cells 
Capture HIV-1 and Mediate Viral trans-Infection of CD4+ T Cells. Journal of virology. 
2015;90(6):2928-37. 
 133 
93. Yu HJ, Reuter MA, McDonald D. HIV traffics through a specialized, surface-accessible 
intracellular compartment during trans-infection of T cells by mature dendritic cells. PLoS 
pathogens. 2008;4(8):e1000134. 
94. Dopper S, Wilflingseder D, Prodinger WM, Stiegler G, Speth C, Dierich MP, et al. 
Mechanism(s) promoting HIV-1 infection of primary unstimulated T lymphocytes in 
autologous B cell/T cell co-cultures. European journal of immunology. 2003;33(8):2098-
107. 
95. Jakubik JJ, Saifuddin M, Takefman DM, Spear GT. Immune complexes containing human 
immunodeficiency virus type 1 primary isolates bind to lymphoid tissue B lymphocytes 
and are infectious for T lymphocytes. Journal of virology. 2000;74(1):552-5. 
96. Moir S, Malaspina A, Li Y, Chun TW, Lowe T, Adelsberger J, et al. B cells of HIV-1-
infected patients bind virions through CD21-complement interactions and transmit 
infectious virus to activated T cells. The Journal of experimental medicine. 
2000;192(5):637-46. 
97. Pudney J, Quayle AJ, Anderson DJ. Immunological microenvironments in the human 
vagina and cervix: mediators of cellular immunity are concentrated in the cervical 
transformation zone. Biology of reproduction. 2005;73(6):1253-63. 
98. Trifonova RT, Lieberman J, van Baarle D. Distribution of immune cells in the human 
cervix and implications for HIV transmission. American journal of reproductive 
immunology. 2014;71(3):252-64. 
99. Kim JT, Chang E, Sigal A, Baltimore D. Dendritic cells efficiently transmit HIV to T 
Cells in a tenofovir and raltegravir insensitive manner. PLoS One. 2018;13(1):e0189945. 
100. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, Trumpfheller C, Finke J, Sun W, et 
al. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. The 
Journal of experimental medicine. 2003;197(7):823-9. 
101. Simmons G, Reeves JD, Grogan CC, Vandenberghe LH, Baribaud F, Whitbeck JC, et al. 
DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of 
macrophages and endothelial cells. Virology. 2003;305(1):115-23. 
102. Granelli-Piperno A, Pritsker A, Pack M, Shimeliovich I, Arrighi JF, Park CG, et al. 
Dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin/CD209 is 
abundant on macrophages in the normal human lymph node and is not required for 
dendritic cell stimulation of the mixed leukocyte reaction. Journal of immunology. 
2005;175(7):4265-73. 
103. Soilleux EJ, Morris LS, Leslie G, Chehimi J, Luo Q, Levroney E, et al. Constitutive and 
induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ 
and in vitro. Journal of leukocyte biology. 2002;71(3):445-57. 
 134 
104. Dominguez-Soto A, Sierra-Filardi E, Puig-Kroger A, Perez-Maceda B, Gomez-Aguado F, 
Corcuera MT, et al. Dendritic cell-specific ICAM-3-grabbing nonintegrin expression on 
M2-polarized and tumor-associated macrophages is macrophage-CSF dependent and 
enhanced by tumor-derived IL-6 and IL-10. Journal of immunology. 2011;186(4):2192-
200. 
105. Martinez-Nunez RT, Louafi F, Sanchez-Elsner T. The interleukin 13 (IL-13) pathway in 
human macrophages is modulated by microRNA-155 via direct targeting of interleukin 13 
receptor alpha1 (IL13Ralpha1). The Journal of biological chemistry. 2011;286(3):1786-
94. 
106. Maxfield FR, van Meer G. Cholesterol, the central lipid of mammalian cells. Current 
opinion in cell biology. 2010;22(4):422-9. 
107. Chen HW, Kandutsch AA, Waymouth C. Inhibition of cell growth by oxygenated 
derivatives of cholesterol. Nature. 1974;251(5474):419-21. 
108. Grouleff J, Irudayam SJ, Skeby KK, Schiott B. The influence of cholesterol on membrane 
protein structure, function, and dynamics studied by molecular dynamics simulations. 
Biochimica et biophysica acta. 2015;1848(9):1783-95. 
109. Rog T, Vattulainen I. Cholesterol, sphingolipids, and glycolipids: what do we know about 
their role in raft-like membranes? Chemistry and physics of lipids. 2014;184:82-104. 
110. Simons K, Sampaio JL. Membrane organization and lipid rafts. Cold Spring Harbor 
perspectives in biology. 2011;3(10):a004697. 
111. Petrov AM, Zefirov AL. [Cholesterol and lipid rafts in the biological membranes. Role in 
the release, reception and ion channel functions]. Uspekhi fiziologicheskikh nauk. 
2013;44(1):17-38. 
112. Simons K, Toomre D. Lipid rafts and signal transduction. Nature reviews Molecular cell 
biology. 2000;1(1):31-9. 
113. Ikonen E. Cellular cholesterol trafficking and compartmentalization. Nature reviews 
Molecular cell biology. 2008;9(2):125-38. 
114. Seo HS, Choi MH. Cholesterol homeostasis in cardiovascular disease and recent advances 
in measuring cholesterol signatures. The Journal of steroid biochemistry and molecular 
biology. 2015;153:72-9. 
115. Yu XH, Fu YC, Zhang DW, Yin K, Tang CK. Foam cells in atherosclerosis. Clinica 
chimica acta; international journal of clinical chemistry. 2013;424:245-52. 
116. Kuzu OF, Noory MA, Robertson GP. The Role of Cholesterol in Cancer. Cancer research. 
2016;76(8):2063-70. 
 135 
117. Allinquant B, Clamagirand C, Potier MC. Role of cholesterol metabolism in the 
pathogenesis of Alzheimer's disease. Current opinion in clinical nutrition and metabolic 
care. 2014;17(4):319-23. 
118. Go GW, Mani A. Low-density lipoprotein receptor (LDLR) family orchestrates 
cholesterol homeostasis. The Yale journal of biology and medicine. 2012;85(1):19-28. 
119. Jay AG, Chen AN, Paz MA, Hung JP, Hamilton JA. CD36 binds oxidized low density 
lipoprotein (LDL) in a mechanism dependent upon fatty acid binding. The Journal of 
biological chemistry. 2015;290(8):4590-603. 
120. Lange Y, Ye J, Steck TL. How cholesterol homeostasis is regulated by plasma membrane 
cholesterol in excess of phospholipids. Proceedings of the National Academy of Sciences 
of the United States of America. 2004;101(32):11664-7. 
121. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, et al. A PPAR 
gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and 
atherogenesis. Molecular cell. 2001;7(1):161-71. 
122. Zanotti I, Favari E, Bernini F. Cellular cholesterol efflux pathways: impact on intracellular 
lipid trafficking and methodological considerations. Current pharmaceutical 
biotechnology. 2012;13(2):292-302. 
123. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by 
proteolysis of a membrane-bound transcription factor. Cell. 1997;89(3):331-40. 
124. Assmann G, Nofer JR. Atheroprotective effects of high-density lipoproteins. Annual 
review of medicine. 2003;54:321-41. 
125. Castelli WP. Epidemiology of coronary heart disease: the Framingham study. The 
American journal of medicine. 1984;76(2A):4-12. 
126. Annema W, Tietge UJ. Regulation of reverse cholesterol transport - a comprehensive 
appraisal of available animal studies. Nutrition & metabolism. 2012;9(1):25. 
127. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 
1990;343(6257):425-30. 
128. Liao Z, Graham DR, Hildreth JE. Lipid rafts and HIV pathogenesis: virion-associated 
cholesterol is required for fusion and infection of susceptible cells. AIDS research and 
human retroviruses. 2003;19(8):675-87. 
129. Liao Z, Cimakasky LM, Hampton R, Nguyen DH, Hildreth JE. Lipid rafts and HIV 
pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS 
research and human retroviruses. 2001;17(11):1009-19. 
 136 
130. Hanley TM, Blay Puryear W, Gummuluru S, Viglianti GA. PPARgamma and LXR 
signaling inhibit dendritic cell-mediated HIV-1 capture and trans-infection. PLoS 
pathogens. 2010;6:e1000981. 
131. Danthi P, Chow M. Cholesterol removal by methyl-beta-cyclodextrin inhibits poliovirus 
entry. Journal of virology. 2004;78(1):33-41. 
132. Vashishtha M, Phalen T, Marquardt MT, Ryu JS, Ng AC, Kielian M. A single point 
mutation controls the cholesterol dependence of Semliki Forest virus entry and exit. The 
Journal of cell biology. 1998;140(1):91-9. 
133. Felmlee DJ, Hafirassou ML, Lefevre M, Baumert TF, Schuster C. Hepatitis C virus, 
cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver 
disease. Viruses. 2013;5(5):1292-324. 
134. Martin JJ, Holguera J, Sanchez-Felipe L, Villar E, Munoz-Barroso I. Cholesterol 
dependence of Newcastle Disease Virus entry. Biochimica et biophysica acta. 
2012;1818(3):753-61. 
135. Sun Y, Xiao S, Wang D, Luo R, Li B, Chen H, et al. Cellular membrane cholesterol is 
required for porcine reproductive and respiratory syndrome virus entry and release in 
MARC-145 cells. Science China Life sciences. 2011;54(11):1011-8. 
136. Shaikh SR, Fessler MB, Gowdy KM. Role for phospholipid acyl chains and cholesterol in 
pulmonary infections and inflammation. Journal of leukocyte biology. 2016;100(5):985-
97. 
137. Desplanques AS, Pontes M, De Corte N, Verheyen N, Nauwynck HJ, Vercauteren D, et 
al. Cholesterol depletion affects infectivity and stability of pseudorabies virus. Virus 
research. 2010;152(1-2):180-3. 
138. Poh MK, Shui G, Xie X, Shi PY, Wenk MR, Gu F. U18666A, an intra-cellular cholesterol 
transport inhibitor, inhibits dengue virus entry and replication. Antiviral research. 
2012;93(1):191-8. 
139. Carro AC, Damonte EB. Requirement of cholesterol in the viral envelope for dengue virus 
infection. Virus research. 2013;174(1-2):78-87. 
140. Medigeshi GR, Hirsch AJ, Streblow DN, Nikolich-Zugich J, Nelson JA. West Nile virus 
entry requires cholesterol-rich membrane microdomains and is independent of 
alphavbeta3 integrin. Journal of virology. 2008;82(11):5212-9. 
141. Guyader M, Kiyokawa E, Abrami L, Turelli P, Trono D. Role for human 
immunodeficiency virus type 1 membrane cholesterol in viral internalization. Journal of 
virology. 2002;76(20):10356-64. 
 137 
142. Gummuluru S, Rogel M, Stamatatos L, Emerman M. Binding of human 
immunodeficiency virus type 1 to immature dendritic cells can occur independently of 
DC-SIGN and mannose binding C-type lectin receptors via a cholesterol-dependent 
pathway. Journal of virology. 2003;77(23):12865-74. 
143. Nguyen DH, Taub D. CXCR4 function requires membrane cholesterol: implications for 
HIV infection. Journal of immunology. 2002;168(8):4121-6. 
144. Nguyen DH, Taub D. Cholesterol is essential for macrophage inflammatory protein 1 beta 
binding and conformational integrity of CC chemokine receptor 5. Blood. 
2002;99(12):4298-306. 
145. Cambi A, Lidke DS, Arndt-Jovin DJ, Figdor CG, Jovin TM. Ligand-conjugated quantum 
dots monitor antigen uptake and processing by dendritic cells. Nano letters. 
2007;7(4):970-7. 
146. Hatch SC, Archer J, Gummuluru S. Glycosphingolipid composition of human 
immunodeficiency virus type 1 (HIV-1) particles is a crucial determinant for dendritic 
cell-mediated HIV-1 trans-infection. Journal of virology. 2009;83(8):3496-506. 
147. Longenecker CT, Hileman CO, Funderburg NT, McComsey GA. Rosuvastatin preserves 
renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the 
SATURN-HIV trial. Clinical infectious diseases : an official publication of the Infectious 
Diseases Society of America. 2014;59(8):1148-56. 
148. Funderburg NT, Jiang Y, Debanne SM, Storer N, Labbato D, Clagett B, et al. 
Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects 
on antiretroviral therapy. Clinical infectious diseases : an official publication of the 
Infectious Diseases Society of America. 2014;58(4):588-95. 
149. Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA. Effect of 24 weeks 
of statin therapy on systemic and vascular inflammation in HIV-infected subjects 
receiving antiretroviral therapy. The Journal of infectious diseases. 2014;209(8):1156-64. 
150. Calza L, Manfredi R, Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia 
in HIV-infected patients receiving HAART. Aids. 2003;17(6):851-9. 
151. Lo J, Lu MT, Ihenachor EJ, Wei J, Looby SE, Fitch KV, et al. Effects of statin therapy on 
coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients 
with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. The 
lancet HIV. 2015;2(2):e52-63. 
152. Rasmussen LD, Kronborg G, Larsen CS, Pedersen C, Gerstoft J, Obel N. Statin therapy 
and mortality in HIV-infected individuals; a Danish nationwide population-based cohort 
study. PloS one. 2013;8(3):e52828. 
 138 
153. Drechsler H, Ayers C, Cutrell J, Maalouf N, Tebas P, Bedimo R. Current use of statins 
reduces risk of HIV rebound on suppressive HAART. PloS one. 2017;12(3):e0172175. 
154. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, et al. 
Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative 
volunteers: ACTG Study A5047. Aids. 2002;16(4):569-77. 
155. del Real G, Jimenez-Baranda S, Mira E, Lacalle RA, Lucas P, Gomez-Mouton C, et al. 
Statins inhibit HIV-1 infection by down-regulating Rho activity. The Journal of 
experimental medicine. 2004;200(4):541-7. 
156. Nagy L, Szanto A, Szatmari I, Szeles L. Nuclear hormone receptors enable macrophages 
and dendritic cells to sense their lipid environment and shape their immune response. 
Physiological reviews. 2012;92(2):739-89. 
157. Frantz S, Nahrendorf M. Cardiac macrophages and their role in ischaemic heart disease. 
Cardiovascular research. 2014;102(2):240-8. 
158. Bogie JF, Stinissen P, Hendriks JJ. Macrophage subsets and microglia in multiple 
sclerosis. Acta neuropathologica. 2014;128(2):191-213. 
159. McNelis JC, Olefsky JM. Macrophages, immunity, and metabolic disease. Immunity. 
2014;41(1):36-48. 
160. Cao Q, Wang Y, Harris DC. Pathogenic and protective role of macrophages in kidney 
disease. American journal of physiology Renal physiology. 2013;305(1):F3-11. 
161. Pappas K, Papaioannou AI, Kostikas K, Tzanakis N. The role of macrophages in 
obstructive airways disease: chronic obstructive pulmonary disease and asthma. Cytokine. 
2013;64(3):613-25. 
162. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and 
disease. Nature. 2013;496(7446):445-55. 
163. Campbell GM, Nicol MQ, Dransfield I, Shaw DJ, Nash AA, Dutia BM. Susceptibility of 
bone marrow-derived macrophages to influenza virus infection is dependent on 
macrophage phenotype. The Journal of general virology. 2015;96(10):2951-60. 
164. Schaeffer E, Flacher V, Papageorgiou V, Decossas M, Fauny JD, Kramer M, et al. Dermal 
CD14(+) Dendritic Cell and Macrophage Infection by Dengue Virus Is Stimulated by 
Interleukin-4. The Journal of investigative dermatology. 2015;135(7):1743-51. 
165. Yeung AW, Wu W, Freewan M, Stocker R, King NJ, Thomas SR. Flavivirus infection 
induces indoleamine 2,3-dioxygenase in human monocyte-derived macrophages via tumor 
necrosis factor and NF-kappaB. Journal of leukocyte biology. 2012;91(4):657-66. 
 139 
166. Dahlmann F, Biedenkopf N, Babler A, Jahnen-Dechent W, Karsten CB, Gnirss K, et al. 
Analysis of Ebola Virus Entry Into Macrophages. The Journal of infectious diseases. 
2015;212 Suppl 2:S247-57. 
167. Bayer C, Varani S, Wang L, Walther P, Zhou S, Straschewski S, et al. Human 
cytomegalovirus infection of M1 and M2 macrophages triggers inflammation and 
autologous T-cell proliferation. Journal of virology. 2013;87(1):67-79. 
168. Linnavuori K, Hovi T. Restricted replication of herpes simplex virus in human monocyte 
cultures: role of interferon. Virology. 1983;130(1):1-9. 
169. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annual review 
of immunology. 1999;17:593-623. 
170. da Silva RP, Platt N, de Villiers JS, Gordon S. Membrane molecules and macrophage 
endocytosis: scavenger receptor and macrosialin as markers of plasma-membrane and 
vacuolar functions. Biochemical Society transactions. 1996;24(1):220-4. 
171. Galindo I, Cuesta-Geijo MA, Hlavova K, Munoz-Moreno R, Barrado-Gil L, Dominguez J, 
et al. African swine fever virus infects macrophages, the natural host cells, via clathrin- 
and cholesterol-dependent endocytosis. Virus research. 2015;200:45-55. 
172. van Wilgenburg B, Moore MD, James WS, Cowley SA. The productive entry pathway of 
HIV-1 in macrophages is dependent on endocytosis through lipid rafts containing CD4. 
PloS one. 2014;9(1):e86071. 
173. Arango Duque G, Descoteaux A. Macrophage cytokines: involvement in immunity and 
infectious diseases. Frontiers in immunology. 2014;5:491. 
174. Bobryshev YV. Monocyte recruitment and foam cell formation in atherosclerosis. Micron. 
2006;37(3):208-22. 
175. Yao ST, Zhao L, Miao C, Tian H, Yang NN, Guo SD, et al. [Endoplasmic reticulum stress 
mediates oxidized low density lipoprotein-induced scavenger receptor A1 upregulation in 
macrophages]. Sheng li xue bao : [Acta physiologica Sinica]. 2014;66(5):612-8. 
176. Li DZ, Wang BY, Yang BJ, He SL, Lin J, Dong JC, et al. Thymic stromal lmphopoietin 
pomotes macrophage-derived foam cell formation. Journal of Huazhong University of 
Science and Technology Medical sciences = Hua zhong ke ji da xue xue bao Yi xue Ying 
De wen ban = Huazhong keji daxue xuebao Yixue Yingdewen ban. 2014;34(1):23-8. 
177. Bekkering S, Quintin J, Joosten LA, van der Meer JW, Netea MG, Riksen NP. Oxidized 
low-density lipoprotein induces long-term proinflammatory cytokine production and foam 
cell formation via epigenetic reprogramming of monocytes. Arteriosclerosis, thrombosis, 
and vascular biology. 2014;34(8):1731-8. 
 140 
178. Zhang BC, Zhang CW, Wang C, Pan DF, Xu TD, Li DY. Luteolin Attenuates Foam Cell 
Formation and Apoptosis in Ox-LDL-Stimulated Macrophages by Enhancing Autophagy. 
Cellular physiology and biochemistry : international journal of experimental cellular 
physiology, biochemistry, and pharmacology. 2016;39(5):2065-76. 
179. Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L, Mukhamedova N, et al. 
Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. 
PLoS biology. 2006;4(11):e365. 
180. Wu L, Paxton WA, Kassam N, Ruffing N, Rottman JB, Sullivan N, et al. CCR5 levels and 
expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. The 
Journal of experimental medicine. 1997;185(9):1681-91. 
181. Mashiba M, Collins DR, Terry VH, Collins KL. Vpr overcomes macrophage-specific 
restriction of HIV-1 Env expression and virion production. Cell host & microbe. 
2014;16(6):722-35. 
182. Zhang Z, Schuler T, Zupancic M, Wietgrefe S, Staskus KA, Reimann KA, et al. Sexual 
transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. 
Science. 1999;286(5443):1353-7. 
183. Mann DL, Gartner S, Le Sane F, Buchow H, Popovic M. HIV-1 transmission and function 
of virus-infected monocytes/macrophages. Journal of immunology. 1990;144(6):2152-8. 
184. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 
2004;116(2):281-97. 
185. Park JH, Shin C. MicroRNA-directed cleavage of targets: mechanism and experimental 
approaches. BMB reports. 2014;47(8):417-23. 
186. Dalmay T. Mechanism of miRNA-mediated repression of mRNA translation. Essays in 
biochemistry. 2013;54:29-38. 
187. de Yebenes VG, Bartolome-Izquierdo N, Ramiro AR. Regulation of B-cell development 
and function by microRNAs. Immunological reviews. 2013;253(1):25-39. 
188. Jeker LT, Bluestone JA. MicroRNA regulation of T-cell differentiation and function. 
Immunological reviews. 2013;253(1):65-81. 
189. Santoro MM, Nicoli S. miRNAs in endothelial cell signaling: the endomiRNAs. 
Experimental cell research. 2013;319(9):1324-30. 
190. Pobezinsky LA, Etzensperger R, Jeurling S, Alag A, Kadakia T, McCaughtry TM, et al. 
Let-7 microRNAs target the lineage-specific transcription factor PLZF to regulate 
terminal NKT cell differentiation and effector function. Nature immunology. 
2015;16(5):517-24. 
 141 
191. Roy S. miRNA in Macrophage Development and Function. Antioxidants & redox 
signaling. 2016;25(15):795-804. 
192. Redis RS, Calin S, Yang Y, You MJ, Calin GA. Cell-to-cell miRNA transfer: from body 
homeostasis to therapy. Pharmacology & therapeutics. 2012;136(2):169-74. 
193. Acunzo M, Romano G, Wernicke D, Croce CM. MicroRNA and cancer--a brief overview. 
Advances in biological regulation. 2015;57:1-9. 
194. Karnati HK, Panigrahi MK, Gutti RK, Greig NH, Tamargo IA. miRNAs: Key Players in 
Neurodegenerative Disorders and Epilepsy. Journal of Alzheimer's disease : JAD. 
2015;48(3):563-80. 
195. Bekris LM, Leverenz JB. The biomarker and therapeutic potential of miRNA in 
Alzheimer's disease. Neurodegenerative disease management. 2015;5(1):61-74. 
196. Burgos K, Malenica I, Metpally R, Courtright A, Rakela B, Beach T, et al. Profiles of 
extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and 
Parkinson's diseases correlate with disease status and features of pathology. PloS one. 
2014;9(5):e94839. 
197. Jackson AL, Linsley PS. Noise amidst the silence: off-target effects of siRNAs? Trends in 
genetics : TIG. 2004;20(11):521-4. 
198. van Rooij E, Purcell AL, Levin AA. Developing microRNA therapeutics. Circulation 
research. 2012;110(3):496-507. 
199. Chen Y, Wang C, Liu Y, Tang L, Zheng M, Xu C, et al. miR-122 targets NOD2 to 
decrease intestinal epithelial cell injury in Crohn's disease. Biochemical and biophysical 
research communications. 2013;438(1):133-9. 
200. Wang Y, Xing QF, Liu XQ, Guo ZJ, Li CY, Sun G. MiR-122 targets VEGFC in bladder 
cancer to inhibit tumor growth and angiogenesis. American journal of translational 
research. 2016;8(7):3056-66. 
201. Jeon TI, Osborne TF. miRNA and cholesterol homeostasis. Biochimica et biophysica acta. 
2016;1861(12 Pt B):2041-6. 
202. Jeon TI, Esquejo RM, Roqueta-Rivera M, Phelan PE, Moon YA, Govindarajan SS, et al. 
An SREBP-responsive microRNA operon contributes to a regulatory loop for intracellular 
lipid homeostasis. Cell metabolism. 2013;18(1):51-61. 
203. Ng R, Wu H, Xiao H, Chen X, Willenbring H, Steer CJ, et al. Inhibition of microRNA-24 
expression in liver prevents hepatic lipid accumulation and hyperlipidemia. Hepatology. 
2014;60(2):554-64. 
 142 
204. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, et al. 
MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. 
Science. 2010;328(5985):1566-9. 
205. Horton JD, Shimomura I. Sterol regulatory element-binding proteins: activators of 
cholesterol and fatty acid biosynthesis. Current opinion in lipidology. 1999;10(2):143-50. 
206. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, et al. MiR-33 
contributes to the regulation of cholesterol homeostasis. Science. 2010;328(5985):1570-3. 
207. Ouimet M, Ediriweera HN, Gundra UM, Sheedy FJ, Ramkhelawon B, Hutchison SB, et 
al. MicroRNA-33-dependent regulation of macrophage metabolism directs immune cell 
polarization in atherosclerosis. The Journal of clinical investigation. 2015;125(12):4334-
48. 
208. Horie T, Baba O, Kuwabara Y, Chujo Y, Watanabe S, Kinoshita M, et al. MicroRNA-33 
deficiency reduces the progression of atherosclerotic plaque in ApoE-/- mice. Journal of 
the American Heart Association. 2012;1(6):e003376. 
209. Loyer X, Mallat Z, Boulanger CM, Tedgui A. MicroRNAs as therapeutic targets in 
atherosclerosis. Expert opinion on therapeutic targets. 2015;19(4):489-96. 
210. Ramirez CM, Rotllan N, Vlassov AV, Davalos A, Li M, Goedeke L, et al. Control of 
cholesterol metabolism and plasma high-density lipoprotein levels by microRNA-144. 
Circulation research. 2013;112(12):1592-601. 
211. Sun D, Zhang J, Xie J, Wei W, Chen M, Zhao X. MiR-26 controls LXR-dependent 
cholesterol efflux by targeting ABCA1 and ARL7. FEBS letters. 2012;586(10):1472-9. 
212. Ou Z, Wada T, Gramignoli R, Li S, Strom SC, Huang M, et al. MicroRNA hsa-miR-613 
targets the human LXRalpha gene and mediates a feedback loop of LXRalpha 
autoregulation. Molecular endocrinology. 2011;25(4):584-96. 
213. Yang M, Liu W, Pellicane C, Sahyoun C, Joseph BK, Gallo-Ebert C, et al. Identification 
of miR-185 as a regulator of de novo cholesterol biosynthesis and low density lipoprotein 
uptake. Journal of lipid research. 2014;55(2):226-38. 
214. Alvarez ML, Khosroheidari M, Eddy E, Done SC. MicroRNA-27a decreases the level and 
efficiency of the LDL receptor and contributes to the dysregulation of cholesterol 
homeostasis. Atherosclerosis. 2015;242(2):595-604. 
215. Peng XP, Huang L, Liu ZH. miRNA-133a attenuates lipid accumulation via TR4-CD36 
pathway in macrophages. Biochimie. 2016;127:79-85. 
 143 
216. Gupta A, Nagilla P, Le HS, Bunney C, Zych C, Thalamuthu A, et al. Comparative 
expression profile of miRNA and mRNA in primary peripheral blood mononuclear cells 
infected with human immunodeficiency virus (HIV-1). PloS one. 2011;6(7):e22730. 
217. Houzet L, Yeung ML, de Lame V, Desai D, Smith SM, Jeang KT. MicroRNA profile 
changes in human immunodeficiency virus type 1 (HIV-1) seropositive individuals. 
Retrovirology. 2008;5:118. 
218. Aqil M, Naqvi AR, Mallik S, Bandyopadhyay S, Maulik U, Jameel S. The HIV Nef 
protein modulates cellular and exosomal miRNA profiles in human monocytic cells. 
Journal of extracellular vesicles. 2014;3. 
219. Yahyaei S, Biasin M, Saulle I, Gnudi F, De Luca M, Tasca KI, et al. Identification of a 
Specific miRNA Profile in HIV-Exposed Seronegative Individuals. Journal of acquired 
immune deficiency syndromes. 2016;73(1):11-9. 
220. Wang X, Ye L, Hou W, Zhou Y, Wang YJ, Metzger DS, et al. Cellular microRNA 
expression correlates with susceptibility of monocytes/macrophages to HIV-1 infection. 
Blood. 2009;113(3):671-4. 
221. Wang J, Xiang G, Mitchelson K, Zhou Y. Microarray profiling of monocytic 
differentiation reveals miRNA-mRNA intrinsic correlation. Journal of cellular 
biochemistry. 2011;112(9):2443-53. 
222. Sisk JM, Clements JE, Witwer KW. miRNA profiles of monocyte-lineage cells are 
consistent with complicated roles in HIV-1 restriction. Viruses. 2012;4(10):1844-64. 
223. Huang J, Wang F, Argyris E, Chen K, Liang Z, Tian H, et al. Cellular microRNAs 
contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nature medicine. 
2007;13(10):1241-7. 
224. Reynoso R, Laufer N, Hackl M, Skalicky S, Monteforte R, Turk G, et al. MicroRNAs 
differentially present in the plasma of HIV elite controllers reduce HIV infection in vitro. 
Scientific reports. 2014;4:5915. 
225. Castanho MA, Coutinho A, Prieto MJ. Absorption and fluorescence spectra of polyene 
antibiotics in the presence of cholesterol. The Journal of biological chemistry. 
1992;267(1):204-9. 
226. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nature reviews 
Immunology. 2005;5(12):953-64. 
227. Pohlmann S, Baribaud F, Lee B, Leslie GJ, Sanchez MD, Hiebenthal-Millow K, et al. DC-
SIGN interactions with human immunodeficiency virus type 1 and 2 and simian 
immunodeficiency virus. Journal of virology. 2001;75(10):4664-72. 
 144 
228. Thurnher M, Nussbaumer O, Gruenbacher G. Novel aspects of mevalonate pathway 
inhibitors as antitumor agents. Clinical cancer research : an official journal of the 
American Association for Cancer Research. 2012;18(13):3524-31. 
229. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from 
protein prenylation to immunomodulation. Nature reviews Immunology. 2006;6(5):358-
70. 
230. Saez-Cirion A, Hamimi C, Bergamaschi A, David A, Versmisse P, Melard A, et al. 
Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. 
Blood. 2011;118(4):955-64. 
231. Fan Y, Siklenka K, Arora SK, Ribeiro P, Kimmins S, Xia J. miRNet - dissecting miRNA-
target interactions and functional associations through network-based visual analysis. 
Nucleic acids research. 2016;44(W1):W135-41. 
232. von Andrian UH, Mempel TR. Homing and cellular traffic in lymph nodes. Nature 
reviews Immunology. 2003;3(11):867-78. 
233. Carr JM, Hocking H, Li P, Burrell CJ. Rapid and efficient cell-to-cell transmission of 
human immunodeficiency virus infection from monocyte-derived macrophages to 
peripheral blood lymphocytes. Virology. 1999;265(2):319-29. 
234. Rappaport J, Volsky DJ. Role of the macrophage in HIV-associated neurocognitive 
disorders and other comorbidities in patients on effective antiretroviral treatment. Journal 
of neurovirology. 2015;21(3):235-41. 
235. Clifford DB, Ances BM. HIV-associated neurocognitive disorder. The Lancet Infectious 
diseases. 2013;13(11):976-86. 
236. Jolly C, Kashefi K, Hollinshead M, Sattentau QJ. HIV-1 cell to cell transfer across an 
Env-induced, actin-dependent synapse. The Journal of experimental medicine. 
2004;199(2):283-93. 
237. Joshi A, Sedano M, Beauchamp B, Punke EB, Mulla ZD, Meza A, et al. HIV-1 Env 
Glycoprotein Phenotype along with Immune Activation Determines CD4 T Cell Loss in 
HIV Patients. Journal of immunology. 2016;196(4):1768-79. 
238. d'Ettorre G, Paiardini M, Ceccarelli G, Silvestri G, Vullo V. HIV-associated immune 
activation: from bench to bedside. AIDS research and human retroviruses. 
2011;27(4):355-64. 
239. Buzon MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, et al. HIV-1 
replication and immune dynamics are affected by raltegravir intensification of HAART-
suppressed subjects. Nature medicine. 2010;16(4):460-5. 
 145 
240. Bello G, Velasco-de-Castro CA, Bongertz V, Rodrigues CA, Giacoia-Gripp CB, Pilotto 
JH, et al. Immune activation and antibody responses in non-progressing elite controller 
individuals infected with HIV-1. Journal of medical virology. 2009;81(10):1681-90. 
241. Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A, et al. Severe CD4+ 
T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus 
type 1 infection and substantial delay in restoration following highly active antiretroviral 
therapy. Journal of virology. 2003;77(21):11708-17. 
242. Li L, Meng G, Graham MF, Shaw GM, Smith PD. Intestinal macrophages display reduced 
permissiveness to human immunodeficiency virus 1 and decreased surface CCR5. 
Gastroenterology. 1999;116(5):1043-53. 
243. Zalar A, Figueroa MI, Ruibal-Ares B, Bare P, Cahn P, de Bracco MM, et al. Macrophage 
HIV-1 infection in duodenal tissue of patients on long term HAART. Antiviral research. 
2010;87(2):269-71. 
244. Doitsh G, Cavrois M, Lassen KG, Zepeda O, Yang Z, Santiago ML, et al. Abortive HIV 
infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. 
Cell. 2010;143(5):789-801. 
245. Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, Zepeda O, et al. Cell death by 
pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature. 2014;505(7484):509-
14. 
246. Wang S, Hottz P, Schechter M, Rong L. Modeling the Slow CD4+ T Cell Decline in HIV-
Infected Individuals. PLoS computational biology. 2015;11(12):e1004665. 
247. Galloway NL, Doitsh G, Monroe KM, Yang Z, Munoz-Arias I, Levy DN, et al. Cell-to-
Cell Transmission of HIV-1 Is Required to Trigger Pyroptotic Death of Lymphoid-Tissue-
Derived CD4 T Cells. Cell reports. 2015;12(10):1555-63. 
248. Sattentau QJ, Stevenson M. Macrophages and HIV-1: An Unhealthy Constellation. Cell 
host & microbe. 2016;19(3):304-10. 
249. Orenstein JM, Fox C, Wahl SM. Macrophages as a source of HIV during opportunistic 
infections. Science. 1997;276(5320):1857-61. 
250. Yang K, Liu X, Liu Y, Wang X, Cao L, Zhang X, et al. DC-SIGN and Toll-like receptor 4 
mediate oxidized low-density lipoprotein-induced inflammatory responses in 
macrophages. Scientific reports. 2017;7(1):3296. 
251. Tamma SL, Sundaram SK, Lev M, Coico RF. Inhibition of sphingolipid synthesis down-
modulates CD4 expression by peripheral blood T lymphocytes and T lymphoma cells. 
Biochemical and biophysical research communications. 1996;220(3):916-21. 
 146 
252. Matsuda K, Hattori S, Kariya R, Komizu Y, Kudo E, Goto H, et al. Inhibition of HIV-1 
entry by the tricyclic coumarin GUT-70 through the modification of membrane fluidity. 
Biochemical and biophysical research communications. 2015;457(3):288-94. 
253. Hong PW, Flummerfelt KB, de Parseval A, Gurney K, Elder JH, Lee B. Human 
immunodeficiency virus envelope (gp120) binding to DC-SIGN and primary dendritic 
cells is carbohydrate dependent but does not involve 2G12 or cyanovirin binding sites: 
implications for structural analyses of gp120-DC-SIGN binding. Journal of virology. 
2002;76(24):12855-65. 
254. Campbell JH, Hearps AC, Martin GE, Williams KC, Crowe SM. The importance of 
monocytes and macrophages in HIV pathogenesis, treatment, and cure. Aids. 
2014;28(15):2175-87. 
255. Cory TJ, Schacker TW, Stevenson M, Fletcher CV. Overcoming pharmacologic 
sanctuaries. Current opinion in HIV and AIDS. 2013;8(3):190-5. 
256. Petersen J, Drake MJ, Bruce EA, Riblett AM, Didigu CA, Wilen CB, et al. The major 
cellular sterol regulatory pathway is required for Andes virus infection. PLoS pathogens. 
2014;10(2):e1003911. 
257. Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes 
to statins. Cell. 2015;161(1):161-72. 
258. Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl 
coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having 
hypocholesterolemic activity. FEBS letters. 1976;72(2):323-6. 
259. Amet T, Nonaka M, Dewan MZ, Saitoh Y, Qi X, Ichinose S, et al. Statin-induced 
inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for 
protein prenylation in HIV-1 replication. Microbes and infection / Institut Pasteur. 
2008;10(5):471-80. 
260. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, et al. Berberine is a novel cholesterol-
lowering drug working through a unique mechanism distinct from statins. Nature 
medicine. 2004;10(12):1344-51. 
261. Chen N, McCarthy C, Drakesmith H, Li D, Cerundolo V, McMichael AJ, et al. HIV-1 
down-regulates the expression of CD1d via Nef. European journal of immunology. 
2006;36(2):278-86. 
262. Moll M, Kuylenstierna C, Gonzalez VD, Andersson SK, Bosnjak L, Sonnerborg A, et al. 
Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells 
retained during chronic HIV-1 infection. European journal of immunology. 
2009;39(3):902-11. 
 147 
263. Zaunders J, van Bockel D. Innate and Adaptive Immunity in Long-Term Non-Progression 
in HIV Disease. Frontiers in immunology. 2013;4:95. 
264. Chiozzini C, Arenaccio C, Olivetta E, Anticoli S, Manfredi F, Ferrantelli F, et al. Trans-
dissemination of exosomes from HIV-1-infected cells fosters both HIV-1 trans-infection 
in resting CD4(+) T lymphocytes and reactivation of the HIV-1 reservoir. Archives of 
virology. 2017;162(9):2565-77. 
265. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al. 
Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and 
provide diagnostic biomarkers. Nature cell biology. 2008;10(12):1470-6. 
266. Dominiczak MH, Caslake MJ. Apolipoproteins: metabolic role and clinical biochemistry 
applications. Annals of clinical biochemistry. 2011;48(Pt 6):498-515. 
267. Record M, Poirot M, Silvente-Poirot S. Emerging concepts on the role of exosomes in 
lipid metabolic diseases. Biochimie. 2014;96:67-74. 
268. Fernandez-Hernando C, Suarez Y, Rayner KJ, Moore KJ. MicroRNAs in lipid 
metabolism. Current opinion in lipidology. 2011;22(2):86-92. 
269. Moore KJ, Rayner KJ, Suarez Y, Fernandez-Hernando C. microRNAs and cholesterol 
metabolism. Trends in endocrinology and metabolism: TEM. 2010;21(12):699-706. 
270. Rotllan N, Price N, Pati P, Goedeke L, Fernandez-Hernando C. microRNAs in lipoprotein 
metabolism and cardiometabolic disorders. Atherosclerosis. 2016;246:352-60. 
271. Wagschal A, Najafi-Shoushtari SH, Wang L, Goedeke L, Sinha S, deLemos AS, et al. 
Genome-wide identification of microRNAs regulating cholesterol and triglyceride 
homeostasis. Nature medicine. 2015;21(11):1290-7. 
272. de Aguiar Vallim TQ, Tarling EJ, Kim T, Civelek M, Baldan A, Esau C, et al. 
MicroRNA-144 regulates hepatic ATP binding cassette transporter A1 and plasma high-
density lipoprotein after activation of the nuclear receptor farnesoid X receptor. 
Circulation research. 2013;112(12):1602-12. 
273. Hu YW, Hu YR, Zhao JY, Li SF, Ma X, Wu SG, et al. An agomir of miR-144-3p 
accelerates plaque formation through impairing reverse cholesterol transport and 
promoting pro-inflammatory cytokine production. PloS one. 2014;9(4):e94997. 
274. Li J, Zhang S. microRNA-150 inhibits the formation of macrophage foam cells through 
targeting adiponectin receptor 2. Biochemical and biophysical research communications. 
2016;476(4):218-24. 
 148 
275. Goedeke L, Rotllan N, Canfran-Duque A, Aranda JF, Ramirez CM, Araldi E, et al. 
MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating 
lipoprotein levels. Nature medicine. 2015;21(11):1280-9. 
276. Zhou Q, Li M, Wang X, Li Q, Wang T, Zhu Q, et al. Immune-related microRNAs are 
abundant in breast milk exosomes. International journal of biological sciences. 
2012;8(1):118-23. 
277. Kulkarni S, Qi Y, O'HUigin C, Pereyra F, Ramsuran V, McLaren P, et al. Genetic 
interplay between HLA-C and MIR148A in HIV control and Crohn disease. Proceedings 
of the National Academy of Sciences of the United States of America. 
2013;110(51):20705-10. 
278. Apps R, Qi Y, Carlson JM, Chen HY, Gao XJ, Thomas R, et al. Influence of HLA-C 
Expression Level on HIV Control. Science. 2013;340(6128):87-91. 
279. Nathans R, Chu CY, Serquina AK, Lu CC, Cao H, Rana TM. Cellular microRNA and P 
bodies modulate host-HIV-1 interactions. Molecular cell. 2009;34(6):696-709. 
280. Adoro S, Cubillos-Ruiz JR, Chen X, Deruaz M, Vrbanac VD, Song M, et al. IL-21 
induces antiviral microRNA-29 in CD4 T cells to limit HIV-1 infection. Nature 
communications. 2015;6:7562. 
281. Tano N, Kim HW, Ashraf M. microRNA-150 regulates mobilization and migration of 
bone marrow-derived mononuclear cells by targeting Cxcr4. PloS one. 
2011;6(10):e23114. 
282. Zehavi L, Avraham R, Barzilai A, Bar-Ilan D, Navon R, Sidi Y, et al. Silencing of a large 
microRNA cluster on human chromosome 14q32 in melanoma: biological effects of mir-
376a and mir-376c on insulin growth factor 1 receptor. Molecular cancer. 2012;11:44. 
283. Yang L, Wei QM, Zhang XW, Sheng Q, Yan XT. MiR-376a promotion of proliferation 
and metastases in ovarian cancer: Potential role as a biomarker. Life sciences. 
2017;173:62-7. 
284. Zhang Y, Wu JH, Han F, Huang JM, Shi SY, Gu RD, et al. Arsenic trioxide induced 
apoptosis in retinoblastoma cells by abnormal expression of microRNA-376a. Neoplasma. 
2013;60(3):247-53. 
285. Pescador N, Perez-Barba M, Ibarra JM, Corbaton A, Martinez-Larrad MT, Serrano-Rios 
M. Serum circulating microRNA profiling for identification of potential type 2 diabetes 
and obesity biomarkers. PloS one. 2013;8(10):e77251. 
286. Avalos CR, Abreu CM, Queen SE, Li M, Price S, Shirk EN, et al. Brain Macrophages in 
Simian Immunodeficiency Virus-Infected, Antiretroviral-Suppressed Macaques: a 
Functional Latent Reservoir. mBio. 2017;8(4). 
 149 
287. Arainga M, Edagwa B, Mosley RL, Poluektova LY, Gorantla S, Gendelman HE. A mature 
macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with 
long acting antiretroviral therapy. Retrovirology. 2017;14(1):17. 
288. Barton K, Winckelmann A, Palmer S. HIV-1 Reservoirs During Suppressive Therapy. 
Trends in microbiology. 2016;24(5):345-55. 
289. Preza GC, Tanner K, Elliott J, Yang OO, Anton PA, Ochoa MT. Antigen-presenting cell 
candidates for HIV-1 transmission in human distal colonic mucosa defined by CD207 
dendritic cells and CD209 macrophages. AIDS research and human retroviruses. 
2014;30(3):241-9. 
 
